

Greater Miami Valley EMS Council



2024 Standing Orders



Acknowledgement

Region 3 EMS Providers,

This Protocol and the supporting Training Manual has been produced as a result of countless hours of work by a diverse cross section of the regional EMS community. This group includes the members of the Standing Orders Committee and the Regional Physician's Advisory Board. In editing the protocol many things were considered to include changes in State of Ohio- EMS scope of practice changes, medication availability, patient management best practices and EMS care procedural improvements. Additionally, the input given by you, the providers operating under this protocol, were integral in making this document possible. The overall goal of this document is to make it easier to provide quality care to your patients.

There are companion documents and additional resources that are available for you to view online or download for further explanation on the Training and Testing process for 2024. The first of these is the "2024 Implementation Guide". It addresses the new philosophy, CEUs, and other important information regarding the testing process. These documents, along with the GMVEMSC Quick Sheet and the mobile app are available through the website at https://www.gmvemsc.org/index.html under the Regional Protocols tab.

The entire protocol, the training manual and testing processes would not have been possible without the strong foundation left by the many past chairpersons of the Standing Orders and Education Committees and all of the other council members. Thank you to all who have volunteered to edit and critique these manuals.

I would also like to thank Dr. Randy Marriott and all the many RPAB members for their work.

Sincerely,

John Russell Standing Orders Co-Chair



General Patient Management	1000 Series
0	
1001	Introduction to Treatment Protocols
1002	Communication with Hospital or Medical Control
1003	
1004	
1005	General Patient Management
1006	Patient Abuse and Neglect
1007	Basic Airway Maintenance
1008	Advanced Airway Management
1009	Advanced Airway Confirmation Devices
1010	
1011	Tracheostomy and Laryngectomy Care
1012	
1013	Alternate Vascular Access
1014	Pain Management
Couling Protocol	2000 Caritan
Cardiac Protocol	2000 Series
2001	Resuscitation Guidelines
	Ventricular Assist Device
	Suspected Cardiac Chest Pain
	Cardiac Alert Program
	Bradycardia
	Tachycardia
Trauma Protocol	3000 Series
	General Trauma Management
	Major Trauma
	Glasgow Coma Score
	Trauma Arrest
	Burns and Smoke Inhalation
	Crush Syndrome Trauma
	Cyanide Poisoning & Antidotes
	Drowning
3010	Extremity Injuries

Table of Contents Page 1 of 4

3011	Eye Injuries
	Frostbite
	Head Injury
3014	Heat Exposure
3015	Hemorrhage Control
3016	Hypothermia
3017	Spinal Motion Restriction
3018	Trauma Triage Guidelines
3019	SALT Triage Systems
3020	Regional Hospital Notification System
3021	Crisis Standard of Care in MCI
Medical Protocol	4000 Series
4001	Abdominal Pain
4002	Allergic Reactions/Anaphylaxis
4003	Asthma/Emphysema/COPD
4004	Behavioral Emergencies
4005	Childbirth
4006	Childbirth with Complications
4007	Combative Patients/Emergency Sedation
4008	Diabetic Emergencies - Hypoglycemia/Hyperglycemia
4009	Diabetic Emergencies - Refusal of Transport
4010	Extrapyramidal Reactions
4011	Obstetrical Emergencies
4012	Overdose/Poisonings
4013	Respiratory Distress/Pulmonary Edema
4014	Seizures
4015	Sepsis
4016	Shock
4017	Stroke
Pediatric Considerations	5000 Series
5004	
	Apparent Life Threatening Event
	Newborn Care and Resuscitation
	Pediatric Assessment Triangle
5004	Safe Harbor
Special Operations Protocol	6000 Series
6001	General Management for Haz Mat
	Antidote Resources

Table of Contents Page 2 of 4

6003	Hazardous Drug Exposure
6004	
6005	Organophosphate Exposure
6006	Other Hazardous Materials
Administration	7000 Series
	Drug Bag Program: General Operating Guidelines
·	Drug Bag Program: Wasted Drug Procedure
	Drug Bag Program: Exchange Process
·	
·	Drug Bag Program: Lost or Stolen Drug Bag Policy
	Drug Bag Program: Hospital Participation Policy
	Drug Bag Program: New Member Agency Policy
	Drug Bag Program: Protocol Compliance Letter
	Drug Bag Program: GMVEMSC Drug Bag Discrepancy Report
	ag Program: Report of Theft or Loss of Dangerous Drugs, Controlled Substances and Drug Documents
7011	Ambulance Restocking Policy
7012	
7013	Hospital Capabilities Chart
7014	Hospital Contact Information
7015	Infectious Disease Exposure Policy
7015 EMS Drug Formular	
EMS Drug Formular	
EMS Drug Formular	y 8000 Series
80018002	y 8000 Series Adenosine
8001	y 8000 Series Adenosine Albuterol
8001	Adenosine Albuterol Amiodarone Aspirin
8001	Adenosine Albuterol Amiodarone
8001	Adenosine Albuterol Amiodarone Aspirin Atropine
8001	Machine Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride
8001	Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride Calcium Gluconate
8001	Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride Calcium Gluconate Ciprofloxacin
8001	Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride Calcium Gluconate Ciprofloxacin Dextrose 10%
8001	Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride Calcium Gluconate Ciprofloxacin Dextrose 10% Diazepam
8001	y 8000 Series Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride Calcium Gluconate Ciprofloxacin Dextrose 10% Diazepam Diphenhydramine
8001	y 8000 Series Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride Calcium Gluconate Ciprofloxacin Dextrose 10% Diazepam Diphenhydramine Dopamine
8001	y 8000 Series Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride Calcium Gluconate Ciprofloxacin Dextrose 10% Diazepam Diphenhydramine Doppamine Doxycycline
8001	y 8000 Series Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride Calcium Gluconate Ciprofloxacin Dextrose 10% Diazepam Diphenhydramine Dopamine Doxycycline Duodote
8001	y 8000 Series Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride Calcium Gluconate Ciprofloxacin Dextrose 10% Diazepam Diphenhydramine Dopamine Doxycycline Doxycycline Duodote Epinephrine

Table of Contents Page 3 of 4

B Hydroxocobalam	8018
)lpratropiu	8019
) Ketamir	
Lactated Ringe	8021
Lidocaine 2	8022
BLidocaine 2% G	
Magnesium Containing Antac	
5 Midazola	
/ Morphir	
B	
)	
)	
Normal Salir	
S	
Oral Glucos	
Plasmalyte-	
D	
' Sodium Bicarbona	
Sodium Nitri	
Sodium Thiosulfa	
)	

Appendices

Table of Contents Page 4 of 4

1000 Series

General Protocol



1001

Subject: Introduction to Protocols

June 1, 2021

Last Modified:

Dec. 21, 2023

1001.1 Introduction to Treatment Protocols

- a. Each protocol has been approved by the Greater Miami Valley EMS Council and the Regional Physician Advisory Board for Region 3 (as defined by the State Board of Emergency Medical, Fire and Transportation Services [EMFTS]).
- b. Each tab bears an effective date and a last modified date marking it as the latest version.

Effective:

- c. A new addition to protocol would reflect a duplicate "Effective" and "Last Modified" date.
- d. When changes or revisions are made to a tab, only the "Last Modified" date will be changed.
- e. Each time changes or additions are made; they can be referred to by their specific line in the protocol. i.e. A change was made to "1001.1.e".
- f. Each year, changes or additions will be listed in an addendum in the appendix.

1001.2 **Printing, Retention, and Display**

- a. All GMVEMSC Treatment Protocols are intended for color printing, and hard copy retention.
- b. These protocols are also intended for electronic display in Adobe Portable Document Format (PDF).
 - i. The PDF version includes links to the different tabs throughout the document.
 - ii. The GMVEMSC logo on most pages is a hyperlink back to the table of contents.
- c. Distribution is provided by means of the GMVEMSC official website.

1001.3 Application

- a. This protocol is for use by those individuals operating in and under the authority of the Greater Miami Valley EMS Council (GMVEMSC) Drug Bag Exchange Program and certified by the State of Ohio as an EMS provider.
- b. The provider must pass both the skills check-off and Computer Based Testing (CBT) for the current year.
- c. The GMVEMSC Treatment Protocols apply to the following certification levels:
 - i. Emergency Medical Responder (EMR)
 - ii. Emergency Medical Technician (EMT)
 - iii. Advanced Emergency Medical Technician (AEMT)
 - iv. Paramedic (PM)

1001.4 Stipulations

- a. The protocol is to be used in the field only.
- b. Communicate with the receiving facility as soon as practical:
 - i. When transporting unstable patients
 - ii. Transporting to hospitals that request contact for all patients delivered to their facility.
- c. No procedures, techniques, or drugs will be used without the proper equipment or beyond the training or capabilities of the prehospital personnel.
- d. Nothing in this protocol may be used without specific pre-approval of the Medical Director for the local department or agency.
- e. The protocol is to be utilized as clinically indicated. Not every standing order in a treatment protocol must be carried out on every patient treated under that treatment protocol.
- f. Discretionary judgment is required and stepwise adherence to specific protocols may not be in the patient's best interest.

1001 – Introduction to Protocols Page 1 of 3

1001

Introduction to Protocols

Effective: June 1, 2021

Last Modified:

Dec. 21, 2023

g. At no time should treatment options exceed those authorized without direct consultation with the Medical Control Physician (MCP).

1001.5 Protocol Design

Subject:

- a. The GMVEMSC protocols are organized around the General Patient Management Protocol which must be followed for all patients. This universally applicable protocol/flowchart allows the providers to integrate additional treatment protocols beyond general patient management as clinically necessary for specific patient care, emergency stabilization, and treatment.
 - i. As an example, while caring for a specific patient with chest pain, shortness of breath, and nausea the provider would:
 - 1. Follow the General Patient Management Protocol
 - 2. Integrate and follow the Chest Pain Protocol
 - 3. Integrate and follow the Respiratory Distress Protocol if indicated
 - 4. Integrate and follow the Cardiac Alert Protocol if indicated
 - 5. Integrate and follow the Abdominal Pain Protocol if indicated
 - 6. Refer to protocol for specific medication concentrations, dosages, and volumes.
 - 7. Complete the General Patient Management Protocol
- b. In most cases, a specific guideline will only be mentioned once within the protocol. All other circumstances where that guideline would be applicable will simply refer to the original guideline.
- c. Where applicable, a guideline mentioned in another section will have a hyperlink provided.
- d. Formatting
 - i. All attempts will be made to keep the protocol focused and specific.
 - ii. Extracurricular and enhancing information will be provided in an official study guide.
 - iii. All levels of providers will be addressed within a single protocol.
 - iv. Procedures and treatments marked with a diamond (♦) always require a physician's order.
 - v. Items enclosed in brackets ({ }) are at the option of the agency and their Medical Director.
 - vi. Sections that apply only to adults are bulleted with an "A".
 - vii. All pediatric treatments will be in pink and bulleted with a "P".
 - viii. There are also sections which apply to only Geriatric patients and are bulleted with a "G."

1001.6 Clinical Management Tables

- a. In addition to general statements, this protocol will utilize table-based algorithms where applicable.
- b. The table will demonstrate what care can be given at each provider level.
 - i. The level of certifications will be signified by the colored tabs to the right of each section.
- c. Even with a step-by-step algorithm in place, critical thinking is encouraged.
- d. While the table is sequential and listed by provider level, many elements in each section can be completed simultaneously.
- e. The following is an annotated example of a Clinical Management Table:

1001 – Introduction to Protocols Page 2 of 3

1001

Subject:

END OF SECTION

Introduction to Protocols

Effective:

June 1, 2021

Last Modified:

Dec. 21, 2023

Assessment Differential Diagnosis Pediatric Considerations Signs & Symptoms This is where pediatric specific info might go. This is where S&S will go This is where differentials will go Dosing and treatment will still be listed in the algorithm **Treatment Algorithm** This will be where guidelines for all certification levels will go EMR Any EMR and above information will be listed in this box. Treatment directives for the EMT and above will be here. If no EMT directives apply, then this box would read "No additional orders at this level". **AEMT** Treatment directives for the AEMT and above will be here. If no AEMT specific directives apply, then this box would read "No additional orders at this level". Treatment directives for the Paramedic will be listed here. If no Paramedic specific directives apply, then this box would read "No additional orders at this level". Consult If requirements exist for any level to call for orders, that will be listed here. If there is a guideline to call an alert, that will be listed here. If there is a recommendation to call for MCP advice, that will be listed here. If there is a request to call the receiving facility prior to arrival, that will be listed here. **Clinical Pearls** Any important guidelines or clinical information will be added here.

This will not be a study guide nor a skill sheet. That information will be supplied in a separate format.

1001 – Introduction to Protocols Page **3** of **3**



1002

Subject: Communication with Hospital or Medical Control

Effective: June 1, 2021

Last Modified:

Mar. 16, 2022

1002.1 Reasons to Contact the Hospital

- a. To notify the hospital when time is needed to prepare for patient arrival. Examples include:
 - i. Cardiac arrest
 - ii. Any of the defined alerts such as Cardiac Alert, Stroke Alert, Trauma Alert
 - iii. Indications of sepsis
 - iv. Significant communicable disease
 - v. Other serious patients that may require acute care
 - vi. Hazardous material exposures (mandatory)
 - vii. Bedbugs

1002.2 Reasons to Contact Medical Control

- a. To obtain orders for procedures or medications as indicated within the protocol.
- b. For field termination or DNR clarification.
- c. To obtain advice in a difficult situation or circumstance. Examples include:
 - i. Before a medication is given, even though protocol allows it to be used without permission.
 - ii. A situation where the patient has an unfamiliar condition.
 - iii. To discuss a destination decision.

1002.3 Call-in Procedures

- a. When contacting a hospital, make sure a clear picture is painted.
- b. When calling about a trauma patient, include:
 - i. MIVT Mechanism, Injuries, Vital Signs and Treatment
 - ii. Estimated time of arrival (ETA)
 - iii. The components of the Glasgow Coma Score (GCS)
 - iv. Patient assessment findings which are relevant to the decision to transport to a Trauma Center.
- c. If consultation with a physician is desired, specifically request the Medical Control Physician.
- d. When calling with an Alert (Cardiac, Stroke, Trauma, etc.):
 - i. Request to speak directly to the Medical Control Physician at the beginning of the call.
 - ii. Verbalize, "We recommend a Alert."
 - iii. The MCP has the discretion to withhold the Alert and may decide not to activate it.



1003

Subject: Non-Initiation of Care

Effective: June 1, 2021

Last Modified:

Feb. 11, 2024

1003.1 General Guidelines

- a. This protocol may be applied by EMT, AEMT and Paramedic providers only. The EMR cannot determine that a patient is deceased.
- b. All patients (Adult, Pediatric, and Geriatric) may meet criteria for non-initiation of care.
- c. If care had begun and is readily apparent to the provider that the patient meets non-initiation of care criteria, **RESUSCITATION EFFORTS MAY CEASE.**

1003.2 Criteria for Non-Initiation of Care

- a. Resuscitation will not be initiated in the following circumstances:
 - i. Deep, penetrating, cranial injuries
 - ii. Massive truncal wounds
 - iii. DNR Order—present and valid (see 1004 Do Not Resuscitate)
 - iv. Frozen body
 - v. Rigor mortis, tissue decomposition, or severe dependent lividity
 - vi. Triage demands
 - vii. For patients in arrest resulting from **BLUNT OR PENETRATING TRAUMA** consider not initiating care for injuries obviously incompatible with life.
 - 1. Prolonged arrest (greater than 10 minutes)
 - 2. Consider possibility of MIXED MECHANISMS

1003.3 Exclusionary Conditions

- a. The following conditions will not meet non-initiation of care criteria:
 - i. Traumatic arrest in female patient with either:
 - 1. Known pregnancy greater than 24 weeks or
 - 2. Uterine fundus palpable at or above the umbilicus
 - ii. Possible medical etiology for traumatic cardiac arrest
 - iii. Arrest witnessed by EMS providers
 - iv. Lightning strike
 - v. Signs or symptoms of a hypothermic patient
 - vi. Focused blunt trauma to the chest, (commotio cordis)

1003.4 For an inquiry about organ donation, direct the call to Life Connection of Ohio at 1-800-535-9206.

END OF SECTION

1003 – Non-Initiation of Care Page 1 of 1



1004

Subject: Do Not Resuscitate

Effective: June 1, 2021

Last Modified:

Jan. 28, 2024

1004.1 General Guideline

- a. Per ORC 2133.21-2133.26, providers will consider and honor all valid Ohio Do Not Resuscitate orders.
- b. The two valid DNR orders are DNR: Comfort Care and DNR: Comfort Care Arrest.

1004.2 Do-Not-Resuscitate Orders Defined

- a. Do-Not-Resuscitate: Comfort Care Arrest (DNR-CCA)
 - i. Permits any GMVEMSC Protocol treatment until the order is initiated.
 - ii. The order is initiated at the moment the patient goes into cardiac or respiratory arrest.
 - iii. Once the patient meets the above criteria, then only permitted DNR treatment is performed.
- b. Do-Not-Resuscitate: Comfort Care (DNR-CC)
 - i. Permits any medical treatment to diminish pain or discomfort
 - ii. No treatment should be used to postpone the patient's death.
 - iii. The order is initiated at the moment it is signed by the patient's physician.

1004.3 Permissible and Impermissible Treatments Once the DNR is Initiated

- a. The following treatments are permitted once an order is valid and effective:
 - i. Conduct an initial assessment
 - ii. Perform basic medical care
 - iii. Clear airway of obstruction or suctioning
 - iv. If necessary, for comfort or to relieve distress, may administer oxygen, CPAP or BiPAP
 - v. If necessary, may obtain IV access for hydration or pain medication to relieve discomfort, but not to postpone death
 - vi. If possible, may contact other appropriate health care providers
- b. The following treatments are not permitted once an order is valid and effective:
 - i. Perform CPR
 - ii. Administer resuscitation medications with the intent of restarting the heart or breathing
 - iii. Insert an airway adjunct
 - iv. Defibrillation, cardioversion or initiate pacing
 - v. Initiate continuous cardiac monitoring

1004.4 Stipulations

- a. If more than one living will declaration or DNR exists, the most recent supersedes the previous.
- b. The authority of a DPOA-HC supersedes the DNR if the DPOA-HC previously consented to the DNR.
- c. The GMVEMSC protocol will recognize the following special situations as valid. If these scenarios present, then contact MCP and request to honor the DNR with physician permission.
 - i. Out-of-State DNR orders
 - ii. Pediatric DNR orders
- d. Blood glucose checks and treatment of <u>4008 Diabetic Emergencies Hypoglycemia/Hyperglycemia</u>, is acceptable even with a valid DNR.
- e. While <u>1005 General Patient Management</u> requires continuous cardiac monitoring when administering pain medications, this focused protocol supersedes that requirement in valid DNR patients.
- f. In situations where there are questions about the documents, try to keep the patient's intent in mind.
- g. If there is any confusion on scene, ♦ Call MCP for clarification.

END OF SECTION

1004 – Do Not Resuscitate Page **1** of **1**



1005

Subject:

General Patient Management

Effective: June 1, 2021

Last Modified:

Dec. 22, 2023

1005.1 Guideline

- **a.** The General Patient Management protocol is to be applied to all patients.
- **b.** Once a primary impression and differential diagnosis is made, then the provider should look to specific treatment algorithms within these standing orders.

1005.2 Basic Patient Care

- a. The emphasis in patient care should ensure airway protection, oxygenation, and adequate ventilation without causing harm.
- b. Injury reduction strategies may include noninvasive ventilation when appropriate, titration of oxygen in certain settings, and being cautious not to over ventilate.
- c. Tailor treatment to the overall clinical picture.
- d. With the exception of suspected acute cerebral herniation, the rate and depth of ventilation in the prehospital setting should not be guided by the EtCO₂ reading alone.
- e. For the patient with cerebral herniation, ventilate the patient at approximately 20 times per minute to obtain an EtCO₂ of 30 mmHg.
- f. "Permissive hypercapnia" in most cases is appropriate, particularly in those with chronic lung disease who may chronically retain CO₂.
- g. It is recommended to listen to the chest to ensure that adequate exhalation is occurring during manual ventilation.

1005.3 EMT Assisting the Advanced Provider

- a. Per Ohio Revised Code, the EMT is permitted to assist the advanced provider with skills that are outside of the EMT's scope of practice.
- b. The EMT is only allowed to prepare ALS equipment under the direct supervision of the AEMT or Paramedic.
- c. The skills that an EMT may set up for and assist with are:
 - i. Endotracheal intubation
 - ii. Intravenous access
 - iii. IV fluid administration
 - iv. Saline locks
 - v. Placement of 4 Lead and/or {12 Lead EKG} for cardiac monitoring
 - vi. Accessing the GMVEMSC Drug Bag to locate drugs and/or to assemble pre-jects.

1005.4 General Patient Management

	Assessment	
Pediatric Considerations	Signs & Symptoms	Differential Diagnosis
Pediatric patients are defined as patients less than 16 years old	• None	• None
 A Pediatric reference guide or length-based resuscitation tape may be used to reference pediatric equipment recommendations. 		
 Pedi-Wheel may be used as a reference for pediatric vital signs. 		
Unless otherwise specified, the maximum dose for pediatric medication administration is the adult dose.		

1005

Subject:

General Patient Management

Effective: June 1, 2021

Last Modified:

Dec. 22, 2023

Treatment Algorithm

- Scene/Crew Safety/PPE; with appropriate equipment/medications to patient side.
- Initial Assessment/Physical Exam
- Follow basic life support and airway algorithms as indicated based on current AHA guidelines.
- An unresponsive patient with gasping breaths and poor color should get supplemental oxygen via BVM
- Obtain chief complaint, OPQRST, SAMPLE history, and other pertinent information.
- Vital Signs
 - o Blood Pressure (EMR are limited to obtaining manual blood pressures)
 - Pulse, rate and quality
 - o Respirations; Rate, quality, and work-of-breathing
 - o Assess every 5 to 15 minutes per patient condition
 - o Temperature as needed
- Utilize monitoring devices, pulse oximeter, CO-oximetry, capnography, etc. as appropriate and approved by medical direction.
- Perform blood glucose check.
- Where indicated, the EMT may obtain a {12 Lead EKG} for the purpose of transmission.
- The EMT may assist the advanced provider with:
 - {12 Lead EKG} application assisting a Paramedic who is present
 - Set up an IV administration kit in the presence of an AEMT or Paramedic
- Utilize cardiac monitor as appropriate.
- Where indicated, the AEMT may obtain a {12 Lead EKG} for the purpose of transmission.
- The AEMT may apply a {12 Lead EKG} when assisting a Paramedic who is present.
- Start IV crystalloid solutions or saline lock as appropriate.
- IV Therapy: Follow 4016 Shock Protocol.
 - o For medical emergencies, head trauma, cardiac issues with stable BP, etc.: Use **TKO** rate.
 - Shock (not related to penetrating trauma):
 - Run IV fluid wide-open
 - Use macro-drip or blood tubing
 - Decrease fluid rate if SBP greater than 100
 - P IV fluid 20 ml/kg using macro-drip tubing. Titrate to maintain adequate perfusion.
- Use of IO devices for both adults and pediatrics is limited to patients who are unresponsive or hemodynamically unstable, and only when less invasive means are not available or are ineffective (e.g., Narcan IN, and Versed IN).
- Provide continuous cardiac monitoring, EtCO₂ and pulse oximetry (if available) for all patients with fentanyl, ketamine, morphine or midazolam if not already doing so.
- If a patient with an existing IV pump experiences an allergic reaction, consider discontinuing the pump.
- Use of an {IV pump} is optional for any agency with approval from their Medical Director.
- Existing central venous catheters, dialysis catheters, fistulas, or grafts may be utilized for infusion of IV fluids and medication if the patient is hemodynamically unstable. These may also be used when the patient is deteriorating rapidly.

Consult

- Do not stop the flow of medication in an established medication pump except under direct orders from Medical Control.
- If a patient with an existing IV pump experiences an allergic reaction, call the MCP for an order to discontinue the pump.

Clinical Pearls

- If a patient was discharged from a hospital in the last 24 hours, it is recommended to return to the same facility or at the very least, the same network of hospitals.
- If the patient is experiencing complications from a recent surgery, if possible, transport the patient back to the facility where the surgery was performed. If that is not practical, then try to transport to the same network.
- If possible, bring medications or a list of the medications to the hospital; include the dose and frequency of administration.
- Crystalloid fluids include Normosol, Plasmalyte, Lactated Ringers or Normal Saline in that order. Their pH is closer to neutral.
 - o Medical emergencies, head trauma, cardiac problems with stable BP: Use TKO rate.
- IV medication administration: Slow IV = over 2 minutes, unless otherwise specified.
- Any medication given IV can also be administered intraosseous, IO.
- Maintain normothermia.

END OF SECTION

AENAT

Subject: Patient Ah

Patient Abuse and Neglect

Effective:

June 1, 2021

Last Modified:

Feb. 9, 2021

1006.1 Guideline

- a. EMS providers MUST, by law, report all alleged or suspected pediatric and adult abuse/neglect.
- b. Ohio Revised Code requires providers to report incidents of pediatric and adult abuse/neglect to:
 - A Their county's adult protective services agency (for patients over 60 years old)
 - P Their county's public children services agency
 - iii. Or for both adults and pediatrics; Law enforcement
 - iv. For adult patients see ORC 5101.63 and for pediatric patients see ORC 2151.421
- c. Simply notifying hospital personnel does not meet mandated EMS reporting responsibilities.
- d. Hospitals have copies of the EMS Social Services Referral Form, supplied by GDAHA, for documenting cases of abuse/neglect.
- e. Use of this form can help providers in providing information needed to their reporting agency, as well as provide for a continuum of care with hospital social services departments.
- f. Document on the Patient Care Report, all efforts that EMS made to report the suspected abuse; include name of agency notified, method used, and name of person contacted.

1006.2 Pediatric Abuse and Neglect

P Report all alleged or suspected child abuse or neglect to the appropriate agency.

Pediatric Public Social Services Agencies			
County	Phone	After Hours Phone	Fax
Butler	513-887-4055	513-868-0888	513-887-4260
Champaign	937-484-1500	Contact County SO: 937-484-6092	937-484-1506
Clark	937-327-1700	937-324-8687	937-327-1910
Darke	937-548-7129	937-548-2020	937-548-8723
Greene	937-562-6600	937-372-4357	937-562-6650
Miami	937-335-4103	Contact County SO: 937-440-3965	937-339-7533
Montgomery	937-224-5437	937-224-5437 (same as daytime)	937-276-6597
Preble	937-456-1135	937-456-1135 (same as daytime)	937-456-6086
Shelby	937-498-4981	Contact County SO: 937-498-1111	937-498-1492
Warren	513-695-1558	513-695-1600	513-695-1800

1006.3 Adult Abuse or Neglect

A Report all alleged or suspected abuse or neglect to the appropriate agency.

Adult Public Social Services Agencies			
County	Phone	After Hours Phone	Fax
Butler	513-887-4081	Contact County SO: 513-785-1000	513-785-5969
Champaign	937- 484-1500	Contact County SO: 937-484-6092	937-484-1506
Clark	937-327-1700	937-324-8687	937-327-1910
Darke	937-548-7129	937-548-2020	937-548-4928
Greene	937-562-6315	Contact County SO: 937-562-4800	937-562-6177
Miami	937-440-3471	Contact County SO: 937-440-3965	937-335-2225
Montgomery	937-225-4906	Contact County SO: 937-225-4357	937-496-7464
Preble	937-456-1135	937-456-1135 (same as daytime)	937-456-6086
Shelby	937-498-4981	Contact County SO: 937-498-1111	937-498-1492
Warren	513-695-1420	513-425-1423	513-695-2940



1007

Subject:

Basic Airway Maintenance

Effective: June 1, 2021

Last Modified:

Feb. 5, 2023

1007.1 Clinical Management

Assessment Differential Diagnosis Pediatric Considerations Signs & Symptoms Repeated and prolonged suctioning Respiratory difficulty or distress None could cause hypoxia and bradycardia. Poor SpO₂ or EtCO₂ Respirations by Age Mechanism of Injury or Nature of Illness that would require O2 therapy Impending airway issues Adventitious respiratory sounds **Treatment Algorithm** EtCO₂ monitors can be used on all patients with or without adequate perfusion, and with or without artificial airways. Administer Oxygen as needed. Use the following rates as guidelines: **2 LPM** by nasal cannula (NC) for patient with COPD, or as prescribed. **4-6 LPM** by nasal cannula (NC) for other patients. 0 12-15 LPM by non-rebreather mask (NRM) for any patients with increased respiratory rates or effort (including COPD). Ventilate patients who are symptomatic with an insufficient respiratory rate, depth or effort. Patient less than 2 years old showing respiratory distress with nasal congestion, cough, rales, rhonchi or wheezing - without previous history of wheezing, reactive airway disease, breathing treatments: Nasopharyngeal suctioning in both nares (3-5 seconds) with an appropriate device If distress continues, repeat nasopharyngeal suctioning for 3-5 seconds For patients less than 6 years old showing respiratory distress with agitation, upper airway noise, stridor, and/or "barky cough,": Lower temperature of ambulance as much as possible. Deliver oxygen as the patient tolerates Often these symptoms resolve with less intervention. Consider keeping distance from the patient. Consider patient airway anatomy for the appropriate selection of the airway adjunct. If indicated, suction the tracheostomy. If patient has history of reactive airway disease with prescribed breathing treatments then treat with 4003 Asthma protocol. Consider the need for a supraglottic or dual lumen rescue airway. • The EMT may only place a rescue airway in a pulseless, apneic patient. For guidelines to placement of rescue airways, see protocol 1008 Advanced Airway Management Oxygen flow rate for nebulized medications should be 8-10 LPM. EMT o Nebulized medication may be administered while ventilating a patient with a BVM. Preferably use two oxygen sources. Consider the need for intubation. The AEMT may only intubate if patient is apneic. AEMT If routine ventilation procedures are unsuccessful, try to visualize obstruction with laryngoscope. If a foreign body is seen, attempt to remove it using suction or Magill forceps. When deciding whether to intubate, consider the following: Insufficient respiratory rates, less than 10 or greater than 29, that are not rapidly controlled by other measures 0 Irregular respiratory rhythm Abnormal breath sounds 0 0 Inadequate chest expansion and respiratory depth 0 Excessive effort to breathe 0 Use of accessory muscles 0 Nasal flaring 0 Pallor or cyanosis Cardiac dysrhythmias 0 Consult None

Clinical Pearls

COPD patients in severe respiratory distress or with chest pain need the same O₂ devices and flow rates as any other patient in such condition.



Subject:

Advanced Airway Management

Effective: June 1, 2021 Last Modified:

Dec. 22, 2023

	Assessment		
ediatric Considerations None	 Signs & Symptoms Patient unable to manage their own airway Patient in cardiac arrest Patient in respiratory arrest (AEMT & Paramedic) Rapidly collapsing airway 	Differential DiagnosisNone	
	Treatment Algorithm		
Advanced Airway Manageme	nt is not an EMR skill	EMR	
Always secure the advanced a	advanced airways by at least 5 methods, see protocol 1009 Advance irway in place, preferably with a commercial tube-securing device. cement every time the patient is moved.	ed Airway Confirmation Devices	
If a total of two attempts with P Supraglottic airway A cervical collar is effective in If there are indications of tens	my and condition for proper advanced airway device selection. In an ET tube are not successful, move to a rescue airway. It is recommended as the <u>primary airway</u> except in extreme cases suc maintaining patient's head in a neutral position during the intubation pneumothorax and the patient is hemodynamically unstable: est with a 14-gauge or larger, 3 ¼" angiocath	· · · · · · · · · · · · · · · · · · ·	
Location options incFourth or	fifth intercostal space in the mid-axillary line third intercostal space in the mid-clavicular line a 8 years old, site choice will be limited to the second or third interc	ostal space at the mid-clavicular	
 Location options inc Fourth or Second or P If less that 	third intercostal space in the mid-clavicular line		

- SBP is greater than 100, consider Midazolam 2.5 mg slow IV.
- Α SBP less than 100, consider **Ketamine 100 mg slow IV**.
- For patients greater than 69 y/o, reduce dosing for sedatives and analgesics to one half ($\frac{1}{2}$) of the adult doses.
- is age/weight appropriate consider **Midazolam 0.1 mg/kg** (max dose 2.5 mg), **slow IV**.
- As an alternative to advanced oral airway procedures, consider nasal intubation.
- {If a patient needs intubation but is combative, agitated, or has jaws clenched, use 1010 {Sedate to Intubate or RSI} procedures if approved to do so by Medical Direction.}
- Whenever all reasonable attempts to provide an adequate airway by less invasive means have failed due to a total airway occlusion and you are unable to ventilate:
 - A Perform a needle cricothyrotomy or surgical airway utilizing an approved method.

Consult

None

Clinical Pearls

- Each agency should check with their individual Medical Director(s) to determine what approved basic and advanced airway devices will be.
- For the AEMT and Paramedic, {Lighted Stylet Intubation} or {Camera Assisted Intubation} may be utilized.
- For the Paramedic, Nebulized Lidocaine can be administered simultaneously with Albuterol and Ipratropium.
 - If feasible, wait one to two minutes before intubation



1009

Subject:

Advanced Airway Confirmation Devices

Effective: June 1, 2021

Last Modified:

Dec. 22, 2023

1009.1 General Guidelines

- a. Confirm correct placement of advanced airways with waveform capnography and at least 4 other methods as listed below.
- b. Reassess advanced airway placement every time the patient is moved.

1009.2 Confirmation Methods

	Assessment		
Pedia	ntric Considerations	Signs & Symptoms	Differential Diagnosis
• 1	None	Inserted advanced airway	None
	Treatment Algorithm		
• /	Advanced Airway Management is not an EN	⁄IR skill	ENNE
• /	 Auscultate the epigastrium, the lun for ventilation sounds. Observe rise and fall of the chest w 	datory for advanced airway confirmation gs at the anterior chest, the lungs at the mid-axillary areas ith each breath	, and then the epigastrium again
	4. Look for condensation in the tube of the advanced airway 5. Look at patient's appearance If signs of cerebral herniation are present, hyperventilate at 20 ventilations per minute to an EtCO ₂ value of 30 mmHg.		
• 1	P Proper endotracheal tube placem	t: e at the 21-23 cm mark at the teeth is recommended ir tent in the pediatric patient can be calculated by: th of tube at teeth or gum line) = Tube size x 3.	
	Avoid placing the ETT too deeply and the possibility of a right main stem bronchus intubation. Do not confuse right main stem intubation for a pneumothorax.		
	Consult		
• [None		
		Clinical Pearls	
• 1	Intravenous sodium bicarbonate will produ	ce more carbon dioxide and affect EtCO ₂ values.	

1009.3 Confirmation Devices

- a. These devices can help recognize esophageal intubation, but cannot identify bronchial placement.
- b. Maintain EtCO₂ devices until patient care is transferred to the receiving ED staff.
- c. Electronic End Tidal CO₂ (EtCO₂) Monitors (Capnography)
 - i. Continuous waveform capnography is a required confirmation device.
 - ii. EtCO₂ should be used on **EVERY** advanced airway
- d. End Tidal CO₂ Detector (EtCO₂) Colorimetric
 - i. In cardiac arrest, if there is no color change, use other confirmation methods.
 - ii. Secretions, emesis, etc. can ruin the device.
 - iii. Large amounts of carbonated beverage in the stomach can give a false positive.
 - iv. The device can be used for no more than two hours.
 - v. Follow manufacturer's recommendations for weight restrictions.
- e. Beck Airway Airflow Monitor (BAAM) is authorized for use by the Paramedic during nasal intubation.



1010

Subject:

{Sedate to Intubate or RSI}

Effective:

June 1, 2021

Last Modified:

Dec. 12, 2023

1010.1 General Guidelines

- a. Sedate to Intubate and Rapid Sequence Intubation are optional skills in the GMVEMSC protocol.
- b. These skills are to be performed by the Paramedic only.
- c. This standing order applies to agencies whose personnel have received the appropriate training and Medical Director's approval only.
- d. Under no circumstances is RSI to be used as "behavioral control" or restraint in patients with otherwise intact airways.
- e. Some Medical Directors may recommend Rapid Sequence Intubation as a primary airway control procedure.
- f. While this protocol recommends Succinylcholine as a short-term paralytic, a Medical Director may choose to use a different medication. Should a different paralytic be used, the Medical Director will be responsible to establish dosing and training.
- g. Inclusion criteria:
 - i. The patient must be 16 years old or older
 - ii. The patient cannot have suffered a paralyzing injury more than one week and less than 6 months ago (specific to Succinylcholine)

1010.2 Clinical Management

Assessment			
Pe	diatric Considerations	Signs & Symptoms	Differential Diagnosis
•	This protocol does not apply to pediatric patients.	 Decreased LOC Ineffective or absent breathing Patient unable to maintain their own airway Respiratory failure or inevitable loss of airway 	 Cardiac arrest Anaphylaxis Esophageal obstruction
		Treatment Algorithm	
•	Sedate-to-Intubate nor Rapid Sequence	Intubation are EMR skills	EMR
•	Sedate-to-Intubate nor Rapid Sequence	Intubation are FMT skills	EM
	<u> </u>		AE MATERIAL PROPERTY OF THE PR
•	Sedate-to-Intubate nor Rapid Sequence	Intubation are EMT skills	N N
	 {If the paramedics d {Must have cardiac monitor, IV {Sedate the patient}: {Administer Etomida 	ent. Remove dentures or dental appliances.} boubt that they will be able to successfully intubate, the property and pulse oximetry in place} ate 0.3 mg/kg IV (maximum dose 40 mg) OR V (in hemodynamically unstable patients), may repeat 100 OR	
	■ {Midazolam 5 mg sl	DW IV (in patients who are normotensive), may repeat up	to 10 mg }
	o <u>DO NOT</u> reduce Ketamine or Midazolam doses by half for patients greater than 69 y/o.		
	o Instead, give full doses to all patients over 16 y/o in order to achieve sedation.		
•	If stopping at {Sedate-to-Intubate}, then intubate the patient. {Rapid Sequence Intubation}:		
	 {Sedate the patient as outlined {Paralyze the patient with Suc		}
	■ {Midazolam 5-10 m		
	■ {If hypotensive, then Ketamine 100-200 mg IV }		
•	 {Midazolam 5-10 mg IV} If hypotensive, then Ketamine 100-200 mg IV} Maintain continuous waveform capnography after intubation. 		

1010

Subject:

{Sedate to Intubate or RSI}

Effective: June 1, 2021

Last Modified:

Dec. 12, 2023

Consult

Paramedics may seek guidance or approval from medical control prior to initiating the protocol; however, this is not required

Clinical Pearls

- Paralytics or sedation do not change poor airway anatomy.
- The most important decision may be when <u>NOT</u> to paralyze the patient or intubate them.
- Succinylcholine paralyzes the muscles but does not affect LOC. ALWAYS SEDATE THE PATIENT.
- Tachycardia may be a sign that the patient is paralyzed but not adequately sedated.
- No more than 2 intubation attempts.
- If you can still ventilate the patient with a BLS airway, a cricothyroidotomy is not necessary.

1010.3 RSI Educational Recommendations

- a. Rapid Sequence Intubation should not be available to all paramedics in the system.
- b. Only those paramedics willing to undergo additional initial training and continuing training should be allowed to perform it.
- c. In initial training, the paramedic should demonstrate proficiency during the following practical evaluations:
 - i. 2 endotracheal intubations on airway simulators
 - ii. 3 endotracheal intubations on airway simulator with C-spine immobilization
 - iii. 5 surgical cricothyrotomies on simulators using surgical technique or an approved device
 - iv. 4 intubations using the eschmann stylet (gum bougie) on airway simulators (optional)
 - v. 5 insertions of a rescue airway on airway simulators
- d. Once a quarter, the paramedic should demonstrate proficiency during the following practical evaluations:
 - i. 1 endotracheal intubation on airway simulators
 - ii. 2 endotracheal intubations on airway simulator with C-spine immobilization
 - iii. 1 surgical cricothyrotomy on airway simulator
 - iv. 1 intubation using the eschmann stylet (gum bougie) on airway simulators (optional)
 - v. 1 insertion of rescue airway on airway simulators
- e. Any of the above evaluations could be credited if the procedure is performed under direct supervision by the Medical Director, Supervisor or Training Officer the field or a clinical setting.

1011

Subject:

Tracheostomy and Laryngectomy Care

Effective: June 1, 2021

Last Modified:

Dec. 8, 2021

1011.1 General Guidelines

- a. Consult the patient's caregiver for assistance. They are typically trained to manage these airways.
- b. Find out why they have an artificial airway (cancer, stroke, ventilator dependent, etc.)
- c. Ask if there have been any prior difficulties (reinserting, plugging, etc).
- d. Find out when the airway was first placed (newer airways may be more difficult to replace).
- e. For assessing failed tracheostomies and laryngectomies, consider:
 - i. D displaced, dislodged or damaged
 - ii. O obstructed (mucus, food, blood, secretions)
 - iii. P pulmonary problems
 - iv. E equipment failure (bent tubing, ventilator malfunction, depleted oxygen supply
- f. Look for subcutaneous air in the neck as it might indicate a false passage of tube.

1011.2 Clinical Management

	Assessment	
diatric Considerations	Signs & Symptoms	Differential Diagnosis
None	Patient with tracheostomy or larynged tube with signs of respiratory distress of the signs of the sign o	
	Treatment Algorithm	
Administer high-flow oxygo Consider assisting ventilati BVM typically wi If there is no innot be inserted into	sess the artificial airway for easily reversible causes of distress	half size larger than the trach tube may
Suction the tracheostomy tu Unable to ventilat Coarse upper airw If respiratory distr If the airway tube Use the patient's DO NOT force the Determine the probeyond this meas If no obturator is A Insert the su P Use the patient Consider inserting 2 - 3 mL of Suction on the way out, for its	e with BVM. yay sounds are heard. yess continues despite BVM ventilation. has an inner cannula, remove it prior to suctioning. suctioning supplies or a catheter that is no more than 1/2 the tube suction catheter into the tracheostomy tube. oper suction catheter depth by measuring the length of the obtur- ure.	ator or inner cannula and advancing slightly
If no replacement tube is a	eeded in improving respiratory status, consider replacing the a vailable, insert an ETT as a replacement.	-
If all other means fail, inclu	iding tube replacement, consider attempting oral tracheal int	ubation.
	Consult	

1011

Subject:

Tracheostomy and Laryngectomy Care

Effective: June 1, 2021

Last Modified:

Dec. 8, 2021

Clinical Pearls

- Patients with laryngectomy airways have the larynx removed, completely separating oral- and nasal- pharynx from the trachea and lungs.
 - These patients are sometimes referred to as neck breathers.
- Established stomas are less likely to close off.
 - o Closed off stomas require surgical techniques to replace the tube and replacement should be avoided in the field.
- Often the cuff is deflated allowing the patient to have more air movement past the vocal cords thus enabling speech.
- There may also be speaking valve (a one-way valve allowing air in not out) attached to the outside end of the tracheal tube.
- Tube replacement is a clean procedure (mask, splash protection, and clean gloves). Keep the patient's airway as clean as possible.

1011.3 Artificial Airway Tube Replacement (AEMT & Paramedic)

- a. Necessary Equipment:
 - i. Replacement tracheostomy tube or laryngectomy tube (from the patient or care giver).
 - 1. If patient is pediatric, there is a one size smaller tracheostomy tube in the GoBag that should always be with the patient.
 - ii. If no replacement tracheostomy tube is available, use an ETT of similar internal diameter
 - iii. If possible, water-based lubricant jelly.

b. Procedure:

- i. Apply high-flow O₂, pulse oximetery, EtCO₂, and cardiac monitor.
- ii. Place patient semi-recumbent with slight neck extension (consider a roll under the neck).
- iii. Keep the head midline (May need additional personnel to maintain head position).
- iv. For adults, consider use of a bougie when removing the old tube. (this is not a pediatric practice)
- v. Lubricate the new tracheostomy tube or replacement ETT.
- vi. Deflate the old tracheostomy tube's balloon and remove during exhalation by gently pulling and rotating towards the patient's feet.
- vii. Remove the stoma dressing, then wipe area clean with only saline or medically packaged water.
- viii. Using the replacement tracheostomy tube's obturator or (in adults only)the bougie, gently advance the replacement tracheostomy tube in a fluid fashion, using the natural curvature of the tube until the flange is flush against the neck.
- ix. If present, remove the obturator and insert the hollow internal cannula
 - 1. Internal cannulas are not part of the most commonly used tracheostomy tubes for pediatric patients).
 - 2. If possible, use a non-fenestrated (no window) inner cannula.
 - a. Note: A fenestrated inner cannula will allow air leak through the glottis; potentially allowing air to enter the stomach and not allowing PEEP (positive end-expiratory pressure) to be achieved.
- x. If using an ETT as a replacement:
 - 1. Insert a bougie (adults only) into the stoma directed downward.
 - 2. Slowly advance the lubricated ETT into the stoma.
 - 3. Only advance the ETT a few centimeters into the stoma (as deep as the trach tube).
 - 4. Consider shortening the ETT by cutting the tube AFTER the takeoff for the pilot balloon.
- xi. Inflate the cuff of the replacement tracheostomy tube or ETT with the minimum amount of air to stop any audible leak at the stoma.
- xii. Place clean gauze around the stoma to absorb mucous.
 - 1. Never cut this gauze.

1011

Subject: Tracheostomy and Laryngectomy Care

Effective: June 1, 2021


Last Modified:


Dec. 8, 2021

- 2. Fold it to size, to avoid creating small particulates of lint that could enter the airway.
- xiii. Secure the device to the patient's neck.

c. Emergency Procedures

i. If the airway has been surgically altered and the glottis is hard to recognize, consider pushing on the chest to force air into the pharynx. Where air bubbles are seen, insert bougie (in adults) and/or insert the ETT into the opening.







General Protocol

1012

Subject: Intraosseous Infusion

Effective: June 1, 2021

Last Modified:

July 22, 2023

1012.1 General Guidelines

- a. Use of IO devices is limited to patients who are unresponsive or hemodynamically unstable; and then, only when less invasive means are ineffective or not available (e.g., IN Narcan or Versed).
- b. In patients with acceptable perfusion, and all other routes of access have failed, then consider an intraosseous access of the proximal tibia.
- c. For an adult in cardiac arrest, the preferable order of vascular access is:
 - i. External jugular (EJ) vein IV
 - ii. Antecubital (AC) vein IV
 - iii. Proximal humeral head IO (the proximal tibia is not to be used in cardiac arrest)

1012.2 Intraosseous Equipment Sizing

- A The longer yellow (45 mm) needle should be used for proximal humeral IOs in adults.
- P For pediatrics, access the proximal tibia in all cases.
 - **P** Use the blue IO needle for 3-30 kg.
 - P Use the pink IO needle for 0-3 kg.

1012.3 Clinical Management

	Assessment	
Pediatric Considerations	Signs & Symptoms	Differential Diagnosis
Consider weight for IO selection	Hemodynamically unstable patient needing vascular access with no IV	• None
	Treatment Algorithm	
IO Insertion is not an EMR skill		EMR
IO Insertion is not an EMT skill		FA
 After IO confirmation, IV pressure bags ma For the pain associated with infusion: A Lidocaine 2% 1.5 mg/kg via IO u P Lidocaine 2% 0.5 mg/kg via IO (r 	p to 100 mg.	AEMIT
No additional orders at this level		<u><</u>
	Consult	
• None		
	Clinical Pearls	
• None		
END OF SECTION		

1012 - Intraosseous Infusion Page 1 of 1



General Protocol

1013

Alternate Vascular Access

Effective: June 1, 2021

Last Modified:

July 22, 2023

1013.1 General Guidelines

Subject:

a. This guideline is not for EMR, EMT or AEMT. Only Paramedics may utilize alternative vascular routes.

1013.2 Central Vascular Access Devices (CVAD)

- a. Patients who require long-term intravascular therapy may have Central Vascular Access Devices (CVAD).
- b. CVADs may be used for IV access if the patient is hemodynamically unstable or in arrest.
 - i. Central catheter: Catheter placed through chest wall into the internal jugular or subclavian vein.
 - 1. Central catheters can be single or multilumen.
 - 2. Distal portion of catheter has two access ports, either of which may be used for access.
 - ii. PICC Line: Catheter placed in arm.
 - 1. Distal portion of catheter is external with access port.
 - 2. Do not force fluids or drugs through the device or failure could result in an embolism.
 - 3. PICC line diameter creates significant resistance to fluid flow making it difficult to infuse large quantities of fluids.
 - iii. Subcutaneously Implanted Port: Device surgically placed under the skin on the chest.
 - 1. No external access.
 - 2. PARAMEDICS ARE NOT PERMITTED TO ACCESS THIS DEVICE.

c. Complications of CVADs

- i. Infection: Thorough cleaning of the port must be done three times during the procedure:
 - 1. Before attaching each syringe
 - 2. Before attaching the IV tubing.
- ii. Air Embolism: The catheter must be clamped before attaching or removing the syringes.
- iii. <u>Heparin Bolus</u>: These catheters remain in place without fluids continually flowing through them. To prevent blood clot formation, a bolus of Heparin or other anticlotting agents will be in the catheter. Remove 5 ml of blood to insure that the Heparin is not systemically administered to the patient resulting in a potentially significant complication.
- iv. Catheter Damage:
 - 1. Use a 10 ml syringe or larger when drawing off the blood. Smaller syringes create too much pressure.
 - 2. After verifying blood return, flush catheter with 10 ml of NS with a 10 ml or larger syringe utilizing a pulsating technique.
 - 3. Administer medications slowly to avoid creating too much pressure. Do not use catheter if unable to get blood return.
 - 4. DO NOT USE A PRESSURE INFUSION DEVICE ON CVADs.

1013.3 Internal Dialysis Fistula

- a. An artificial passage between an artery and a vein used to gain access for hemodialysis.
- b. Usually located in the inner aspect of the patient's forearm or bicep.
- c. A bulge under the skin that should be visible or easily palpated.
- d. In cardiac arrest or with a profoundly unstable patient, a dialysis fistula may be used to administer IV fluids or medication.
 - i. Use aseptic technique.
 - ii. Be careful not to puncture back wall of vessel.
 - iii. Use IV pressure bag.
 - iv. Blood may still back-up into tubing.
 - v. Control bleeding with direct pressure.
- e. Dialysis patients are usually on anticoagulants.

END OF SECTION

1013 - Alternate Vascular Access Page 1 of 1



General Protocol

1014

Subject:

Pain Management

Effective: June 1, 2021

Last Modified:

Dec. 12, 2023

1014.1 General Considerations

- **a.** This protocol is for management of acute moderate to severe pain, including pain from suspected cardiac events, trauma (including thermal and chemical burns), crush syndrome, frostbite, fractures, dislocations, sprains, and abdominal pain (including unilateral flank pain).
- **b.** It is not for the treatment of exacerbations of chronic pain.
- **c.** Prehospital pain management reduces time to pain relief, avoids exacerbation of pain during movement, is compassionate, and is good medical care.
- d. Ketamine is not to be administered to patients with suspected cardiac chest pain

1014.2 Clinical Management

END OF SECTION

Assessment Differential Diagnosis Pediatric Considerations Signs & Symptoms Fentanyl is not to be administered to anyone Severity of pain (pain scale) Chronic pain less than 2 years old Quality (sharp, dull, etc.) If unable to obtain a blood pressure, look for Radiation of pain evidence adequate perfusion (skin color, Pain upon movement capillary refill and mental status) prior to Increased pain upon palpation Fentanyl administration. To account for medication remaining in the needle and syringe, add an additional 0.1 ml Fentanyl for pediatric intranasal doses. **Ketamine** not to be administered for pain to anyone less than 16 years old Fentanyl IN, is the first choice for pediatrics **Treatment Algorithm** Use ice packs, position of comfort, and splinting to reduce pain. Provide oxygen as indicated. No additional orders at this level. For an alert patient with moderate to severe pain, give **Fentanyl** for relief. Ketamine should be considered a second line medication for the management of pain If Fentanyl dosing does not relieve pain or if the patient refuses Fentanyl, then administer Ketamine ♦ Call for orders if you feel narcotics are needed for pain from a chronic condition. G For patients greater than 69 y/o, reduce dosing for sedatives and analgesics to one half ($\frac{y}{2}$) of the adult doses. A If SBP is greater than 100, then Fentanyl 50-100 mcg IV A May repeat Fentanyl 50-100 mcg IV after 5 minutes. If no IV, Fentanyl 50-100 mcg IN, SQ, or IM May repeat Fentanyl 50-100 mcg IN, SQ or IM after 10 minutes. If SBP is normal for patient's age (80 + 2 times age) or evidence of adequate perfusion then Fentanyl 1 mcg/kg IN, max 100 mcg May repeat Fentanyl 1 mcg/kg IN, max 100 mcg after 10 minutes If unable to administer IN, Fentanyl 1 mcg/kg IV, max 100 mcg P May repeat Fentanyl 1 mcg/kg IV, max 100 mcg after 5 minutes As a last resort, Fentanyl 1 mcg/kg SQ or IM, max 100 mcg May repeat Fentanyl 1 mcg/kg SQ or IM, max 100 mcg after 10 minutes Ketamine 25 mg IV A May repeat Ketamine 25 mg IV after 5 minutes If no IV, Ketamine 25 mg IN or 50 mg IM May repeat Ketamine 25 mg IN or 50 mg IM after 10 minutes No additional orders at this level. Consult MCP contact required before administration of Fentanyl for pe **Clinical Pearls** Always consider the weight of your patient when dosing pain meds, especially for the elderly. Document patient's reported pain during initial patient contact, during treatment, and after any intervention.

1014 – Pain Management Page 1 of 1



2000 Series

Cardiac Protocol



2001

Subject:

Resuscitation Guidelines

Effective: June 1, 2021

Last Modified:

Feb. 5, 2023

2001.1 Guideline

- **a.** A patient's BEST CHANCE for resuscitation is at the scene with high quality CPR and code management.
- **b.** Paramedics are expected to provide ALS resuscitative care at the scene.

2001.2 Resuscitation and Field Termination

The EMR will continue resuscitation until the patient of the second of t	t is handed off to a higher-level provider. rt. C) should be transported to an interventional transport time to a medical facility will excell if: per minute nt EtCO ₂ greater than or equal to 20 mmHg, transport to a Trauma Center.	refractory to VF or VT.
The EMT will continue resuscitation until the patient of no higher-level provider is available, then transport Patient with return of spontaneous circulation (ROS than 30 minutes. If no ALS equipment is available at the scene, and may be considered. Patients will require prolonged resuscitation efforts They have PEA with a rate greater than 40 They have an upward trending or persister of the scene of	t is handed off to a higher-level provider. t is handed off to a higher-level provider. rt. C) should be transported to an interventional transport time to a medical facility will excell if: per minute nt EtCO ₂ greater than or equal to 20 mmHg, transport to a Trauma Center.	al facility if transport time is less eed 20 minutes, field termination refractory to VF or VT.
The EMT will continue resuscitation until the patient of no higher-level provider is available, then transport Patient with return of spontaneous circulation (ROS than 30 minutes. If no ALS equipment is available at the scene, and may be considered. Patients will require prolonged resuscitation efforts They have PEA with a rate greater than 40 They have an upward trending or persister of the scene of	t is handed off to a higher-level provider. rt. C) should be transported to an interventional transport time to a medical facility will excell if: per minute nt EtCO ₂ greater than or equal to 20 mmHg, transport to a Trauma Center.	al facility if transport time is less eed 20 minutes, field termination refractory to VF or VT.
If no higher-level provider is available, then transport Patient with return of spontaneous circulation (ROS than 30 minutes. ◆ If no ALS equipment is available at the scene, and may be considered. Patients will require prolonged resuscitation efforts ○ They have PEA with a rate greater than 40 ○ They have an upward trending or persister of the profound hypothermia, then rapidly the following all appropriate efforts, field termination criteria are met: ○ 18 years or older ○ In asystole or PEA, with rates less than 40 ○ Not be in arrest due to hypothermia ○ Have an advanced airway in place ○ Have vascular access in place	rt. C) should be transported to an interventional transport time to a medical facility will excell if: per minute nt EtCO ₂ greater than or equal to 20 mmHg, transport to a Trauma Center.	refractory to VF or VT.
Patients will require prolonged resuscitation efforts	per minute nt EtCO ₂ greater than or equal to 20 mmHg, transport to a Trauma Center.	refractory to VF or VT.
The following should be transported to a cardiac int	n such as reactive pupils, response to pain or	
A documented STEMI and a witnessed car A return of spontaneous circulation (ROSC)	diac arrest	ion 30 miliaces.
	Consult	
 When the AEMT or Paramedic contacts MCP directle The duration of the resuscitation How long the patient may have been in an Whether it was a witnessed or unwitnessed The current EtCO₂ The presenting rhythm 	rest prior to EMS arrival	ey must provide the following information:
	Clinical Pearls	

END OF SECTION

In pseudo PEA, the patient may not be in true cardiac arrest, but simply not have palpable pulses due to profound shock.

Consider aeromedical transport for transports greater than 30 minutes if the patient has ROSC.

Send a copy of the run sheet to the EMS Coordinator of the authorizing MCP's hospital.



2002

Subject:

Cardiac Arrest - BLS

Effective: June 1, 2021

Last Modified:

Dec. 21, 2023

2002.1 This protocol has adopted the 2020 American Heart Association CPR Guidelines

	ADULTS	CHILDREN	INFANTS	NEWBORNS
CPR Order	CAB: Compression, Airway, Breathing			
Compression to Breaths Ratio <u>Without</u> Advanced Airway	1 or 2 Rescuers 1 Rescuer - 30:2 30:2 2+ Rescuers - 15:2		3:1	
Compression to Breaths Ratio <u>With</u> Advanced Airway	Continuous compressions at a rate of 100-120 /min. Give 1 breath every 6 seconds.	•	ns at a rate of 100-120 /min. every 2-3 seconds.	40-60 breaths/min
Compression Rate	100 to 120 per minute		120 per minute	
Compression Notes	Minimize interruptions in chest compressions. Limit interruptions to less t		than 10 seconds	
Compression Depth	At Least 2 Inches	1/3 Depth of Chest (About 2")	1/3 Depth of Chest (About 1 ½ ")	1/3 Depth of Chest
Rescue Breathing	1 breath every 5-6 seconds (10-12 breaths/min)		ery 2-3 seconds oreaths/min)	40-60 breaths/min

2002.2 Basic Life Support

Pediatric Considerations Signs & Symptoms **Differential Diagnosis** Signs of irreversible death If available, use age-appropriate AEDs or Unresponsive Pulseless and apneic Other causes of unresponsiveness **Treatment Algorithm** If witnessed or unwitnessed arrest, initiate quality CPR for 1-2 minutes If available, initiate mechanical CPR using an approved device Attach and use AED after at least 2 minutes of CPR Utilize AED as it is programmed. (Even if it is not to AHA guidelines) Repeat cycles of defibrillation and CPR for 2 minutes Patient should be transported as appropriate Patient with return of spontaneous circulation (ROSC) should be transported to an interventional facility if transport time is less than 30 minutes. Obtain and transmit 12 Lead EKG if patient has ROSC **AEMT** No additional orders at this level Paramedics are expected to provide resuscitative care at the scene. Cardiac arrests should not be transported unless: Return of spontaneous circulation (ROSC) The airway cannot be secured Vascular access is not established MCP declines to authorize Field Termination 0 Consult No consult required unless applying Field Termination Guideline **Clinical Pearls** Use jaw-thrust method to open airway on trauma patients Allow the chest to fully recoil after each compression Change person compressing chest every 2 minutes Resume CPR beginning with compressions after each defibrillation Minimize interruptions to compressions before and after each shock to less than 10 seconds For pregnant patients in cardiac arrest Consider need for manual uterine displacement In all cardiac arrests, consider the ACLS treatable causes (Hs & Ts) to your level of certification: **EMR EMT AEMT Paramedic** Hydrogen Ion Hypoxia Hypovolemia Toxins Tension pneumothorax Hypothermia Tamponade, Cardiac Thrombosis (Coronary, Pulmonary)



June 1, 2021

2003

Subject: Cardiac Arrest:

Asystole or PEA

Effective:

Last Modified:

Oct. 10, 2021

2003.1 Guideline

- a. In all cardiac arrest patients, apply the 2002 Cardiac Arrest: Basic Life Support protocol.
- b. Apply the appropriate guideline after rhythm interpretation.
- c. The rhythms may change and will require flexibility to move between the different protocols.
- d. If ROSC, then follow 2001 Resuscitation Guidelines

2003.2 Asystole or PEA

	Assessment	
Pediatric Considerations Pediatric dosing should never exceed adult doses	Signs & Symptoms Unresponsive Pulseless and apneic Either: No electrical activity on cardiac monitor Electrical activity on monitor with no pulse present	 Differential Diagnosis Ventricular Fibrillation Pulseless Ventricular Tachycardia Other causes of unresponsiveness Device (lead) error Signs of irreversible death
	Treatment Algorithm	
 Follow 2002 Cardiac Arrest -BLS present the Apply the Automatic External Defiling If no defibrillation is indicated, core Obtain and transmit {12 Lead EKG Consider possible causes 	brillator (AED) and check for a shockable rhythm. htinuous CPR	EMR EMT
	r IO, repeat every 3-5 minutes. g, IV or IO, repeat every 3-5 minutes. Termination after administering Epinephrine	Paramodic
	Consult	
 No consult required unless applying The AEMT or paramedic may considered Contact for Cardiac Alert if application 	ult MCP to field terminate	
	Clinical Pearls	
 Contact receiving hospital prior to 	arrival	
END OF SECTION		





2004

Subject: Cardiovascular Emergencies-Renal Failure/Dialysis Effective: June 1, 2021


Last Modified:

Oct. 10, 2021

2004.1 Guideline

- a. This protocol is for cardiac patients who receive renal dialysis treatment and is only to be administered by Paramedics.
- **b.** Dialysis patients who are bradycardic or experience cardiac arrest should be given both calcium (chloride or gluconate) and sodium bicarbonate.

2004.2 Clinical Management





2005

Subject: Cardiac Arrest:

V-Fib or Pulseless V-Tach

Effective:

June 1, 2021 Last Modified:

Dec. 17, 2023

2005.1 Guideline

- a. In all cardiac arrest patients, apply the 2002 Cardiac Arrest: Basic Life Support protocol.
- b. Apply the appropriate guideline after rhythm interpretation.
- c. The rhythms may change and will require flexibility to move between the different protocols.
- d. If ROSC, then follow 2001 Resuscitation Guidelines

2005.2 Alternate Defibrillation Techniques

- a. Vector Change and Double Sequential Defibrillation are optional skills in the GMVEMSC Protocol
- b. Providers SHOULD NOT apply these techniques without the explicit consent of their Medical Director.
- c. These procedures are approved for adult patients only.
- d. Vector Change Defibrillation (for Advanced EMTs and Paramedics)
 - i. This technique is for refractory ventricular fibrillation/pulseless ventricular tachycardia.
 - ii. Refractory V-Fib/PVT is defined as NOT CONVERTED by three standard defibrillations.
 - iii. The AEMT or Paramedic will place a second set of defib pads in an anterior-posterior position.
 - iv. There should be minimal interruption in CPR when placing the second set of pads.
 - v. Subsequent defibrillations will be through the anterior-posterior placed pads.
- e. <u>Double Sequential Defibrillation</u> (for Paramedics)
 - i. This technique is for refractory V-Fib/PVT following three standard defibrillations and a least one round of an antiarrhythmic agent (amiodarone or lidocaine).
 - ii. This requires the presence of two manual biphasic defibrillators.
 - iii. One set of pads will be placed in the anterior-apical (traditional) position and one set will be placed in the anterior-posterior position.
 - iv. With both sets of pads in place and both machines charged to maximum energy level, the discharge of the monitors should be as simultaneous as possible.
 - v. Repeat as indicated. All subsequent defibrillations should be double sequential.
 - vi. CAUTION: Every agency considering applying this procedure needs to consult with the manufacturer of their cardiac monitor for advice. This technique is considered "off-label".
- f. Neither Vector Change nor Double Sequential Defibrillation is indicated in Recurrent V-Fib/PVT, which is defined as V-Fib/PVT that reoccurs episodically after successful conversion with intervening episodes of organized electrical activity.

2005.3 Ventricular Fibrillation and Pulseless Ventricular Tachycardia

Assessment		
Pediatric Considerations Pediatric dosing should never exceed adult doses	Signs & Symptoms Unresponsive Pulseless and apneic Ventricular fibrillation or ventricular tachycardia on cardiac monitor or AED	 Differential Diagnosis Asystole Artifact/Device failure Signs of irreversible death Other causes of unresponsiveness
	Treatment Algorithm	
 If witnessed or unwitnessed arrest, initiate quality CPR for 1-2 minutes and proceed to first defibrillation Follow Basic Life Support protocol Defibrillate as indicated by the Automatic External Defibrillator (AED) 		
Obtain and transmit 12 Lead EKG if patient has ROSC		

2005

Subject: Cardiac Arrest:

V-Fib or Pulseless V-Tach

Effective:

June 1, 2021

Last Modified:

Dec. 17, 2023

- Defibrillate as required based on EKG interpretation
- A {For refractory V-Fib/PVT after three shocks, consider Vector Change Defibrillation for subsequent shocks}
- Consider possible causes
- Alternate between CPR/Defibrillation/Medication Administration
- A Epinephrine 1 mg 1:10,000, IV or IO, repeat every 3-5 minutes
- P Epinephrine (1:10,000) 0.01 mg/kg, IV or IO, repeat every 3-5 minutes
- After third defibrillation:
 - A Amiodarone 300 mg, IV or IO
 - P Amiodarone 5 mg/kg IV or IO (max first dose 300 mg)
 - o If Amiodarone is not available, use Lidocaine
 - A Lidocaine 150 mg, IV or IO
 - P Lidocaine 1.0 mg/kg IV or IO (max first dose 100 mg)
- A {After three traditional defibrillations and at least one antiarrhythmic medication, consider Double Sequential Defibrillation for subsequent shocks}
- After sixth defibrillation:
 - A Amiodarone 150 mg, IV or IO
 - P Amiodarone 5 mg/kg IV or IO (max first dose 150 mg)
 - o If Amiodarone is not available, use Lidocaine
 - A Lidocaine 75 mg, IV or IO
 - P Lidocaine 1.0 mg/kg IV or IO (max first dose 75 mg)
- If patient converts with ROSC from a ventricular arrhythmia and no anti-arrhythmic has been given, then:
 - A Amiodarone 150 mg in 250 ml NS, IV over 10 minutes using 60 drop/ml tubing
 - Do not infuse unless SBP is greater than 100
 - Consider IV fluid 500 ml to increase SBP to 100 or higher prior to infusion

Consult

- The AEMT or Paramedic may consult MCP to field terminate
- Contact for Cardiac Alert if applicable

Clinical Pearls

- For initial and subsequent defibrillations, follow manufacturer recommendation for energy settings
- Pediatric defibrillation settings will start at 2 J/kg (or biphasic equivalent) and increase by 2 J/kg (or biphasic equivalent) each shock.
- Maximum pediatric shock will be 10 J/kg (or biphasic equivalent)
- Resume chest compressions immediately following each defibrillation, without performing pulse check, for 1-2 minutes
- Contacting receiving hospital prior to arrival.

END OF SECTION

AEMT

2006

Subject: AICD Activations

Effective: June 1, 2021

Last Modified:

May 17, 2023

2006.1 General Guidelines

a. A patient experiencing repeated AICD (Automatic Implantable Cardioverter-Defibrillator) activations should receive sedation or pain management from the AEMT or Paramedic.

2006.2 Clinical Management

	Assessment			
Pediatric ConsiderationsNone	 Signs & Symptoms AICD in place and firing Sudden pain Muscle spasms 	Differential DiagnosisNone		
	Treatment Algorithm			
 Monitor and be prepared to provide BLS care. Be prepared to defibrillate in the event of AICD 	failure.		EMR	
Monitor and transport as indicated.Consider calling for ALS care.			EMT	
 Be prepared to defibrillate in the event of AICD Midazolam 2.5 mg slow IV for sedation. Consider 1014 Pain Management Protocol. G For patients greater than 69 y/o, reduce dosing 	failure. for sedatives and analgesics to one half ($\frac{1}{2}$) of t	ne adult doses.		AEMT
Be prepared to manually cardiovert in the even	t of AICD failure.			Paramedic
	Consult			
• None				
	Clinical Pearls			
None				
END OF SECTION				•



2007

Subject: Ventricular Assist Devices

June 1, 2021

Last Modified:

Dec. 23, 2021

2007.1 General Guidelines

- a. It is important to recognize the patient with a ventricular assist device (VAD).
- b. Routinely, your agency will be advised when a VAD patient is in your community.
- c. Otherwise, these patients could be travelling through, or visiting in your jurisdiction.

Effective:

d. The patient or family members are generally knowledgeable about the VAD and how to troubleshoot it.

2007.2 Assessing the VAD Patient

- a. Skin color and mental status are the best indicators of stability in the VAD patient.
- b. A pulse is usually not palpable in the VAD patient. Nearly all VADs are continuous flow devices.
- c. If the device is a pulsatile flow device, a pulse should be palpable.
- d. Blood pressure may or may not be obtainable and auscultated readings are usually unreliable.
 - i. In a continuous flow device, mean arterial blood pressure (MAP) can be obtained by auscultating with a {Doppler}.
 - ii. The first sound heard during auscultation reflects the MAP.
 - iii. The MAP displayed by an automated non-invasive measurement may also be used.
 - iv. A normal MAP is 65 90 mmHg.
 - v. If the device is a pulsatile flow device, a blood pressure should be measurable.
- e. Pulse oximetry readings seem to be accurate, despite the manufacturer stating otherwise.
- f. Quantitative waveform capnography should be accurate and can be reflective of cardiac output
- g. An EtCO₂ of less than 30 mmHg can be indicative of low perfusion secondary to poor pump function.
- h. {ECG 12-lead} as usual, no interference from the VAD is expected
- i. Temperature should be measured as infection and sepsis are common.

2007.3 Transporting the VAD Patient

- a. Patients with or without a VAD problem should be transported to the nearest appropriate Hospital ED.
- b. Do NOT delay ground transportation waiting to speak with the patient's VAD Coordinator.
- c. Always bring the patients resource bag with you. It should contain:
 - i. Spare batteries and a battery charging unit
 - ii. Spare control unit
 - iii. Contact information for the VAD Coordinator.
 - iv. Directions for equipment and alarm troubleshooting.
- d. Always bring spare batteries for the VAD with the patient, even if it is not a VAD related problem.
- e. If the transport is going to be prolonged or it is expected that the patient will be away for a while, try to bring the VAD base power unit with you.
 - i. Alternately, you can ask the patient's family/caregiver to bring it to the hospital.
 - ii. There may be a need to bring it with the patient and plug it into an inverter for power.

2007 - Ventricular Assist Devices Page 1 of 2

2007

Subject:

Ventricular Assist Devices

Effective: June 1, 2021

Last Modified:

Dec. 23, 2021

2007.4 Clinical Management

	Assessment		
iatric Considerations	Signs & Symptoms	Differential Diagnosis	
None	VAD equipment	• None	
	VAD vests or battery packs		
Determine if you have exacting to the WAD	Treatment Algorithm	adical/harman analdana	
Determine if you have a patient with a VAD pro			
If there is no indication of possible VAD malfur Assess the VAD:	iction or failure, exit to appropriate protoco	ols.	
	ion (Should be just to the left of the epigasti	rium, immediately helew the heart)	
·	a low hum should be audible.	indini, inimediately below the heart)	
, ,	mp is functioning just because the control u	unit does not indicate a problem	
 Palpate the control unit. 	mp is runetioning just because the control of	mile does not indicate a problem.	
•	s the pump may be working harder than it sl	hould be	
	p problem such as a thrombosis.		
 Look at the alarms on the control page 			
■ Trouble with the VAD will u	usually be identified by an alarm.		
 The patient will usually have 	ve a resource guide to direct alarm troublesl	hooting.	
 Ask if the device is a continuous or p 	ulsatile flow device.		
 Ask if the patient can receive electric 	cal therapy.		
 Ask if chest compressions can be per 	formed in the event of pump failure.		
Inquire about DNR status.			
If there is indication of possible device malfund			
 Attempt to restart VAD if previously 			
o If VAD off longer than 5 minutes, the			
•	gency Contact Card"/VAD ID Card		
Contact the VAD coordinat Discuss the plan with according.	or.		
O Discuss the plan with caregivers.	with a non-functioning VAD and has proving	usly indicated a desire for resuscitative	
If a VAD patient is unresponsive and pulseless efforts, begin chest compressions.	with a non-functioning VAD and has previou	isly indicated a desire for resuscitative	
AVOID THE USE OF MECHANICAL CPI	P DEVICES		
 Defibrillation pads should be placed 			
·	ts (reconnecting wires, changing batteries, r	replacing the control unit) have failed	
prior to starting chest compressions.			
Follow BLS protocol.		EMR	
Transport urgently.			
No additional directives at this level.			EMT
No additional directives at this level.			A E MT
Only symptomatic dysrhythmias not at the pat			
If indicated, place electrical therapy/defibrillat	ion pads away from VAD site and AICD.		
VAD patients may receive ACLS interventions.	Consult		
None	Consult		
	Clinical Pearls		

- Utilize the patient and family as a resource.
- Always contact the VAD Coordinator if there is a VAD related problem or question.
- Common complications in VAD patients include stroke (incidence up to 25%), bleeding, dysrhythmias, and infection.
- The most common causes of death in VAD patients are sepsis and stroke. Consider this with a VAD patient showing altered mental status.
- VAD patients are preload dependent. Consider that a fluid bolus can often reverse hypoperfusion.

END OF SECTION

2007 - Ventricular Assist Devices Page 2 of 2

Subject:

Suspected Cardiac Chest Pain

Effective: June 1, 2021 Last Modified:

Feb. 13, 2023

2008.1 **General Guidelines**

Unstable cardiac patients are hypotensive, or have chest pain with poor skin color or diaphoresis.

2008.2 **Clinical Management**

	Assessment	
ediatric Considerations	Signs & Symptoms	Differential Diagnosis
Chest pain in the pediatric patient is rarely related to a cardiac event. Assessment for other causes (e.g., muscle pain, respiratory difficulties, injury) should be completed to determine the source of pain. Apply supplemental oxygen and transport.	 Chest pain Shortness of breath Syncope Pallor, Diaphoresis Radiation of pain Weakness 	 Pericarditis Pulmonary embolism Asthma/COPD Pneumothorax Aortic dissection or aneurysm GE reflux or hiatal hernia
THE REST OF CHEST PAIN ALGORITHM DOES NOT APPLY TO PEDS.	Nausea Vomiting	Chest traumaEsophageal spasm
	Treatment Algorithm	

- - Oxygen saturations less than 94%, should be given oxygen via NC and titrated to 94%.
 - Oxygen saturations 94% or higher, should not get any oxygen.
- Do not withhold oxygen from a patient with SOB or respiratory distress.
- ♦ Give Aspirin (ASA) 324 mg (chewed) to every patient greater than 25 y/o with symptoms of Acute Coronary Syndrome (ACS).
- ◆ Administer Nitroglycerin 0.4 mg SL, every 5 minutes, for pain, to a total of three pills with vital signs between doses.
 - SBP must be greater than 100.
 - Patient must be greater than 25 y/o.
- Prior to moving patient, acquire a supine {12-lead EKG} on all patients with ACS symptoms.
- {Transmit 12 Lead EKG} with two identifiers to MCP.
- The MCP shall be contacted after at least the initial {12-lead EKG transmission} is completed.
- Consult MCP for appropriate destination.
- Consider and transmit repeat {12-lead EKGs} during transport.
- ◆ Must obtain MCP permission to administer Aspirin (ASA) to patients 25 y/o or younger
- The AEMT must also transmit the {12-Lead EKGs}
- Administer Nitroglycerin 0.4 mg SL, every 5 minutes, for pain, to a total of three pills with vital signs between doses.
- Prior to Nitroglycerin administration, establish vascular access for patients who have not previously had Nitroglycerin.
- Consider 1014 Pain Management Protocol, provided SBP greater than 100 after first dose of nitroglycerin.
 - DO NOT WAIT UNTIL 3 NITROGLYCERIN TABLETS ARE GIVEN BEFORE CONSIDERING FENTANYL.
- IV fluid, up to 500 ml, may be administered to a patient with SBP less than 100 without pulmonary edema.
- Treat cardiogenic shock with or without pulmonary edema as identified in 4016 Shock.
- If evidence of STEMI, transport to an interventional cardiac catherization lab.
- The Paramedic should only transmit a {12-lead EKG} that meets Cardiac Alert criteria, or that is questionable.

Consult

- Without consultation, the Suspected Cardiac Chest Pain protocol only applies to patients greater than 25 years old with ACS symptoms.
- Contact MCP for further advice with pediatric chest pain as needed.
- For the EMT, the following requires MCP orders:
 - Aspirin administration
 - Nitroglycerin administration 0
 - Accessing the GMVEMSC Drug Bag

Clinical Pearls

- No significant change in patient condition in the field should be expected from the administration of Aspirin.
- Patient must chew Aspirin.
- Aspirin is contraindicated in third trimester of pregnancy.
- Do not administer Nitroglycerin (NTG) if the patient has taken Viagra, Cialis, Levitra, Revatio, or similar medications within the last 24 hours.



2009

Subject: Cardiac Alert Program

Effective: June 1, 2021

Last Modified:

Jan. 9, 2023

2009.1 General Guidelines

- a. The intent of the Program is to decrease the "Door to Balloon" time for pre-hospital AMI Patients.
- b. Providers will make early notification to the receiving facility and speak directly with the Physician.
- c. The Physician may activate a Cardiac Alert, based on provider impression and {12 Lead EKG} interpretations.

2009.2 Inclusionary Criteria

- a. Patients presenting with anginal-type chest pain or an equivalent anginal event may be candidates.
- b. Evidence of an AMI (greater than 1mm ST elevation in 2 contiguous leads) on a diagnostic {12-lead EKG}.

2009.3 Exclusionary Criteria

- a. Patient with a Left Bundle Branch Block (QRS greater than 120 milliseconds).
- b. Patients with a pacemaker rhythm.

2009.4 Clinical Management

	Assessment	
Pediatric Considerations Consider differential diagnosis	Signs & Symptoms	 Differential Diagnosis None in the presence of ACS symptom Chest trauma Pulmonary issues Cardiac Alert imitators on 12 Lead EKG
	Treatment Algorithm	
 Contact the receiving hospital for further Acquire serial {12 Lead ECGs} enroute to The recommendation is to represent the consider applying defibrillation pads to describe the consideration and described the cons		ange in condition/presentation)
	of up to 500 ml to manage cardiogenic shock.	ntional facility.
 If patient develops significant bradycard Monitor blood pressure and administer If patient is still hypotensive after other 		250 ml of IV fluids. Infuse starting at 30
	Consult	
The Paramedic is expected to read and in	MCP after {12 Lead EKG} transmissions for further on terpret the {12-lead EKG}. uter interpretation or expect the physician to inter Clinical Pearls	
 To determine the regional interventiona Rerouting at interventional facilities doe Consider air medical transport if the inte Exceptions to transporting to an intervention It is medically necessary to 	rventional facility is over 30 minutes away.	stabilization.

END OF SECTION

2009 – Cardiac Alert Program Page 1 of 1

Transporting the patient to would cause a critical shortage of local EMS resources. Patient requests transport to a different facility, despite EMS education of patient.



2010

Subject: Bradycardia

• None
END OF SECTION

Effective: June 1, 2021

Last Modified:

Feb. 11, 2024

2010.1 General Guidelines

- a. Bradycardia is any rate less than 60 bpm.
- b. Non-symptomatic bradycardia may be a normal finding in otherwise healthy individuals.
- c. Assess the patient and determine medical history.
- d. Treat unexplained or symptomatic bradycardia

2010.2 Clinical Management

Assessment Pediatric Considerations Signs & Symptoms **Differential Diagnosis** With adequate perfusion, monitor vital signs, Heart rate less than 60 bpm Acute myocardial infarction and apply oxygen if needed. Syncope Hypoxia Hypoxia in pediatric patients will produce Unstable bradycardia Hypothermia bradycardia. 0 Hypotension Elevated ICP (Stroke or Trauma) 0 Altered mental status Spinal cord lesion 0 Unresolved chest pain Sick sinus syndrome 0 Poor skin color Athletic patients Diaphoresis **Treatment Algorithm** Administer oxygen as indicated. Call for transport immediately. EMR For adequate perfusion, observe and monitor vital signs. Obtain {12-lead EKG}, transmit and call receiving facility. Transport immediately unless ALS intercept is less than 5 minutes. For Pediatric patients less than 2 years old: Look for signs and symptoms of shock or hypoperfusion Secure the airway and ventilate with BVM at 1 breath every 3-4 seconds If heart rate and perfusion do not increase within 30 to 60 seconds, then perform CPR AEMT No additional orders at this level. Obtain and interpret {12 Lead EKG} Wide complex bradycardia patients should spark consideration of treatment of hyperkalemia. A ◆ Administer both Calcium Chloride 10% 1 g (Calcium Chloride or Gluconate) and Sodium Bicarbonate 100 mEq. Flush well between these medications. It is critical that these drugs not be given together, as they will precipitate. With evidence of poor perfusion in adults and atrics: A Consider Atropine 1 mg IV, up to total of 3 mg. If treatments are ineffective begin pacing: A If time permits, Ketamine 25 mg IV (preferred method) or Midazolam 2.5 mg slow IV prior to pacing. A DO NOT reduce Ketamine or Midazolam doses by half for patients greater than 69 y/o A Set at 70 BPM, 20 mA and increase until mechanical capture is obtained. Epinephrine (1:10,000) 0.01 mg/kg, IV, repeat every 5 minutes Consider Atropine 0.02 mg/kg IV (minimum dose 0.1 mg, maximum single dose 0.5 mg) May repeat dose every 5 minutes. Max total dose of 1 mg. Consider pacing: Pediatric electrodes should be used on patients less than 15 kg. Consider Midazolam 0.1 mg/kg (max dose 2.5 mg) slow IV prior to pacing. Start with 5 mA increasing as needed to 200 mA at a rate of 80 bpm until capture. Consult The paramedic will consult for administration of Calcium Chloride 10% (or Gluconate) and Sodium Bicarbonate. **Clinical Pearls**

2010 – Bradycardia Page **1** of 1



2011

Subject: Tachycardia

Effective: June 1, 2021


Last Modified:

Feb. 11, 2024

2011.1 General Guidelines

- a. Tachycardia is any heart rate greater than 100 bpm.
- b. Assess the patient and determine medical history.
- c. Treat unexplained or symptomatic tachycardia

2011.2 Clinical Management



END OF SECTION

2011 - Tachycardia

Page **1** of **1**



3000 Series

Trauma Protocol



Trauma Protocol

3001

Subject:

General Trauma Management

Effective: June 1, 2021


Last Modified:

Feb. 11, 2024

3001.1 General Guidelines for Care of a Trauma Patient

- **a.** Minor trauma patients may be transported to non-trauma centers.
- b. Major trauma patients are to be transported as soon as possible to the nearest appropriate facility.
- **c.** Scene size-up, with rapid assessment and recognition of major trauma/multiple system trauma and effective evaluation of the mechanism of injury are essential to the subsequent treatment.
- d. If patient meets criteria as defined in 3018 Trauma Transport Guidelines, then call "Trauma Alert".
- e. If transporting by helicopter, ensure a copy of the patient care report gets to the receiving facility.

3001.2 Clinical Management





Trauma Protocol

3002

Subject:


Major Trauma

Effective: June 1, 2021

Last Modified:

Feb. 11, 2024

3002.1 Clinical Management



END OF SECTION

3002 – Major Trauma Page 1 of 1



3003

Subject: Glasgow Coma Score

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

3003.1 General Guideline

a. When assessing the level of consciousness, use the Glasgow Coma Score.

b. All patients should have at least one recorded and reported GCS.

	LESS THAN 2 YEARS OLD		ADULT & PEDIATRIC OVER 2 YEARS	OLD
	SPONTANEOUSLY	4	Spontaneously	4
EYES	TO VOICE	3	To voice	3
ETES	TO PAIN	2	TO PAIN	2
	NO RESPONSE	1	NO RESPONSE	1
	COOS, BABBLES	5	ORIENTED	5
	IRRITABLE CRY, CONSOLABLE	4	Confused	4
VERBAL	CRIES TO PAIN	3	INAPPROPRIATE WORDS	3
	MOANS TO PAIN	2	GRUNTS, GARBLED SPEECH	2
	NO RESPONSE	1	NO RESPONSE	1
	NORMAL MOVEMENTS	6	OBEYS COMMANDS	6
	WITHDRAWS TO TOUCH	5	LOCALIZES PAIN	5
NACTOR	WITHDRAWS TO PAIN	4	WITHDRAWS TO PAIN	4
MOTOR	FLEXION (DECORTICATE)	3	FLEXION (DECORTICATE)	3
	EXTENSION (DECEREBRATE)	2	EXTENSION (DECEREBRATE)	2
	NO RESPONSE	1	No response	1

END OF SECTION

3003 – Glasgow Coma Score Page 1 of 1



3004

Subject: Trauma Arrest

Effective: June 1, 2021

Last Modified:

Feb. 5, 2023

3004.1 General Guidelines

- a. Traumatic cardiac arrest care will follow the same algorithm as other cardiac arrest scenarios.
- **b.** If appropriate, providers may consider termination of resuscitation (TOR).

3004.2 Termination of Resuscitation

- a. Emergency medical responders (EMRs) may <u>not</u> terminate a trauma cardiac arrest.
- b. The criteria for termination of resuscitation in arrest from blunt or penetrating trauma is:
 - i. No immediately reversible cause can be determined after rapid primary survey and treatment.
 - ii. No signs of life after BLS (e.g. respiratory effort, purposeful movement, reactive pupils, etc.)
 - iii. Sustained EtCO₂ of below 10 mmHg
 - iv. If no ALS equipment is available at the scene and transport will exceed 20 minutes.
- c. Continue care and transport if patient arrests after in the care of EMS.

3004.3 Clinical Management

Assessment **Pediatric Considerations** Signs & Symptoms **Differential Diagnosis** If the pediatric patient does not meet non-Cardiac arrest with traumatic injury or Signs of irreversible death initiation criteria, then begin resuscitation. significant mechanism of injury Other causes of unresponsiveness Unresponsive, pulseless and apneic Meets 1003 Non-initiation of Care Protocol Excessive hemorrhage **Treatment Algorithm** Initiate basic life support as defined in 2002 Cardiac Arrest – BLS Internal/External hemorrhage control (e.g., tourniquets, pelvic binders, etc.) Consider the possibility of both medical and traumatic causes (mixed mechanisms). Initiate a Rapid Primary Survey for reversible causes. TREATMENT OF REVERSIBLE CAUSES SHOULD BE A PRIORITY. Cardiac monitoring/defibrillations via AED. ◆ Consider Termination of Resuscitation. (AEMT and Paramedic will continue through the algorithm before termination). Continue treating any organized rhythm with rate greater than 40 because of the potential of pseudo-PEA. Secure airway and confirm with continuous EtCO₂. Bilateral needle decompression as indicated (ex. high airway resistance, chest trauma, subcutaneous air). Fourth or fifth intercostal space in the mid-axillary line Second or third intercostal space in the mid-clavicular line (use nipple line as a guide) In patients less than 8 years old, decompression site choice will be limited to the 2nd or 3rd intercostal space at the mid-clavicular line Repeat needle decompression as indicated (continued high airway pressure). Administer rapid IV fluid administration: Administer up to 1000 ml IV fluid If ROSC is achieved, transport immediately. No additional orders at this level Consult Contact MCP for Field Termination Be ready to provide the following information: Duration of resuscitation How long the patient was in arrest prior to EMS arrival 0 Witnessed or unwitnessed cardiac arrest Capnography values Presenting rhythm (for AEMT and Paramedic) **Clinical Pearls** For pregnant patient in arrest consider manual uterine displacement In field terminations, send a copy of the run sheet to the EMS Coordinator of the authorizing MCP's hospital **END OF SECTION**

3004 – Trauma Arrest Page **1** of 1



3005

Subject:

Burns and Smoke Inhalation

Effective: June 1, 2021

Last Modified:

Dec. 17, 2023

3005.1 General Guidelines

- a. It is strongly recommended that at dispatch, agencies immediately call for the nearest available cyanide antidote cache whenever any of the following occur:
 - i. Dispatched on a report of a person trapped with exposure to fire or smoke in an enclosed area.
 - ii. Dispatched on a report of an incident involving cyanide.
 - iii. Report of a Mayday or firefighter down with exposure to fire or smoke in an enclosed area.
- b. Estimate and report total Body Surface Area (BSA) involved using universally accepted methods.
 - i. BSA estimates should include only full and partial thickness burns.
- c. Inhalation injuries with an unsecured airway should be transported to the nearest facility.
- d. Chemical burns are hazardous material situations and must be grossly decontaminated at the scene.

3005.2 Specific Care for Different Burns

- a. Radiation burns:
 - i. If there is radioactive material on the patient, then they must be decontaminated.
 - 1. Consider contacting a Hazardous Materials Team for assistance with decontamination.
 - 2. Contact the hospital prior to arrival like with any other hazardous materials case.
 - ii. Treat critical medical conditions first.
 - iii. Treat injuries like thermal burns once the area is decontaminated

3005.3 Clinical Management

	Assessment	
ediatric Considerations None	Signs & Symptoms Burns, pain, swelling Loss of consciousness Hypotension/shock Airway compromise/distress Singed facial or nasal hair Hoarseness/wheezing	Differential Diagnosis
	Treatment Algorithm	
Keep patient warm. Superficial or partial thicknes Burns greater than 10% BSA Do <u>not</u> apply ice or ice packs	ster high flow oxygen via non-rebreather mask. s burns 10% BSA or less may have wet dressings applied. may be covered with clean, dry sheets or dressings. to burns, if ice was applied prior to arrival, then remove. from injured parts. Do not remove items which have adhered	to the skip
If available deliver {humidifie	d} oxygen.	Į.
	midifier is available, administer Saline 3 ml via nebulizer. Repea	at PRN
Apply cardiac monitor, espect Provide endotracheal intuba	ially if patient has suffered a lightning strike or electrical burn.	
	tion it apheic. I perfusion, do not overhydrate. Fluids should be a balanced ele	ectrolyte solution when available
	areas with burnt tissue if necessary and before intraosseous ne	
Consider 1014 Pain Manager	· · · · · · · · · · · · · · · · · · ·	
Early intubation as indicated	Do not wait for complete airway obstruction or respiratory arr	est.
•	nide poisoning, use 3014 Cyanide Poisoning and Antidotes	
	Consult	
None		
	Clinical Pearls	
	nould be transported to a Burn Center unless ETA greater than 3	

END OF SECTION

BP may be taken over damaged tissue if no other site is accessible.



3006

Subject:

Carbon Monoxide Poisoning

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

3006.1 Clinical Management

	Assessment	
Pediatric Considerations None	Signs & Symptoms Malaise, fatigue, drowsiness Flu like symptoms Headache Dyspnea Nausea/vomiting Diarrhea Abdominal pain Syncope Seizures	Differential Diagnosis Flu/Severe cold Chronic fatigue Myocardial infarction Diabetic crisis Altitude sickness Ingested toxins Hypothyroidism
	Treatment Algorithm	
 Remove patients from the environment of the provide high flow O₂ to all suspect of the provide h	ted carbon monoxide poisonings. dings and should not be utilized. considerations.	EMR EMT
	Consult	
 Look to Medical Control for guida 		
	Clinical Pearls	
Underlying cardioGreater than 60 years	cal symptoms, such as any interval of unconsciousness, lo	ess of breath

END OF SECTION



3007

Subject:

Crush Syndrome Trauma

Effective: June 1, 2021

Last Modified:

Dec. 23, 2023

3007.1 Clinical Management

total adu	ric medication doses should exceed	Signs & Symptoms Patient entrapped Patient under a heavy load and crushed Hypotension Hypothermia Abnormal ECG findings Pain Anxiety	Differential Diagnosis ● None		
▲ Contact					
▲ Contact		Treatment Algorithm			
Prepare f	MCP immediately and prior to relieving the patient to decompensate when and reassess	ng the load.		EMR	
{12-lead	CG} as soon as feasible			TANG	
A P ◆ Conside A G P Monitor t	nsive and the patient has been entraped Give additional IV fluid, 1 liter IV. Give additional IV fluid, 20 ml/kg IV. It sedation: Ketamine 250 mg IM, may repeat after For patients greater than 69 y/o, reduce the sedation or fluid overload Gand hemodynamically stable, immessedium Bicarbonate 100 mEq IV	er 10 minutes ace dosing for sedatives and analgesics to one half 250 mg	(½) of the adult doses		AFMT
	ECG and hemodynamically unstable: If after release, hyperkalemia causes Peaked T waves with a ORS	wide bizarre EKG complexes with: greater than or equal to 0.12 seconds			
	 QT ≥ 0.46 seconds Loss of P wave Bundle Branch Blocks Premature ventricular conti Bradycardia 	actions			
0 0 A P	◆ Consider Calcium Chloride, 1 gm, floatherol 10 mg nebulized Sodium Bicarbonate 100 mEq IV Sodium Bicarbonate 1mEq/kg IV	ush line well before Sodium Bicarbonate			
Contact N	ACD immediately and prior to relieving	Consult			
MCP orde	MCP immediately and prior to relieving ers needed for sedation. nedic must call MCP for orders to give	Calcium Chloride to the unstable patient. Clinical Pearls			

END OF SECTION

Consider the potential for multiple system trauma Consider the potential for hypo or hyperthermia



3008

Subject:

Cyanide Poisoning & Antidotes

Effective: June 1, 2021

Last Modified:

Feb. 18, 2024

3008.1 General Guidelines

- a. Cyanide antidotes are located in multiple caches in each of the counties throughout the region, and are available by contacting 937-333-USAR (8727).
- b. The cache agency closest to your incident will be dispatched, which will respond with both a Cyanokit and 3 doses of Sodium Thiosulfate, to provide for the potential of multiple patients.


3008.2 Indications To Call For The Cache

- a. It is strongly recommended that agencies immediately call for the nearest available cyanide antidote cache at the time of dispatch whenever any of the following occur:
 - i. Report of a person trapped with exposure to fire or smoke in an enclosed area.
 - ii. Report of an incident involving cyanide.
 - iii. Report of a Mayday or firefighter down with exposure to fire or smoke in an enclosed area.

3008.3 General Treatment

a. Treatment of cyanide poisoning must include immediate attention to airway patency, adequacy of oxygenation and hydration, cardiovascular support, and management of any seizure activity.

3008.4 Clinical Management





3008

Subject:

Cyanide Poisoning & Antidotes

Effective: June 1, 2021

Last Modified:

Feb. 18, 2024

Clinical Pearls

- If a patient is in arrest, administer Hydroxocobalamin as quickly as possible.
- Only CAB, defibrillation, intubation, and epinephrine should precede use of the cyanide antidotes.
- Hydroxocobalamin is incompatible with numerous drugs including Diazepam.
- Whenever possible establish two IV lines in a different vein or limb, one for standard protocol drugs and one for cyanide antidotes.
- While IV infusion is the preferred method of cyanide antidote administration, in extreme cases the medications could be given via IO.
 - If administering cyanide antidotes via IO, a traditional drip set may not be effective and measures may need to be taken to slowly push the medication in.

3008.5 Pediatric Dosing Chart

Weight (kg)	5	10	15	20	25	30	35	40	50	60	>70
Dose (mg)	350	700	1050	1400	1750	2100	2450	2800	3500	4200	5000
Amount needed for 70mg/kg	14 ml	28 ml	42 ml	56 ml	70 ml	84 ml	98 ml	112 ml	140 ml	168 ml	200 ml

END OF SECTION

3009

Subject: Drowning

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

3009.1 Clinical Management

	Assessment	
Pediatric Considerations None	Signs & Symptoms History of submersion Period of unconsciousness Decreased or absent vital signs Vomiting Coughing	 Differential Diagnosis Trauma Pre-existing medical problem Barotrauma (diving) Decompression sickness
	Treatment Algorithm	
Evaluate neurological status.	ia. If present follow <u>3016 Hypothermia</u>	EMR
 Drowning patients should be tran 	sported to a Trauma Center.	
• Establish vascular access.		AEMT
No additional orders at this level		
	Consult	
• None		
	Clinical Pearls	

3009 - Drowning Page 1 of 1



3010

Subject:

Extremity Injuries

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

3010.1 Clinical Management

	Assessment				
Pediatric ConsiderationsNone	Signs & Symptoms Deformities Inflammation Pain upon movement Immobility Paresthesia	Differential Diagnosis ● None			
	Treatment Algorithm				
	t pressure and cover with dry, sterile dressing. es are absent, apply gentle traction in an attempt to untered, splint the extremity in the angulated posit	_	EMR	1	
Consider 1014 Pain Management Protocol				AEMT	Paramedic
No additional orders at this level					Parar
	Consult				
None					
	Clinical Pearls				

- Document distal motor, sensation and circulation before and after splinting, or spinal motion restriction.
- Open wounds should be covered with a sterile dressing before splinting.
- Immobilize above and below the injury.
- The patient who requires a load and go approach can be adequately immobilized by careful packaging on the long spine board. Do additional splinting enroute to the hospital as time and the patient's condition permit.

END OF SECTION

3010 – Extremity Injuries Page 1 of 1



3011

Subject:

Eye Injuries

Effective: June 1, 2021

Last Modified:

Oct. 11, 2021

3011.1 Clinical Management

	Assessment			
Pediatric Considerations None	 Signs & Symptoms Irritation to eye Visual disturbances or loss of vision Obvious penetrating injury Burns Nausea 	Differential DiagnosisHypertensionContact lens issue		
	Treatment Algorithm			
Use nasal cannula with IV tubing for ir Chemical Burns: Irrigate immediately with IV Determine chemical involved Major Eye Trauma: Do not irrigate if there is per Cover both eyes to limit mov	fluid or water for a minimum of 30 minutes or until pation. d. Bring Safety Data Sheets, if available. netrating trauma to the eye. vement. norbent dressing on or near any eye that may have ruptu		EMR	
No additional orders at this level.			EMT	
No additional orders at this level.				AEMT
- The state of the	gnificant eye pain, Tetracaine 2 drops in affected eye. aine if penetrating trauma to the eye is present. ith IV tubing for irrigation.			
	Consult			
• None				_
None None	Clinical Pearls			

3011 – Eye Injuries Page 1 of 1



3012


Subject: Frostbite

Effective: June 1, 2021

Last Modified:

Dec. 8, 2020

3012.1 Clinical Management



3012 - Frostbite Page 1 of 1



3013

Subject:

Head Injury

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

3013.1 Clinical Management

	Assessment	
Pediatric Considerations Assess the fontanelles in younger patients	Signs & Symptoms Visible head trauma Altered LOC Cushing's Triad or similar V/S Ataxic Respirations Increased B/P Bradycardia Pupillary changes Posturing	Differential Diagnosis Alcohol/Acidosis Epilepsy/Endocrine Infection Overdose/Oxygen Deficiency Uremia Tumor Insulin Psychogenic/Poison Stroke/Shock
	Treatment Algorithm	- Stroke/Shock
 Evaluate level of consciousness, pupillary size Establish Glasgow Coma Score and reassess fr Ventilate at 20 breaths per minute when signs {Ventilate to maintain EtCO₂ reading Never ventilate at less than 8 per m P Ventilate at a rate of ten faster than normal reads 	equently. s of cerebral herniation are present: gs of 30 mmHg (30 torr)}. inute.	rniation are present.
 No additional orders at this level 		L EM
No additional orders at this level		AEMT
No additional orders at this level		
	Consult	
• None		
	Clinical Pearls	
Signs of cerebral herniation: Dilated and unreHyperventilation will decrease intracranial pre		eased mental status.

END OF SECTION

3013 – Head Injury Page 1 of 1



3014

Subject:

Heat Exposure

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

3014.1 Clinical Management

	Assessment	
Pediatric Considerations May not exhibit typically Do not thermoregulate well	Signs & Symptoms History of heat exposure Cramping Hot or flushed skin Excessive sweating Nausea/vomiting Mental status changes	Differential Diagnosis Thyroid storm Excited delirium Malignant hyperthermia Alcohol Epilepsy Insulin Trauma Infection Psychosis Stroke
	Treatment Algorithm	
 Apply cold packs to underarms and g Cold water submersion is an accepta bags. The goal is to lower temperatu If conscious and not vomiting or extr Be prepared for seizures 	ole method for cooling heat stroke patients. You may re to less than 102.5°F	encounter patients in cooling body
Hyperthermia patients should be training.		T T
If hypotensive or mental status change A IV fluid 500 ml IV P IV fluid 20 ml/kg IV (max 5) May repeat both adult and pediatric Additional IV fluid, if indicated Consider other medical conditions (e)	500)	AEMT
No additional orders at this level		
	Consult	
 For additional (more than 2) fluid cha 	ullenges in adults	
	Clinical Pearls	
Other contributory factors may incluHeat exposure can occur due to incre	patients with a history of spinal injury, and diabetics of the heart medications, diuretics, cold medications, and eased environmental temperatures, prolonged exercises	psychiatric medications

END OF SECTION

3014 – Heat Exposure Page 1 of 1

Environments with temperatures above 90°F and humidity over 60% present the most risk



3015

Subject:

Hemorrhage Control

Effective: June 1, 2021

Last Modified:

Feb. 13, 2023

3015.1 Clinical Management

	Assessment				
ediatric Considerations	Signs & Symptoms	Differential Diagnosis			
None	Significant bleeding	• None			
	Shock-like symptoms				
	Treatment Algorithm				
Control of life-threatening external hemorrhag		n+			
Control of the threatening external hemorriag	e takes priority over any other treatmen	ιτ.			
Constant, direct pressure is the primary metho	d of bleeding control.				
If direct pressure fails to control bleeding from	· · · · · · · · · · · · · · · · · · ·				
 {Commercial tourniquets such as the 	•				
· · · · · · · · · · · · · · · · · · ·	cravats or BP cuffs as improvised tournic	•			
 Place a tourniquet as proximal as pos Tighten the tourniquet until the bleed 	ssible to the torso on the femur or hume	ı us			
	urniquet abutted to the first tourniquet				
 Document time and location 	arringact abatted to the mot touringact				
 Be sure that the ER staff is aware of t 	he tourniquet				
{For life-threatening hemorrhage that can't be	controlled by tourniquets, consider hen	nostatic dressings}.			
 Combat Gauze, or ChitoFlex PRO are 	examples				
 These can be used on the chest or ab 					
	e of bleeding and apply a pressure dress	sing or use Kerlix			
o DO NOT USE GRANULAR AGENTS					
{Wound Packing may be performed by provide	rs at any level, as long as they have rece	ived proper training}			
· · · · · · · · · · · · · · · · · · ·	ppen wounds to the head, chest or abdo	•			
 Use sterile gauze or approved hemos 	static products				
 Gauze should be placed as deeply in the 	the wound as possible using a gloved dig	git and continuous pressure			
 Excessive force is not necessary and r 					
	al direct pressure over the packed woun	d for at least 3 minutes			
Do not remove wound packing once					
 Notify the ED staff of the use of wour 	nd packing on arrival at the destination				
Treat for hypovolemic shock as indicated.			EMR		
No additional orders at this level				EMT	
No additional orders at this level					AEMT
No additional orders at this level					AEM
	Consult				
None					
	Clinical Pearls				
					_

3015 – Hemorrhage Control Page **1** of **1**



3016

Subject:

Hypothermia

Effective: June 1, 2021

Last Modified:

Oct. 11, 2021

3016.1 Clinical Management

	Assessment	
diatric Considerations None	Signs & Symptoms Cold, clammy skin Shivering Mental status changes Extremity pain or sensory abnormality Bradycardia Hypotension or shock	 Differential Diagnosis Sepsis Hypoglycemia Stroke Head Injury Spinal cord injury
	Treatment Algorithm	
Avoid any rough movement that r It may be beneficial to consider sp Assess neurological status. Oxygenate the patient with 100% If patient goes into cardiac arrest:	O ₂ .	
If available, provide {warmed and Hypothermic patients should be t	humidified} 100% O ₂ .	EMT
Use the least invasive means poss Intubate if necessary, as gently as Establish vascular access and cons	possible.	LIVE V
Treat bradycardia only if patient is	s hypotensive.	
	Consult	
 All levels should consult 	st management of the severely hypothermic patient. with MCP for orders to administer second and subsequent d t with MCP for orders to administer cardiac arrest medication	
	Clinical Pearls	
It may be necessary to assess puls	e and respirations for up to 45 seconds to confirm arrest.	

END OF SECTION

3016 - Hypothermia Page 1 of 1



3017

Spinal Motion Restriction

tion Postriction Effective:

June 1, 2021

Last Modified:

Jan. 6, 2024

3017.1 General Guidelines

- a. Studies indicate traditional spinal restriction has risks and may even cause harm in some cases.
- b. Spinal Motion Restrictions allows for an assessment-based management of the injured patient.
- c. Spinal precautions should always be taken when dealing with at risk patients.
- d. This protocol does not indicate that providers do not immobilize the spine; it simply provides a different means of restriction in selected patients.
- e. These guidelines apply to providers at all certification levels.

3017.2 Blunt Trauma Patients – Full Immobilization

- A All patients with clinical indications of a spinal injury <u>and/or</u> with altered levels of consciousness must be immobilized with both a C-collar and a spinal restriction device. (e.g., spine board, KED, vacuum splint).
- **P** Pediatric trauma patients less than 3 years of age with a GCS of less than 15 must be immobilized with both a C-collar and a spinal restriction device.

3017.3 Blunt Trauma Patients - SMR

- a. Other alert trauma patients, including all those listed below, should have a c-collar placed and moved with caution in-line as a unit to the cot. They would not need a backboard:
 - i. Patients with neck pain
 - ii. Patients with midline neck or spinal tenderness
 - iii. Patients with pain upon motion of the neck
 - iv. Cases with high risk mechanism (high speed MVC, fall greater than 10 feet, axial loading injury)

3017.4 Penetrating Trauma

- a. Patients with penetrating trauma do not need immobilization with either a cervical collar or backboard.
- b. Delays in transport are to be minimized and place the patient at greater risk.

3017.5 Airway or Ventilatory Management

- Patients who are immobilized and require airway and or ventilatory interventions (including intubation)
 may have the cervical collar removed during the intervention.
 - i. In-line stabilization should be maintained while the intervention is performed.
- b. The cervical collar should be reapplied after the intervention is either accomplished or abandoned.

3017.6 Equipment Issues

- a. In an emergency situation with equipment intensive sports such as football, hockey and lacrosse, the protective equipment shall be removed prior to transport to an emergency facility.
- b. Helmets of any kind that prevent either effective SMR or airway management should be removed.

3017.7 Other Considerations

a. Patients greater than 69 y/o should be considered "high risk" patients for spinal injury and require closer assessment. With these patients, lean towards applying a cervical collar.

3017 – Spinal Motion Restriction Page 1 of 2

3017

Subject:

Spinal Motion Restriction

Effective:

June 1, 2021

Last Modified:

Jan. 6, 2024

- b. If the patient meets the standards for a Trauma Alert Activation, consider a cervical collar at a minimum.
- c. Patients who do not tolerate any level of restriction should have that restriction adjusted to the point of removal if necessary based on clinical response.
 - i. Examples include shortness of breath, anxiety, and body habitus
 - ii. They should be transported in the manner of restriction that they can tolerate.
- d. Spinal restriction of the purpose of patient movement
 - i. Spinal restriction devices may be utilized for movement from a site of injury to the cot.
 - ii. Patients who do not require restriction should be removed from the device prior to transport.

3017.8 Clinical Management

Full Spinal Motion Restriction

- Patients with GCS less than 15 including confusion and intoxication
- Patients with altered LOC
- Patients with neurologic deficits including paralysis
- Patients with clinical indications of a spinal injury
- Patients less than 3 y/o with GCS less than 15

C-Collar and Move Inline to Cot

- Patients that have a GCS of 15 and present with:
 - Neck pain
 - o Midline neck tenderness
 - o Pain on motion of the neck
 - High risk Mechanism of Injury (MOI)

SMR Is Not Required

- Penetrating trauma
- Patients that do not fall into the other two conditions

EXCEPTIONS

- Patients who require airway or ventilatory intervention may have the collar removed with inline stabilization during the intervention.
- Patients who do not tolerate restriction should have it adjusted to the point of removal if necessary.

END OF SECTION

3018

Subject:

Trauma Triage Guidelines

Effective:

June 1, 2021

Last Modified:

Jan. 6, 2024

3018.1 Interpretation of Trauma Triage Guidelines

- a. This guideline meets the requirement of OAC 4765-14, defining Trauma Triage Guidelines for the region
- b. This guideline can separately provide direction as to when a provider should call a "Trauma Alert"
- c. Not all patients who meet Trauma Triage Criteria may need a trauma alert

3018.2 State of Ohio Trauma Triage Age Considerations

- a. For the purposes of trauma guidelines, the criteria for patient age are:
 - P Less than 16 years old will be pediatric patients
 - A 16 years old to 69 years old will be adult patients
 - G Greater than 69 years old will be geriatric patients

3018.3 Trauma Center or Facility Capabilities:

- a. Level I and II Trauma Centers can care for the same trauma patients.
- b. Level III Trauma Centers offer services, based on individual hospital resources that provide for initial assessment, resuscitation, stabilization, and treatment of the trauma patient.
- c. In some areas of the region a Level III Trauma Center is the only trauma facility within 30 minutes ground transport time. This hospital may act as the primary receiving facility for the critically injured patient.
- d. In areas where the trauma patient is closer to a Level III Trauma Center, but a Level I or Level II Trauma Center is still within 30 minutes, the EMS Provider should decide whether the patient would benefit more from an immediate evaluation, stabilization, and treatment at the Level III Trauma Center, or from direct transport to a Level I or Level II Trauma Center.
- e. In areas of the region where there are no Trauma Centers within 30 minutes ground transport time, the acute care hospital may act as the primary receiving facility for critically injured trauma patients, or EMS Provider may arrange for air medical transport from the scene.
- P If a pediatric patient meets the trauma triage guidelines, transport to a Pediatric Trauma Center.
- P Pediatric patients should be transported in an appropriately sized child restraint system.
- f. If transportation time is greater than 30 minutes, transport to the nearest acute care hospital, or EMS providers may arrange for air medical transport from the scene.
- g. All pregnant trauma patients should be rapidly transported to the nearest Adult Trauma Center with labor and delivery capabilities, unless transport time is greater than 30 minutes.

3018.4 Air Medical Transportation:

- a. Prolonged delays at the scene waiting for air medical transport should be avoided.
- b. Cardiac arrest is not appropriate for air transport.
- c. In the rural environment, direct transfer of trauma patients by air medical transport may be appropriate.

3018.5 Exceptions to Transportation Guidelines:

- a. It is medically necessary to transport the victim to another hospital for initial assessment and stabilization before transfer to a Trauma Center.
- b. It is unsafe to transport the victim directly to a Trauma Center due to adverse weather or ground conditions or excessive transport time.
- c. Transporting the victim to a Trauma Center would cause a shortage of local EMS resources.
- d. No Trauma Center is able to receive and provide trauma care to the victim without undue delay.
- e. Before transport begins, the patient requests to be taken to a particular hospital even if it is not a Trauma Center.
 - i. If the patient is a minor or otherwise considered incapable of making medical decisions, an adult relative or other legal representative may make this request.

3018

Subject:

Trauma Triage Guidelines

Effective: June 1, 2021

Last Modified:

Jan. 6, 2024

3018.6 Trauma Criteria:

- a. Anatomical Criteria:
 - i. Penetrating trauma to head, neck, torso
 - ii. Significant, penetrating trauma to extremities proximal to elbow or knee with evidence of neurovascular compromise.
 - iii. Injuries to the head, neck, or torso where the following physical findings are present:
 - 1. Visible crush injuries
 - 2. Abdominal injury with tenderness, distention, or seat belt sign
 - 3. Evidence of pelvic fracture
 - 4. Flail chest
 - iv. Injuries to extremities where the following physical findings are present:
 - 1. Amputation proximal to wrist or ankle
 - 2. Visible crush injuries
 - 3. Fractures of two or more proximal long bones
 - G One proximal long bone fracture in MVC only
 - 4. Evidence of neurovascular compromise
 - v. Signs and symptoms of spinal cord injury
 - vi. 2nd or 3rd degree burns greater than 10% total body surface area (BSA) or other significant burns involving the face, feet, hands, genitals, or airway
 - **G** Injury sustained in two or more body regions
 - vii. Open skull fracture

Meets Anatomical Criteria = Transport to Trauma Center	Does Not Meet Above Criteria = Continue Assessment
Call Trauma Alert if patient presentation indicates	Assess for Physiologic Criteria

b. Physiological Criteria:

- i. Adult Physiological Criteria:
 - A GCS less than or equal to 13
 - A Loss of consciousness greater than five minutes
 - A Deterioration in level of consciousness at the scene or during transport
 - A Failure to localize pain
 - A Respirations less than 10 or greater than 29
 - A Needs ventilatory support
 - A Requires relief of tension pneumothorax
 - A Pulse greater than 120 in combination with evidence of hemorrhagic shock
 - A SBP less than 90 or absent radial pulse with carotid pulse present

ii. Pediatric Physiological Criteria:

- P GCS less than or equal to 13
- P Loss of consciousness greater than five minutes
- P Deterioration in level of consciousness at the scene or during transport
- P Failure to localize pain
- **P** Evidence of poor perfusion (e.g., weak distal pulse, pallor, cyanosis, delayed capillary refill, tachycardia)
- P Evidence of respiratory distress or failure (e.g., stridor, grunting, retractions, cyanosis, nasal flaring, hoarseness, or difficulty speaking)
- P Respiratory rate less than 20 per minute in infants less than 1 year old.

3018

Subject:

Trauma Triage Guidelines

Effective:

June 1, 2021

Last Modified:

Jan. 6, 2024

iii. Geriatric Physiological Criteria:

- **G** GCS less than or equal to 13
 - a. GCS less than or equal to 14 with evidence of Traumatic Brain Injury
- **G** Loss of consciousness greater than five minutes
- G Deterioration in level of consciousness at the scene or during transport
- **G** Failure to localize pain
- G Respirations less than 10 or greater than 29
- **G** Needs ventilatory support
- **G** Requires relief of tension pneumothorax
- G Pulse greater than 120 in combination with evidence of hemorrhagic shock
- G SBP less than 100 or absent radial pulse with carotid pulse present

Meets Physiological Criteria = Transport to Trauma Center	Does Not Meet Above Criteria = Continue Assessment
Call Trauma Alert if patient presentation indicates	Look at Special Considerations

c. Special Considerations:

- i. Vehicle telemetry provides data consistent with high risk of injury
- ii. On scene fatality in the same vehicle
- **G** Pedestrian struck by a motor vehicle
- G Falls from any height, including standing falls, with evidence of traumatic brain injury

Special Considerations = Transport to Trauma Center	Does Not Meet Above Criteria = Consider MOI
Call Trauma Alert if patient presentation indicates	Transport to most appropriate hospital

d. Mechanism of Injury:

- i. Auto-pedestrian/auto-bicycle injury with significant (faster than 5 mph) impact
- ii. Ejection from motor vehicle or unrestrained rollover
- iii. Extrication time longer than 20 minutes
- iv. Fall of more than 20 feet
 - P Fall greater than 3 times child's height
- v. High-speed auto crash
 - 1. Estimated speed faster than 40 mph
 - 2. Intrusion into passenger compartment of more than 12 inches
 - 3. Major auto deformity of more than 20 inches
- vi. Open motor vehicle crashes faster than 20 mph or with separation of rider from vehicle
- vii. Pedestrian thrown or run over

e. Special Situations:

- i. Pre-existing cardiac or respiratory disease
- ii. Diabetes, cirrhosis, morbid obesity, seizure disorder
- iii. Patient with bleeding disorder or on anticoagulants or anti-platelets
- iv. Immuno-suppressed patients (renal dialysis, transplant, cancer, HIV)
- v. Congenital disorder

MOI or Special Considerations = Consider Trauma Center	No Significant MOI or Special Considerations
No need to call Trauma Alert if no significant symptoms	Transport to most appropriate hospital

END OF SECTION



3019

SALT Triage System

Effective: June 1, 2021

Last Modified:

Jan. 6, 2024

3019.1 General Guidelines

- a. SALT stands for Sort, Assess, Life-Saving Intervention, and Treatment/Transport.
- b. Developed by the Centers for Disease Control and Prevention to address limitations in other systems.
- The CDC has proposed SALT as the national standard for Mass Casualty Incident (MCI) triage.
- d. SALT has the advantage of being the **fastest mass casualty triage system**.
- e. Notify hospitals of any MCI, especially a MCI involving contaminated patients.
 - i. Consider use of the <u>3020 Regional Hospital Notification System (RHNS)</u>

3019.2 Primary and Secondary Triage Prior to Transport

- a. Initial Triage:
 - i. Use triage ribbons (color-coded strips), not treatment tags, during initial triage.
 - 1. Treatment tags slow the process and should be used later, in the treatment areas.
 - 2. Treatment tags do need to be used at some point as they are sometimes the only documentation of EMS assessments and treatments.
 - ii. Tie the triage ribbon to an upper extremity in a VISIBLE location (on the right wrist, if possible).
 - iii. SALT Triage Levels:
 - 1. RED Immediate
 - 2. YELLOW Delayed
 - 3. GREEN Minimal
 - 4. GRAY Expectant (The patient is unlikely to survive given the current resources)
 - 5. **BLACK Dead** (black & white zebra stripe for easier visibility in low light)
 - 6. **ORANGE and Polka Dot** used in addition to one of the above ribbons to indicate victim has been contaminated with a hazardous material.
 - iv. Move as quickly and safely as possible; making quick decisions.
 - v. Victims will be re-triaged, probably multiple times. Revise the triage category as often as indicated.
 - vi. Over-triage can be as harmful as under-triage. If everyone is tagged red, those who are truly red will receive delayed treatment, delayed transport, and delayed definitive care.
 - vii. Treatment and transport should NOT be delayed especially for critical patients. Get the reds out.
 - viii. If there are extensive delays in the field, consider requesting orders for palliative care, e.g., pain medications if time and resources allow.

b. Secondary Triage:

- i. Reassess (i.e. secondary triage) as often as practical, including when the patient is moved to the Casualty Collection Point (CCP) or Treatment Area, and on all victims prior to transport.
 - 1. Also reassess patients when their condition or resources available change.
- ii. Apply Treatment Tags after patients enter the CCP, or in the Transport Area (by the Transport Officer/Group) if the patient is being directly removed without going to the Treatment Area.
- iii. Crews can also fill in pertinent and available information on the Tag during transport.
- iv. Use the patient's ribbon to tie on the treatment tag
 - 1. Use treatment tags with individual barcodes consistent with this Standing Order and the Ohio patient tracking system (OHTrac).
- v. Orange & Polka-dot ribbons (indicating contaminated patients) are removed after decontamination.
 - Each contaminated patient initially receives two ribbons: one with the triage category (Red, Yellow, Green, Gray, or Black), and the second, the Orange & Polka-dot ribbon indicating contamination.
 - 2. EMS is responsible for performing primary decontamination prior to transport. However, the hospital must be made aware of both contamination and the

3019 – SALT Triage System Page 1 of 4

3019

SALT Triage System

Subject:

Effective: June 1, 2021

Last Modified:

Jan. 6, 2024

decontamination procedures taken.

- 3. Make sure to decontaminate under the ribbons.
- 4. After decontamination, remove the Orange & Polka-dot ribbon.
- 5. Mark treatment tags for contaminated patients with two check marks on the orange strip:
 - a. Mark both the "dirty" and "decontaminated" boxes.
 - b. This indicates to the hospital personnel that the patient has had field decontamination, but may still be somewhat "dirty".

c. Transport

- i. Treatment Area or Transport Group personnel determine priority for transport.
- ii. Distribution of patients among various hospitals is one of EMS' most crucial tasks.
- iii. Do not overload any hospital, regardless of transport distance to other hospitals.
- iv. In an MCI, transport trauma patients to non-Trauma Centers as necessary.
 - 1. All hospitals will accept and stabilize trauma patients during MCIs.
 - 2. Consider transporting minor (**GREEN**) patients to satellite EDs to relieve pressure on Trauma Centers and other hospitals.
- v. When assigning patient allocation, consider the likelihood that the closest hospitals may be overwhelmed by patients who were not transported by EMS.
- vi. In large scenarios, consider activation of the Forward Movement of Patients Plan as defined in 3021.0 Crisis Standards of Care in Massive Events.

3019.3 Sort, Assess, Life-Saving Intervention, Treatment/Transport Process

- a. Sort
 - i. Global Sorting: Action 1
 - 1. Action: "Everyone who can hear me please move to [designated area] and we will help you" (use loudspeaker if available)
 - 2. Goal: Group ambulatory patients using voice commands
 - 3. Result: Those who follow commands are *last* priority for individual assessment (Green)
 - 4. Assign someone to keep them together and notify Incident Command or EMS Group/Branch of number of patients and their location.
 - 5. Do not forget these victims.
 - 6. Someone must re-triage them as soon as possible.
 - 7. In smaller incidents, such as a motor vehicle crash with few victims that you do not want to move on their own, skip Action 1, and go to Global Sorting Action 2
 - ii. Global Sorting: Action 2
 - 1. Action: "If you need help, wave. We will be there to help as soon as possible"
 - 2. Goal: Identify non-ambulatory patients who can follow commands or make purposeful movements
 - 3. Result: Those who follow this command are second priority for individual assessment
 - iii. Global Sorting: Result
 - 1. Casualties are now prioritized for individual assessment
 - a. Priority 1: Still, and those with obvious life threat
 - b. Priority 2: Waving or purposeful movements
 - c. Priority 3: Walking
 - iv. Begin assessing all non-ambulatory victims where they lie, performing Life Saving Interventions (LSIs) as needed, within your scope of practice, using the equipment is readily available.

3019 – SALT Triage System Page 2 of 4

Trauma Protocol

3019

SALT Triage System

Effective: June 1, 2021

Last Modified:

Jan. 6, 2024

b. Assess

- i. Is the patient breathing?
 - 1. If not, open the airway. In children, consider giving two rescue breaths.
 - 2. If the patient is still not breathing, triage them to **BLACK** (dead).
 - 3. Do not move patients triaged **BLACK** except to gain access to a living patient.
 - 4. If patient is breathing, conduct next assessment.
- ii. Assess for the following:
 - 1. Can the patient follow commands or make purposeful movements?
 - 2. Does the patient have a peripheral pulse?
 - 3. Is the patient not in respiratory distress?
 - 4. Is hemorrhaging under control?

iii. Grading the Assessment

- 1. If the answer to <u>any</u> of those questions is <u>no</u> (bad) and the patient <u>IS</u> likely to survive given current resources, tag them as <u>RED</u> (<u>Immediate</u>).
- 2. If the answer to <u>any</u> of those questions is <u>no</u> (bad) and the patient is <u>NOT</u> likely to survive given current resources, tag them as **GRAY** (Expectant).
- 3. If the answer to <u>all</u> of those questions is <u>yes</u> but injuries are not minor and require care, tag patient as <u>YELLOW</u> (Delayed).
 - a. YELLOWs have serious injuries and need care, though not as urgently as REDs.
 - b. On secondary triage, some Yellows will need higher priority transport than others.
- 4. If the answers to <u>all</u> of those questions is <u>yes</u> and the injuries are minor, tag patient as **GREEN** (Minimal).

Two mnemonics to remember the four assessment questions		
C – follows <u>Commands</u> Think of the questions in terms of "bad" or "good"		
R – No Respiratory distress		
A – No (uncontrolled) <u>A</u> rterial bleeding	If the answer to any of the questions is "bad" then the patient is	
P – <u>P</u> eripheral <u>P</u> ulse <u>P</u> resent	tagged either RED (Immediate) or GRAY (Expectant)	

c. Life Saving Interventions

- i. Only correct life-threatening problems during triage.
 - 1. Control major hemorrhage
 - 2. Open airway (if child, consider giving two rescue breaths)
 - 3. Needle chest decompression
 - 4. Auto injector antidotes
 - 5. See 3019.5 Special Situations

d. <u>Treatment/Transport</u>

- i. Transport/treatment priority is typically given (in order) to
 - 1. **RED** (Immediate)
 - 2. YELLOW (Delayed)
 - 3. **GREEN** (Minimal)
 - 4. GRAY (Expectant) patients should be treated and transported as resources allow.

3019.4 General Considerations

Patients must be reassessed periodically, including when moved to the CCP, or when their condition or resources change.

3019 – SALT Triage System Page **3** of **4**

Trauma Protocol

3019

SALT Triage System

Effective: June 1, 2021

Last Modified:


Jan. 6, 2024

- b. Even after applying treatment tags, the main indicator of patient condition is the triage ribbon.
- c. Continue to use the same tag, even if the condition changes repeatedly, changing the ribbon to indicate the patient's current condition.
- d. If the patient's condition or the triage priority changes, indicate that on the tag.

3019.5 Special Considerations

- a. SALT is a clinical guideline, not an absolute.
- b. Every MCI is extraordinary use your clinical judgement
- c. A patient who is **GRAY** (Expectant) initially can become **RED** (Immediate) as soon as resources are available.
- d. MCIs with patients suffering traumatic (aka, compression) asphyxia who are not breathing initially, may start breathing after just a few ventilations.
 - i. Common to crowding situations and crowd surges (i.e the Houston Astroworld Music Fest), it is worth attempting a few ventilations during the LSI step, even in adults.
- e. In MCIs due to lightning strikes, the pathology can be very complex.
 - i. Consider attempting ventilation or defibrillation, depending on resources and the conditions of other victims.

3019.6 SALT Triage Flow Chart



END OF SECTION

3019 – SALT Triage System Page 4 of 4



bject: Regional Hospital Notification System (RHNS)

3020.1 General Guidelines

a. The purpose of the Regional Hospital Notification System is to provide one number for EMS, hospitals, and EMAs to call that will make rapid, simultaneous notifications in a Mass Casualty Incident or Event (MCI/MCE), or other major emergency.

b. The system can be used when an incident could involve a significant number of the region's hospitals.

3020.2 RHNS Activation

- a. To activate the system, an incident commander calls 937-333-USAR (8727), and requests a "Regional Hospital Notification."
- b. The agency calling must ask for a Dispatch Supervisor, and should provide the information below:
 - i. Name of agency
 - ii. Nature of emergency
 - iii. Location of emergency
 - iv. General statement on severity, such as approximate number of victims
 - v. Any other information to be conveyed
- c. The Montgomery County Regional Dispatch Center (RDC) will immediately put out a computerized message to the RHNS Group with the information provided.





Trauma Protocol

3021

Subject: Crisis Standards of Care in

Massive Events

Effective: June 1, 2021

Last Modified:

Dec. 8, 2020

3021.1 General Guidelines

- a. Some incidents are so large as to require extraordinary EMS procedures. Those scenarios are sometimes referred to as Mass Casualty Events (MCEs), instead of Mass Casualty Incidents (MCIs).
- b. These EMS procedures should be utilized in very large emergency scenarios, or when the duration is extended.
- c. In the event of an MCE, especially one lasting days or longer, Greater Miami Valley EMS Council, with the approval of the Regional Physicians Advisory Board (RPAB), may promulgate "Just in Time Standing Orders" (JITSO).
- d. With approval from Ohio Department of Public Safety, these orders might include triage standards for transport to other healthcare facilities and other crisis standards of care; possibly exceeding the standard scope of practice for EMS.
- e. Full information on the process can be found in the Dayton MMRS Regional MCI Plan Template

3021.2 Alternate Transports

- a. In some circumstances, EMS may be authorized to triage selected patients for transport to other healthcare facilities, including:
 - i. Urgent Care Centers
 - ii. Acute Care Center (ACC)
 - iii. Neighborhood Emergency Help Center (NEHC)
 - iv. Disaster Medical Assistance Team (DMAT)

3021.3 Forward Movement of Patients

- a. Planned by Dayton MMRS
- b. The intent is to relieve the burden on local hospitals by transporting patients, possibly directly from the scene, to more distant hospitals.

3021.4 Functional Needs Shelter Triage

- a. A regional protocol for Functional Needs Shelter Triage has been added to the Optional Standing Orders Manual and is also available at gmvemsc.org on the Training Materials page.
- Will help determine whether individuals with functional needs can be safely sheltered in a Red Cross Shelter during a disaster
- c. This Shelter Triage Protocol is a pre-approved Just-In-Time Standing Order (JITSO), authorized by the RPAB for use by an EMS agency assisting the Red Cross with shelter triage.
- d. It is intended to be printed and given to paramedics, nurses, and other healthcare personnel at the time of a shelter operation.
- e. At the option of local department chiefs and medical directors, the same protocol can be used during a
 disaster to determine patients who would be more appropriate for transport to Red Cross Shelters than
 to hospitals.
- f. In those cases, EMS should, if possible, contact the shelter before transporting.
- g. If locations or contact information for shelters is not known, contact the County EMA or the Red Cross.
- h. When transporting these non-emergency patients to shelters, it is critical that the patients bring their medications and medical equipment with them.



4000 Series

Medical Protocol



4001

Subject: Abdominal Pain

Effective:

June 1, 2021

Last Modified:

Feb. 16, 2023

4001.1 General Guidelines

- a. Ensure an abdominal exam which includes inspection, auscultation and palpation is performed and documented on every patient with abdominal pain.
- b. Assess all abdominal pain patients for trauma, pregnancy, illness, or potential ingestion.

4001.2 Clinical Management

	Assessment	
Pediatric Considerations None	Signs & Symptoms Pain (location/migration) Tenderness (point, palpation, rebound) Nausea and/or vomiting Diarrhea Dysuria Constipation Vaginal bleeding/discharge Pregnancy	Differential Diagnosis Hepatitis Peptic ulcer disease/gastritis Gallbladder Pancreatitis Abdominal aneurysm Appendicitis Pelvic (PID, ovarian cyst, ectopic pregnancy) Diverticulitis Gastroenteritis Bladder/prostate disorders Kidney stone Myocardial infarction Pneumonia Pulmonary embolus
	Treatment Algorithm	- Tullionary emboras
P Ondansetron (Zofran) 4 mg	evel. an) 4 mg PO dissolving tablet for nausea or active vomit PO if patient is 12 y/o or older and weight is more than or unilateral flank pain, consider 1014 Pain Management	or equal to 40 kg.
of the IV form PO by spraying	established, Ondansetron (Zofran) 4 mg PO (dissolving t	tablet) or consider administering 4 mg (2 ml)
P Ondansetron 0.1 mg/kg IV (
P Undansetron 0.1 mg/kg IV (Consult	
		pediatric patients.
	Consult	pediatric patients.

END OF SECTION

4001 – Abdominal Pain Page 1 of 1



4002

Subject:

Allergic Reaction/Anaphylaxis

Effective: June 1, 2021

Last Modified:

Jan. 21, 2024

4002.1 General Guidelines

- a. Epinephrine is the mainstay of anaphylaxis in allergic reaction treatment.
- b. Epinephrine is particularly important in cases of any airway edema, hypotension, or when multiple body systems are involved.
- c. Advanced age is not a contraindication to epinephrine.

4002.2 Clinical Management

Assessment Signs & Symptoms **Differential Diagnosis Pediatric Considerations** Itching Rash only Epinephrine is dosed based on Shock (vascular effect) weight not age. Hoarseness or stridor While the protocol lists those Wheezing Angioedema Aspiration/airway obstruction patients under 15 kg as pediatric, Respiratory distress it is understood that patients Altered level of consciousness Vasovagal event equal to or greater than 30 kg will Cyanosis Asthma get both the Adult EpiPen and the Pulmonary edema EpiPen Jr., no matter what their Facial/airway edema age. Urticaria/hives

Treatment Algorithm

- Provide O₂ as needed.
- If allergic reaction:
 - o If equal to or greater than 30 kg, give both Adult EpiPen and EpiPen Jr.
 - P If less than 15 kg, EpiPen Jr.
 - P If equal to or greater than 15 kg and less than 30 kg, Adult EpiPen
- If applicable, apply ice pack.
- If symptoms persist, may repeat Epinephrine in 10 minutes.
- Call for transport.
- If patient develops wheezing, assist them with their prescribed metered dose inhaler or
 - ◆ Albuterol 2.5 mg and Ipratropium 0.5 mg, nebulized with O₂ flowing at 8-10 LPM.
 - Albuterol may be repeated two times.
- [If allergic reaction and an absence of Epi-pens in the drug bag, EMTs are permitted to administer Epinephrine IM via a syringe]
 - {The EMT may only perform this skill after authorization and training from their Medical Director}
 - A If equal to or greater than 30 kg, Epinephrine (1:1,000) 0.5 IM}
 - P {If less than 15 kg, Epinephrine (1:1,000) 0.01 mg/kg IM (max 0.15 mg)}
 - P {If equal to or greater than 15 kg and less than 30 kg, Epinephrine (1:1,000) 0.01 mg/kg IM (max 0.3 mg)}
 - A ♦ {May repeat Epinephrine (1:1,000) 0.5 mg IM after 10 minutes}
 - (May repeat **Epinephrine (1:1,000) 0.01 mg/kg IM** (max dose equal to initial dose) after 10 minutes}
- If an allergic reaction:
 - o If equal to or greater than 30 kg, give both Adult EpiPen and EpiPen Jr or Epinephrine (1:1,000) 0.5 mg IM
 - P If less than 15 kg, EpiPen Jr or Epinephrine (1:1,000) 0.01 mg/kg IM (max 0.15 mg).
 - P If equal to or greater than 15 kg and less than 30 kg, Adult EpiPen or Epinephrine (1:1,000) 0.01 mg/kg IM (max 0.3 mg)
 - o May repeat **Epinephrine (1:1,000) 0.5 mg IM** after 10 minutes.
 - P May repeat Epinephrine (1:1,000) 0.01 mg/kg IM (max dose equal to initial dose) after 10 minutes.
- If apneic, intubate, possibly with smaller than normal ET tube.
- For wheezing, no orders needed for Albuterol 2.5 mg and Ipratropium 0.5 mg, nebulized with O₂ flowing at 8-10 LPM
- If patient intubated, Albuterol 2.5 mg by nebulizer into the ETT. If Ipratropium not given before intubation, add to first Albuterol.
- If hypotensive, IV fluid to maintain adequate BP.
- P If hypotensive, IV fluid 20 ml/kg IV to maintain adequate BP.
- A Diphenhydramine 50 mg IM or IV
- P Diphenhydramine 1 mg/kg IM or IV (max dose 50 mg).

EMR

ΤM

AEMT



4002

Subject:

Allergic Reaction/Anaphylaxis

Effective: June 1, 2021

Last Modified:

Jan. 21, 2024

- If patient deteriorating or unresponsive, consider early intubation, possibly with a smaller than normal size endotracheal tube
- If a conscious patient requires intubation:
 - A Lidocaine 100 mg IN half dose per nostril or added to nebulizer with breathing treatment.
 - P Lidocaine 1.5 mg/kg nebulized with O₂ 8-10 LPM or IN. Maximum dose is 100 mg
- A If patient remains hypotensive after IV fluid, Epinephrine (1:10,000) 0.1 mg, slow IV, every 3 minutes up to 0.5 mg.
- A Solu-Medrol 125 mg IV
- P Solu-Medrol 2 mg/kg IV, max dose 125 mg.

Consult

- The EMR and EMT need MCP orders to administer repeat epinephrine.
- EMT needs MCP orders to administer breathing treatments.

Clinical Pearls

- · No significant change in patient condition in the field should be expected from the administration of Solu-Medrol.
- Solu-Medrol will be given to all patients treated within the allergic reaction or anaphylaxis protocol only <u>after</u> all other applicable first-line medications have been delivered.

Subject:

Asthma/Emphysema/COPD

Effective: June 1, 2021 Last Modified:

Jan. 17, 2023

4003.1 **Clinical Management**

Pediatric Considerations

- Younger patients may exhibit nasal flaring
- Epinephrine is dosed based on weight not age.
- While the protocol lists those patients under 15 kg as pediatric, it is understood that patients equal to or greater than 30 kg will get both the Adult EpiPen and the EpiPen Jr., no matter what their

Signs & Symptoms

- Shortness of breath
- Pursed lip breathing
- Increased respiratory rate and effort
- Wheezing, rhonchi
- Accessory muscle use
- Cough
- Tachycardia
- Tripod position

Differential Diagnosis

- **Anaphylaxis**
- Aspiration
- Pleural effusion
- Pneumonia
- Pulmonary embolus
- Pneumothorax
- Cardiac event (AMI or CHF)
- Pericardial tamponade
- Hyperventilation
- Inhaled toxins

Treatment Algorithm

Assessment

- Provide O₂ as needed.
- Call for transport.
- If patient develops wheezing, assist them with taking their prescribed metered dose inhaler.
- ◆ Consider Albuterol 2.5 mg and Ipratropium 0.5 mg, nebulized with O₂ flowing at 8-10 LPM
- ♦ May repeat Albuterol 2.5 mg nebulized X 2.
- For any patient who is bronchial constricted: CPAP
- Transport unless ALS intercept is less than 5 minutes.
- No orders needed for Albuterol 2.5 mg and Ipratropium 0.5 mg, nebulized with O₂ flowing at 8-10 LPM
- If patient intubated, Albuterol 2.5 mg by nebulizer into the ETT. If Ipratropium not given before intubation, add to first Albuterol.
- After intubation of an asthma patient, limit rate of ventilation to avoid auto-PEEP and hypotension, provided that you can adequately oxygenate the patient at below rate:
 - o 8-10 breaths per minute for adults
 - 10-15 breaths per minute for pediatric patients
- Consider needle decompression in the presence of auto-PEEP or hyperinflation:
 - If the patient is in cardiac arrest, perform bilateral needle decompression
 - If unilateral or bilateral diminished breath sounds and the patient is hemodynamically unstable, consider decompression of only the affected sides
 - Decompression sites:
 - Fourth or fifth intercostal space in the mid-axillary line
 - Second or third intercostal space in the mid-clavicular line (use nipple line as a guide)
 - In patients less than 8 years old, decompression site choice will be limited to the 2nd or 3rd intercostal space at the mid-clavicular line
- Asthmatics in severe distress (NOT for emphysema or COPD):
 - If equal to or greater than 30 kg, give both Adult EpiPen and EpiPen Jr or Epinephrine (1:1,000) 0.5 mg IM
 - If less than 15 kg, EpiPen Jr or Epinephrine (1:1,000) 0.01 mg/kg IM (m
 - If equal to or greater than 15 kg and less than 30 kg, Adult EpiPen or Epinephrine (1:1,000) 0.01 mg/kg IM (max 0.3 mg)
 - May repeat Epinephrine (1:1,000) 0.5 mg IM after 5 minutes.
- If a conscious patient requires intubation:
 - Lidocaine 100 mg IN half dose per nostril or added to nebulizer with breathing treatment.
 - ne 1.5 mg/kg nebulized with O₂ 8-10 LPM or IN. Maximum dose is 100 mg.
- For any patient who is bronchial constricted: CPAP or {Bi-PAP}
- Solu-Medrol 125 mg IV

Consult

The EMT needs MCP orders to administer breathing treatments.

Clinical Pearls

- A patient who has received a breathing treatment should be transported for evaluation.
- No significant change in patient condition in the field should be expected from the administration of Solu-Medrol.



4004

Subject:

Behavioral Emergencies

Effective:

June 1, 2021 Last Modified:

Oct. 10, 2021

4004.1 General Guidelines

- a. Per Ohio Revised Code, EMS providers may not "pink slip" an individual even if they are threatening harm to themselves or others.
- b. Only a health officer such as a police officer, crisis worker, psychiatrist or licensed physician can administer an involuntary admission form ("pink slip") for a patient.
- c. Each EMS department, in consultation with its medical director and local law enforcement, should have a procedure to deal with these types of situations.

4004.2 Precautions

a. Consider staging until law enforcement has made the scene safe.

Electrolyte imbalance

- b. Have law enforcement search patient for weapons.
- c. Consider possible medical causes for patient's condition:

viii. Pulmonary embolism Anemia i. ix. Hemorrhage ii. Hypoxia iii. Metabolic disorders Hypoglycemia х. Stroke Seizures and postictal states iv. xi. Dysrhythmias xii. Shock ٧. Hypertension Infection (especially meningitis /encephalitis) vi. xiii.

xiv.

- xiv. Myocardial ischemia or infarction
- xv. Head trauma or intracranial
- xvi. Drug or alcohol intoxication, side effects, drug withdrawal

4004.3 Clinical Management

Toxicological ingestion

vii.

	Assessment	
Pediatric Considerations None	 Signs & Symptoms Anxiety, agitation, confusion Affect change, hallucinations Delusional thoughts, bizarre behavior Violent or combative Expression of suicidal/homicidal ideations 	Differential Diagnosis Other altered mental status issues Alcohol intoxication Substance abuse Medication effect/overdose Withdrawal symptoms Depression Bipolar (manic-depressive) Schizophrenia Anxiety disorders
	Treatment Algorithm	,
 Do not judge, just treat. Consider possible medical causes If patient is unwilling to go to a factor Transport all patients who are not 	harm to the patient or others, if it is safe to do so.	
A In all other cases, patients should		
A In all other cases, patients should Pediatric patients with mental hea	be transported to the closest ED.	
 A In all other cases, patients should Pediatric patients with mental hea No additional orders at this level. 	be transported to the closest ED.	ental health capabilities.
 A In all other cases, patients should Pediatric patients with mental hea No additional orders at this level. 	be transported to the closest ED. alth issues should be transported to a facility with pediatric me	ental health capabilities.



4004

Subject:

Behavioral Emergencies

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

Clinical Pearls

- Consider that a patient may be incapable to make medical decisions (incompetent) if they are:
 - Suicidal
 - o Confused
 - o Severely developmentally or mentally disabled
 - o Intoxicated
 - o Injured/ill with an altered mental status
 - Physically/verbally hostile
 - Unconscious
- When obtaining medical history, determine:
 - Suicidal or violent history
 - o Previous psychiatric hospitalization, when and where
 - o Location where patient receives mental health care
 - Medications
 - o Recreational drugs/alcohol: amount, names
- Exceptions to the outlined transport recommendations include:
 - o It is medically necessary to transport the patient to the closest hospital for stabilization.
 - It is unsafe to transport the patient to the preferred/recommended facility due to adverse weather or ground conditions or excessive transport time.
 - Transporting the patient to the preferred/recommended facility would cause a critical shortage of local EMS resources.
 - Patient requests transport to a different facility.

END OF SECTION

4004 – Behavioral Emergencies

Page 2 of 2

4005

Subject: Childbirth

Effective: June 1, 2021

Last Modified:

Feb. 11, 2024

4005.1 General Guidelines

- a. Obtain history of patient condition and pregnancy, including:
 - i. Contraction duration and interval
 - ii. Gestation age should be expressed in weeks whenever possible
 - iii. Due date
 - iv. First day of last menstrual period
 - v. Number of pregnancies and number of live births (gravida/para)
 - vi. Presence or absence of prenatal care
 - vii. Possibility of multiple births
 - viii. Any possible complications
 - ix. Any drug use by the mother
- b. The patient should be transported to a hospital with obstetrical capabilities
 - i. Unless delivery is imminent (the baby is crowning during a contraction).
 - ii. ABSOLUTELY NO PREGNANT PATIENTS TO DAYTON or CINCINNATI CHILDREN'S HOSPITALS.
- c. Visualize the perineal area only when contractions are less than five minutes apart.
- d. Run reports must be completed for each patient. The newborn is a separate patient from the mother.

4005.2 Clinical Management

Assessment Pediatric Considerations Signs & Symptoms **Differential Diagnosis** None, unless the pregnant Spasmodic pain Abnormal presentations (foot, and, buttocks) patient is under 16 years old, Vaginal discharge or bleeding Prolapsed cord then manage in the same Lengthening and narrowing contractions Placentia previa manner. Urge to push Abruptio placenta Crowning The EMR may only assist with emergency childbirth management Apply gentle pressure on the baby's head with a flat hand to prevent an explosive delivery. Place a gloved hand inside the birth canal only in the case of: Breech delivery with entrapped head Prolapsed umbilical cord limiting fetal circulation Keep the newborn warm. Cut the umbilical cord and then place the baby to suckle at the mother's breast. Obtain one, five and ten minute APGAR scores if time and patient condition permit. (see table below) Establish an IV for patients in active labor. No additional orders at this level. Consult None **Clinical Pearls** When transporting potentially complicated deliveries or emergent childbirths, consider transporting to the closest L & D capable facility Changes in fundal (upper part of the uterus) height during pregnancy: Above the symphysis pubis = Greater than 12 to 16 weeks gestation At the level of the umbilicus = Greater than 20 weeks gestation Near the xiphoid process = Within a few weeks of term **APGAR Score**

Respiratory Effort END OF SECTION

Appearance

Pulse

Grimace

4005 - Childbirth Page 1 of 1

Cyanosis at the extremities

Slow (less than 100)

Grimace with stimulation

No cyanosis present

Greater than 100

Full body cyanosis

Absent

Flaccid



4006

Subject: Childbirth with Complications

June 1, 2021

Last Modified:

Feb. 29, 2024

4006.1 General Guidelines

- a. With all complicated childbirth scenarios, evaluate the need for rapid transport to a birthing center or possibly, the nearest hospital.
- b. These guidelines apply to all levels of certification.
- c. In all complicated childbirth scenarios, place the mother on oxygen by non-rebreather mask.

Effective:

4006.2 Clinical Management

a. Cord around Baby's Neck:

- i. As baby's head passes out of the vaginal opening, feel for the cord.
- ii. Initially try to slip cord over baby's head.
- iii. If too tight, clamp cord in two places and cut between clamps.

b. Breech Delivery:

- i. When an appendage or buttocks first becomes visible, position patient to discourage delivery, coach patient to avoid pushing and transport patient immediately.
- ii. If the delivery is in progress, take care to support the baby's body.
- iii. If the head is caught in the birth canal:
 - 1. Apply gentle pressure above the pubis symphysis as the mother pushes.
 - 2. If the head will not deliver, you must create an airway for the baby.
 - 3. Support the body and insert two fingers into the birth canal, forming a "V" around the mouth and nose.

c. Prolapsed Cord:

- i. When the umbilical cord is exposed prior to delivery, check cord for pulse.
- ii. Transport immediately with hips elevated and a moist dressing around cord.
- iii. Insert two fingers into the birth canal to displace the presenting part away from cord, distribute pressure evenly if occiput presents.
- iv. Do not attempt to reinsert cord.

d. Excessive Bleeding:

- i. Treat for shock.
- ii. Post-delivery, massage uterus firmly and put baby to mother's breast.



June 1, 2021

4007

Combative Patients/Emergency Subject:

Effective:

Last Modified:

Jan. 21, 2024

Sedation

4007.1 **General Guidelines**

- a. Restrained patients should **not** be transported in a prone position with hands & feet behind their back.
- b. Restrained patient should **not** be sandwiched between backboards or other items.
- c. Always maintain the ability to remove restraints if the patient vomits or develops respiratory distress

4007.2 **Combative Patients**

- a. Identified as irrational behavior like aggression, violence, and/or paranoia in the patient.
- b. This state can result from a number of causes including:
 - i. Stimulant intoxication
 - ii. Psychiatric illness
 - iii. Hypoglycemia
 - iv. Other medical illnesses.
- c. In excited delirium the patient often becomes significantly hyperthermic and/or hypoxic.

4007.3 **Clinical Management**

		Assessment		
Pediatric C None	onsiderations	Signs & Symptoms Patient out of control and dangerous to self or others. Restraint required for patient control without causing harm Combative or violent patient Treatment Algorithm Differential Diagnosis Alcohol intoxication Substance abuse Medication effect/overdo Withdrawal symptoms Mental health history	ose	
Evolai	n the need for restraint to the			
•	n the need for restraint to the	s ability to breathe and distal circulation.	EMR	
	ditional orders at this level.	s ability to breathe and distal circulation.	EMT	
		duce dosing for sedatives and analgesics to one half (½) of the adult doses		
		equice dosing for sedatives and analgesics to one half ($\frac{1}{2}$) of the adult doses eral thigh) or Ketamine 100 mg slow IV .		
	• • • • • • • • • • • • • • • • • • • •	A dose and 5 minutes with IV dose, consider additional medication:		
	_			
•		TAMINE AND MIDAZOLAM SIMULTANEOUSLY.		
•		dative time to work before moving on to a secondary medication and dosing.		
		opposite anterolateral thigh) <u>or</u> repeat Ketamine 100 mg IV .		
_	AND/OR:			
_		ng in each nostril), or Midazolam 2.5 mg slow IV, or Midazolam 5 mg IM.		
A	If necessary, repeat Mida			
		lam 5 mg IN (2.5 mg in each nostril) after 10 minutes.		
	•	zolam 2.5 mg slow IV after 5 minutes.		
		zolam 5 mg IM after 10 minutes.		
	patient is age 8 or greater, co	nsider Ketamine 1 mg/kg slow IV (max dose 100 mg) <u>or</u> Ketamine 5 mg/kg IM (max dose 250).		
<u>or</u>				
		ose 10 mg) or Midazolam 0.1 mg/kg slow IV (max IV dose 2.5 mg) or Midazolam 0.2 mg/kg IM		E
	IM dose 5 mg)			AEMT
	MCP for additional Ketamine			
A If an e	excited delirium patient goes i	nto arrest: ♦ Consider Sodium Bicarbonate 100 mEq IV		
		Consult		
MCP r	needed for pediatric repeat m	edications and (for the paramedic) Sodium Bicarbonate in cardiac arrest.		
		Clinical Pearls		
		sedated should be constantly monitored for an effective airway, adequate breathing and circula		
		ith Ketamine can be deeply unconscious and present with hypersalivation. Management should i	include ι	ıse
		positioning and persistent suctioning to maintain a clear airway.		
	ECTION			



June 1, 2021

4008

Subject: Diabetic Emergencies –

Hypoglycemia/Hyperglycemia

Effective:

Last Modified:

Dec. 12, 2023

4008.1 General Guidelines

- a. Hypoglycemia is defined as a blood glucose level less than 60, or there is strong suspicion of hypoglycemia despite glucometer readings
- b. Hyperglycemia is defined as a blood glucose level at or above 250 mg/dL.

4008.2 Clinical Management

ediatric Considerations		ssment	
None	Signs & Symptoms (Hypo) Altered LOC Dizziness Irritability Diaphoresis Seizures Hunger Confusion Acute onset	Signs & Symptoms (Hyper) Altered LOC Malaise Hypotension Dehydration Polydipsia Muscle cramps Nausea Delayed onset	 Differential Diagnosis Alcohol related issues Toxic overdose Trauma Seizure Syncope CNS disorder Stroke or TIA Pre-existing condition
	Treatmen	t Algorithm	
If Hypoglycemic: O Administer 1 tub O Maintain normo O In a diabetic pati If Hyperglycemic: O Monitor and trai	nger stick and measure blood glucose level oe of Oral Glucose. thermia. Unconscious diabetics are often hy ent with an insulin pump and blood glucose nsport 10% (D10), 250 ml at wide open rate, (250	less than 60 mg/dL, treat the hypogly	vcemia.
P For newborn, Dextro	10% (D10) 5 ml/kg, maximum single dose of se 10% (D10) 2 ml/kg if BGL is less than 40 may be repeated in ten minutes if blood sug	mg/dL.	
	mg/dL or "High" on glucometer, administer lid to a hyperglycemic pediatric patient, unle		AEMT
No additional orders at thi			
		e a ult	
None	Cor	isuit	

- Oral glucose is indicated for any conscious but disoriented patient with BGL less than 60 mg/dL, or in a strong suspicion of hypoglycemia despite BGL readings.
- Oral glucose may be administered carefully under the tongue or between the gum and cheek of an unresponsive patient who then must be
 placed in the lateral recumbent position to promote drainage of secretions away from the airway.
- When documenting the administration of **Dextrose 10% (D10)**, do so in terms of milliliters.
- Insulin Pumps
 - o For a diabetic patient with an insulin pump who is hypoglycemic, treat the hypoglycemia.
 - Do not disconnect or turn off pump.
 - o Take extra tubing and medication reservoir or vials to the receiving facility for patients with insulin pumps.





4009

Subject: Diabetic Emergencies – Refusal of Transport

Effective: June 1, 2021

Last Modified:

Dec. 8, 2021

4009.1 General Guidelines

- a. EMTs and above may allow for diabetic patients to refuse transport after treatment.
- b. EMRs should call for transport or a provider of a higher level certification.

4009.2 Procedures

- a. Patients 18 years of age or older may be permitted to refuse. Follow these guidelines:
 - i. Repeat physical examination and vital signs. Patient must be A&O x 3.
 - ii. Warn the patient that there is a significant risk of going back into hypoglycemia, especially if on oral hypoglycemics.
 - iii. Advise the patient to eat something substantial immediately.
 - iv. Advise the patient to contact their family physician as soon as possible to minimize future episodes.
 - v. Advise the patient to stay with someone.
 - vi. Follow normal patient refusal procedures.
- b. If the diabetic patient is under 18, but a parent or guardian is present, then the responsible adult may refuse patient trasnportation under the same guidelines as listed above in 4009.2.a.
- c. Send a copy of the run sheet to the EMS Coordinator of the hospital that replaces your Drug Bag and supplies.



4010

Subject:

Extrapyramidal (Dystonic) Reactions

Effective:

June 1, 2021

Last Modified:

Dec. 8, 2021

4010.1 General Guidelines

- a. A patient who is currently on a phenothiazine (e.g., Phenergan, Thorazine, Compazine) or a butyrophenone (e.g., Haldol, Droperidol) and exhibiting signs of acute muscle spasm or motor restlessness may be suffering from an Extrapyramidal Reaction.
- b. Extrapyramidal reactions can occur with ingestion of recreational drugs
- c. Physical examination findings may include any of the following:
 - i. Oculogyric crisis (spasmodic deviation of eyes in all directions generally fixed upward.)
 - ii. Buccolingual crisis (protrusion of tongue with slurred speech)
 - iii. Trismus (closing of the jaw due to spasm of the muscles also called lockjaw.)
 - iv. Difficulty in speaking
 - v. Facial grimacing
 - vi. Torticollis crisis (stiff neck with deviation of the head with the chin pointing to the other side)
 - vii. Opisthotonus (extreme back arching)
 - viii. Tortipelvic crisis—Involves hip, pelvis, and abdominal wall muscles, causes difficulty walking.
 - ix. Mental status is unaffected.
 - x. Vital signs are usually normal.
 - xi. Remaining physical examination findings are normal.

4010.2 Clinical Management

	Assessm	ent		
Pediatric Considerations None	Signs & Symptoms • As listed above	Differential Diagnosis Alcohol intoxication Toxin/substance abuse Medication effect Withdrawal syndromes Anxiety disorders Mental health history		
	Treatment A	lgorithm		
Provide basic care.Call for transport.			EMR	
	n 60, or there is strong suspicion of hypoglycemi <u>cies - Hypoglycemia</u> protocol	a despite glucometer readings, then follow	EMT	
 Initiate IV fluid to maint Diphenhydramine 50 Diphenhydramine 1 m 	·		AEMT	Paramedic
Paramedics do not need	a MCP order to administer Diphenhydramine .			Para
	Consu	ılt		
The AEMT needs orders	for Diphenhydramine			
	Clinical P	earls		
• None	·			
END OF SECTION	·		·	



4011

Subject: Obstetrical Emergencies

Effective: June 1, 2021

Last Modified:

Jul. 6, 2022

4011.1 General Guidelines

- a. Consider the possibility of ectopic pregnancy in females of child-bearing age.
- b. Ask for first day of last menstrual period.
- c. Gestational age should be expressed in weeks whenever possible.
- d. Aggressively treat for hypovolemic shock (do not rely on standard vital sign parameters).
- e. Give psychological support to patient and family.
- f. Be sure to take all expelled tissue with you to the hospital.

4011.2 Transport Decisions

- a. Transport to Maternity Department:
 - i. Pregnant patients, 20 weeks or greater gestation with obstetric complaints
 - ii. If unsure of time of gestation, then consider transport to a maternity department
- b. Transport to Emergency Department:
 - i. Pregnant patients with minor trauma or medical (non-obstetric) complaints
 - ii. Pregnant patients less than 20 weeks gestation
- c. Pregnant trauma patients should be rapidly transported to the ED at an Adult Trauma Center with labor and delivery capabilities.
- d. Positional transport considerations:
 - i. Prepare for postural hypotension caused by fetus pressure on venous return.
 - ii. Passively or actively move the fetus off the vena cava by doing either:
 - **1.** Place in left lateral recumbent position or place a pillow under the right abdominal flank/hip.
 - 2. Apply continuous manual displacement of the uterus towards the patient's left side.

4011.3 Cardiac Arrest In Pregnancy

- a. Causes of cardiac arrest in pregnant patients can include:
 - i. Pulmonary embolism
 - ii. Trauma
 - iii. Hemorrhage
 - iv. Congenital or acquired cardiac disease.
- b. Load and go to the closest hospital and follow all cardiac arrest protocols enroute.

4011.4 Third Trimester Bleeding

a. Aspirin is contraindicated in third trimester.

END OF SECTION

4011 – Obstetrical Emergencies Page 1 of 1



4012

Subject: Overdose/Poisoning

Effective: June 1, 2021

Last Modified:

July 22, 2023

4012.1 General Guidelines

- a. ♦ EMS personnel should contact MCP for direction on suspected poisonings.
- b. Poison Control is intended for use by the general public.
- c. If possible, provide receiving facility all available information about the substance:
 - i. Safety data sheets (SDS)
 - ii. The container (if it is safe to do so)
 - iii. The label or an image of the label and warning information if it is unsafe or unpractical to transport the actual substance container

4012.2 Clinical Management

		Assessment	
Ped	diatric Considerations Most pediatric patients with respiratory depression do not have narcotic overdose. They are either septic or have respiratory failure.	Signs & Symptoms Mental status changes Hypo/hypertension Decreased respiratory rate Tachycardia or bradycardia Cardiac dysrhythmias Seizures	 Differential Diagnosis Respiratory depression Insecticides (organophosphates) Solvents, cleaning agents Cardiac medications Stimulants Depressants
		Treatment Algorithm	Depressants
•	P Greater than 20 kg 2 mg, IN, Titrate Naloxone to adequate respirations.	alf dose per nostril) es en 0.1 mg/kg IN , (max dose 2 mg), ma may repeat as needed	ay repeat x one
•	Consider patient restraint before administration	of Naloxone.	
•	No additional orders at this level.		T H
•	P Greater than 20 kg 2 mg, IN, P Naloxone slow IV is preferred P Titrate to adequate respiration	cone is approximately 2 minutes. If narcotic overdose: Ing IV or 4 mg IM IS. IO or inadequate response is noted IV, IM, may repeat as needed IV, IM, may be given IN or IM before IV	is established.
•	A Nitroglycerin 0.4 mg SL, if SBP >100, ev A Midazolam 10 mg, IN (5 mg in each nos A Repeat Midazolam 5 mg IN (2.5 mg in each G For patients greater than 69 y/o, reduced	very 5 minutes to a total of three doses stril) or 2.5 mg slow IV , or 5 mg IM each nostril) or 2.5 mg slow IV or 5 mg	with vital signs between doses IM for unrelieved chest pain

4012 – Overdose or Poisoning Page 1 of 2

4012

Subject:

Overdose/Poisoning

Effective:

June 1, 2021

Last Modified:

July 22, 2023

- <u>Tricyclic Antidepressant Overdose</u> may be evidenced by bradycardia, tachycardia, hypotension and prolongation of the QRS complex. Risk of rapid deterioration or sudden onset V Fib is high.
 - A ◆ Sodium Bicarbonate 100 mEq, slow IV
 - P Sodium Bicarbonate 1 mEq/kg slow IV
 - A ◆ Repeat Sodium Bicarbonate 50 mEq, slow IV for persistent QRS prolongation
 - P Repeat Sodium Bicarbonate 0.5 mEq/kg slow IV for persistent QRS prolongation
- <u>Calcium Channel Blocker Overdose</u>:
 - A ◆ Calcium Chloride, 1 Gm slow IV
 - P Calcium Chloride, 0.2 ml/kg (20 mg/kg) slow IV (max dose 500 mg)

Consult

- For guidance on suspected poisonings contact MCP.
- Calcium Channel Blocker, Beta Blocker and Trycyclic antidotes in this protocol are by MCP order only.

Clinical Pearls

- Consider other causes of altered mental status such as hypoglycemia, head trauma, sepsis, and stroke.
- When Naloxone is given intranasal (IN), the onset of action is approximately 2 minutes.
- Naloxone is not felt to be effective in the reversal of cardiac arrest from opioid overdose. Airway control, ventilation, and quality CPR are still the mainstay of treatment.
- Ondansetron (Zofran) is NOT to be given prophylactically with Naloxone.
- Tricyclic Antidepressant Examples:
 - Amitriptyline (Elavil, Endep, Etrafon, Limbitrol)
 - o Nortriptyline (Pamelor, Aventyl)
 - Amoxapine (Asendin)
 - o Clomipramine (Anafranil)
 - o Desipramine (Norpramine)
 - o Doxepin (Sinequan)
 - o Imipramine (Tofranil)
 - o Protriptyline (Vivactil)
 - o Trimipramine (Surmontil)
- Calcium Channel Blocker examples:
 - Amlodipine (Norvasc)
 - o Diltiazem (Cardizem, Dilacos)
 - Felodipine (Plendil)
 - Isradipine (Dynacirc)
 - Nifedipine (Procardia, Adalat)
 - Verapamil (Calan, Isoptin, Verelan)
- Beta Blocker examples
 - Acebutolol (Sectral)
 - o Atenolol (Tenormin)
 - Carvedilol (Coreg)
 - o Corzide, Inderide, Lopressor, HCT, Tenoretic, Timolide, Ziac
 - Labetalol (Normodyne, Trandate)
 - Metoprolol (Topral, Lopressor)
 - Nadolol (Corgard)
 - o Pindolol (Viskin)
 - Propranolol (Inderal)
 - Sotalol (Betapace)
 - o Timolol (Blocadren)

END OF SECTION

4012 – Overdose or Poisoning Page 2 of 2

4013

Subject:

Respiratory Distress/Pulmonary Edema

Effective: June 1, 2021

Last Modified:

Sept. 9, 2021

4013.1 Clinical Management

Pediatric Considerations	Assessment			
• None	Signs & Symptoms Cyanosis Clammy skin Presence/Absence of fever Coughing Wheezing Labored breathing Diaphoresis Pitting edema Bilateral lower lobe rales Tachypnea Apprehension Jugular vein distension (JVD) Inability to talk.	Differential Diagnosis Myocardial infarction Congestive heart failure Asthma Anaphylaxis Aspiration Chronic obstructive pulmonary disease Pleural effusion Pneumonia Pulmonary embolus Pericardial tamponade		
	Treatment Algorith	nm		
 Evaluate breath sounds. Obtain pulse oximetry reading. Obtain capnography reading. Provide high flow O₂. Call for transport. {Obtain and transmit 12 Lead EKGA If Pulmonary Edema, then Continuous 	i} uous Positive Pressure Airway (CPAP)		EMR	
	prior to the initiation of drug therapy. er than 100, Nitroglycerin 0.4 mg SL up to 3,	1 every 5 minutes.		AEMT
•	encouraged prior to the initiation of drug the ble early endotracheal intubation. Consult	rapy.		Paramedic
None	Consuit			
	Clinical Pearls			
 Wheezes: treat cause (Rales: treat cause (Diminished or abse Unilatera Bilateral: 	e.g. MI, pulmonary embolism, metabolic dist use (e.g. pulmonary edema, FBAO, asthma, al (e.g. pulmonary edema, pneumonia). ent: al: treat cause (e.g., pneumothorax, hemotho treat cause (e.g., respiratory failure, COPD, a	lergic reaction). rax, pneumonia, surgically removed lung).	perat	ure.



4014

Subject:

Seizures

Effective: June 1, 2021

Last Modified:

Dec. 23, 2023

4014.1 Clinical Management

	Assessment			
Pediatric Considerations None	Signs & Symptoms Decreased mental status Sleepiness Incontinence Observed seizure activity Evidence of trauma	Differential Diagnosis Head trauma Tumor Metabolic, hepatic or renal failure Hypoxia Electrolyte abnormality Drugs, medications Infection/fever Alcohol withdrawal Eclampsia Stroke/TIA Hyperthermia Psychogenic Non-epileptic Seizures		
	Treatment Algorit	hm		
 BVM and nasopharyngeal airway Maintain normothermia. Obtain Pulse Oximeter and {Capr 	nography} reading.	ucometer readings, then follow	EMR	
4008 Hypoglycemia/Hyperglycemia Place patient in the recovery position during assessment and transport.				
A Midazolam 10 mg IN (S A If still seizing, repeat Mida A Repeat Mida A Or repeat Mi A Or repeat Mi	an 69 y/o, reduce dosing for sedatives and an 5 mg in each nostril), or Midazolam 2.5 mg sloidazolam doses: zolam 5 mg IN (2.5 mg in each nostril) after 1 dazolam 2.5 mg slow IV after 5 minutes. dazolam 5 mg IM after 10 minutes.	ow IV, or Midazolam 5 mg IM		
mg/kg IM (max IM dos P If still seizing, repeat M P Repeat Mida P Or repeat M	(max IN dose 10 mg) <i>or</i> Midazolam 0.1 mg/k e 5 mg)	mg) after 5 minutes		AEMT
		inter 10 minutes		
No additional orders at this level				
None	Consult			
 None 				
	Clinical Poorle			
 When obtaining history be sure t 	Clinical Pearls			

END OF SECTION

toxicological agents)

4014 - Seizures Page 1 of 1

Other known medical history (e.g., head injury, diabetes, drugs, alcohol, stroke, heart disease, recent fever or illness, possible



4015

Subject: Sepsis

Effective: June 1, 2021

Last Modified:

Feb. 18, 2024

4015.1 General Guidelines

- a. Severe sepsis is characterized by poor perfusion, leading to a buildup of serum lactate and resulting metabolic acidosis.
- b. To compensate for metabolic acidosis, patients increase their minute ventilation.
- c. This increased respiratory rate "blows off" carbon dioxide and lowers EtCO₂.
- d. EtCO₂ levels decline in the setting of both poor perfusion and metabolic acidosis.
- e. Poor tissue perfusion decreases the amount of blood flow to the alveoli of the lungs, reducing the amount of carbon dioxide that can be exhaled
- f. Sepsis is often associated with a high mortality rate. The key to improve patient outcomes in septic shock is early recognition, fluid resuscitation, O₂ therapy and rapid transport.

4015.2 Clinical Management

	Assessment					
Pediatric ConsiderationsNone	Signs & Symptoms • Known or suspected infection • EtCO₂ less than 32 or greater than 47 with 2 or more of the following criteria: ○ Respiratory rate greater than or equal to 22 ○ Altered mental status (GCS less than 13) ○ Temperature over 100.4 (38 C) or under 96.8 (36 C) ○ Heart rate greater than 90 ○ Systolic BP less than 100 or Mean Arterial Pressure (MAP) below 65	 Differential Diagnosis Fever Flu-like symptoms 				
	Treatment Algorithm					
Administer oxygenCall for transport immediate	ly.	EMR				
 No additional orders at this level. If possible, obtain blood sample via finger stick and measure blood glucose level 						
Administer a bolus of 1 liter of IV fluid. ◆ For additional fluid administration.						
 Consider Norepinephrine by adding 4 mg to 250 ml of IV fluids. Infuse starting at 30 drops per minute (max 45 drops) with 60 drop tubing and titrate to effect. Increase by 5 drops/minute every 5 minutes. 						
	Consult					
Consult with MCP to give more than 1 liter of fluids.						
	Clinical Pearls					
 MAP = (SBP + 2 X DBP) / 3 ar Patients may be in septic sho CAUTION: Be especially susp 	P) is considered to be the organ perfusion pressure. Indicate the is normally 70 – 110 mm/hg. Indicate the is normal blood pressure. Indicate the isolated in a series of potentially septic patients.					

END OF SECTION

4015 - Sepsis Page **1** of **1**



4016

Subject: Shock

Effective: June 1, 2021

Last Modified:

Apr. 15, 2022

4016.1 General Guidelines

- a. Shock is inadequate tissue perfusion.
- b. Be proactive in treatment of shock. Do not wait for symptoms to present.
- c. Management of shock should include trying to find and correct the underlying cause (if possible).

4016.2 Clinical Management

Assessment Pediatric Considerations Differential Diagnosis Signs & Symptoms Pediatric patients will compensate longer Restlessness, confusion Hypovolemia than adults. Cardiogenic Weakness and dizziness Apparent signs and symptoms of shock can Tachycardia Septic indicate a critical patient. Tachypnea Neurogenic Hypotension Anaphylactic Decreased mentation Pulmonary emboli Pale, cool, clammy skin Tension pneumothorax Medications or overdose Vasovagal hypotension **Treatment Algorithm** Call for transport immediately. Provide O2 as appropriate Keep patient warm. EMR Control external bleeding and treat for hypovolemic shock as indicated. Transport immediately unless ALS intercept is less than 5 minutes. Only give fluids for specific signs and symptoms of shock and not to every trauma patient. For persistent shock, establish additional vascular access. Non-traumatic shock without Pulmonary Edema: Patient does not have JVD, edema, or rales. IV fluid 500 ml IV. Maintain adequate perfusion. IV fluid 20 ml/kg IV. Titrate to maintain adequate perfusion. A Additional IV fluid 500 ml IV, if needed. ◆ Additional IV fluid 20 ml/kg IV, if needed. Non-traumatic shock with Pulmonary Edema: Patient may have JVD, edema, or rales present. A Consider IV fluid 250 ml IV. **Exsanguinating Hemorrhage:** A IV fluid to maintain approximately 100 SBP enroute to hospital. Do not allow blood pressure to get too high. AEMT IV fluid 20 ml/kg IV. May repeat x 2. Titrate to maintain adequate perfusion. For non-traumatic shock: Treat arrhythmias as indicated. If SBP remains less than 100, begin Norepinephrine by adding 4 mg to 250 ml of IV fluids. Infuse starting at 30 drops per minute (max 45 drops) with 60 drop tubing and titrate to effect. Increase by 5 drops/minute every 5 minutes. Consult • For repeat fluid challenges in non-traumatic shock without pulmonary edema. **Clinical Pearls**

END OF SECTION

4016 - Shock Page **1** of 1

Perform manual BP on all patients presenting with signs and symptoms of shock.



4017

Stroke

Subject:

Effective: June 1, 2021 Last Modified:

Feb. 18, 2024

4017.1 **General Guidelines**

- a. If one or more signs of the Cincinnati Prehospital Stroke Scale (CPSS) are abnormal, and less than 24 hours since patient was last seen normal, call a "Stroke Alert", and transport to the closest appropriate Stroke Center.
- b. In addition to the CPSS, providers should screen patients for possible large vessel occlusions (LVO) before making transport destination decisions.
- c. If greater than 24 hours since last known well, consider transport to a Comprehensive or Thrombectomy Capable facility.
- d. When reporting last known well, state actual clock time. Do not say, "20 minutes ago."
- e. With such a diverse group of agencies and receiving hospital capabilities covered by this protocol, all agencies should discuss "best practices" for assessment, management, and transport of possible strokes with their Medical Directors. With approval, agencies may deviate from this guideline in the following manners:
 - i. Agencies may use alternative stroke screening scales (RACE, MEND, LAPSS, etc.) for evaluation of possible CVAs. All screening tools should include the routine assessments found in the CPSS and methods to screen for large vessel occlusions.
 - ii. Agencies may make transport destination decisions based on their proximity to stroke management facilities and the capabilities of those hospitals.
 - iii. All modifications to this protocol should be made in the form of a supplemental guideline specifically approved and signed off by the medical director.

4017.2 **Clinical Management**

Assessment Pediatric Considerations Signs & Symptoms **Differential Diagnosis** None Facial drooping Seizure Subdural hematoma Arm drift or weakness Slurred or difficult speech Brain tumor Aphasia (expressive or receptive) Syncope Toxic or metabolic disorders (e.g., hypoglycemia) Pupillary changes (in hemorrhagic strokes) Gaze deviation/abnormal eye movement Migraine headaches (indicative of large vessel occlusions) **Treatment Algorithm**

- Perform a Cincinnati Pre-hospital Stroke Scale (or alternative approved by Medical Direction) assessment.
- A patient in respiratory distress with pale, moist skin and altered mental status should get oxygen via NRB mask.
- Be prepared to assist ventilations with OPA/NPA and Bag-valve-mask.
- If signs of cerebral herniation are present, ventilate at the following rates:
 - A Approximately 20 times per minute.
 - Ventilate at a rate of ten faster than normal respiratory rate if the signs of cerebral herniation are present.
 - {If numeric EtCO2 readings are available, ventilate at a rate to maintain readings at approximately 30 mmHg (30 torr)}
 - Never ventilate at less than 8 per minute.
- A patient with indications of stroke with a SpO₂ less than 94%, should be given oxygen via NC and titrated to 94%.
- A patient with indications of stroke with a SpO₂ greater than 94%, should not get any oxygen.

EMR

4017 - Stroke Page 1 of 2

4017

Subject: Stroke

Effective: June 1, 2021

Last Modified:

Feb. 18, 2024

- The presence of a single a bnormal finding in the CPSS (or a Iternative screening approved by Medical Direction) should dictate a stroke alert and transport to the closest stroke center (unless contraindicated by greater than 24-hour onset, presence of LVO indicators or thrombolytic considerations).
- Perform a Large Vessel Occlusion (LVO) screening looking for:
 - o Difficulty in balance or gait
 - Eye deviation eyes may only move to one side, or be forced to one side
 - O Visual disturbances field of view cut, double vision, new onset blindness
 - Aphasia expressive (inability to speak or paraphasic errors) or receptive (not understanding or following commands)
 - o Denial/Neglect can a patient feel you touch both of their arms and do they recognize their own hand?
- Consider the following contradictions to thrombolytics:
 - o Neurosurgery, head trauma or stroke in the last 3 months
 - o Major surgery or serious non-head trauma in the previous 14 days
 - o History of gastrointestinal or urinary tract hemorrhage within 21 days
 - O Current (within the last 48 hours) use of anticoagulants. Examples include:
 - Warfarin (Coumadin, Jantoven)
- Edoxaban (Savaysa)

- Apixiban (Eliquis)
- Ri va roxaban (Xarelto)
- Abigatran (Pradaxa)
- Lovenoxinjections
- Patients with onset greater than 24 hours, clinical findings indicative of LVO or with contraindications to thrombolytics consider transport to a Comprehensive Stroke Center or Thrombectomy Capable Facility.
 - Patients with signs or symptoms that strongly indication a possible hemorrhagic stroke should not be transported to a Thrombectomy Capable Facility
- Transport the patient with the bed flat, if a ble to tolerate. If showing signs of increased ICP, do not lay patient flat.
- If glucose is less than 60, or there is strong suspicion of hypoglycemia despite glucometer readings, then follow 4008 Diabetic Emergencies - Hypoglycemia protocol
- No additional orders at this level
- No additional orders at this level

Consult

Contact MCP for Stroke Alerts or for advice regarding transport destination, if not clear.

Clinical Pearls

- Cincinnati Prehospital Stroke Scale: (normal or a bnormal)
 - o Facial Droop (patient shows teeth or smiles).
 - Arm Drift (patient closes eyes and holds both arms straight out for about 10 seconds).
 - o Abnormal Speech (have patient say "You can't teach an old dog new tricks." or any other phrase).
- Possible indicators of a large vessel occlusion (LVO):
 - o The presence of a bnormal findings in all three categories of the Cincinnati Prehospital Stroke Test increase the possibility of LVO
 - O Visual neglect, gaze deviation, or abnormal eye movement are key clinical findings
 - o New onset loss of balance or coordination may indicate a possible LVO stroke
- Arrange for transport a historian with patient both to provide patient history and for permission to treat.

4017.3 Stroke Centers

- a. <u>Telemedicine Stroke Center</u>: Also known as drip and ship, has thrombolytic capabilities and immediate access to a Neurologist via telemedicine.
- b. **Primary Stroke Center:** Facility with capability to administer thrombolytics and has an ICU.
- c. <u>Comprehensive Stroke Centers or Thrombectomy Capable</u>: Facilities with 24/7 endovascular capabilities.
 - i. Miami Valley Hospital (Comprehensive)
 - ii. Kettering (Comprehensive)
 - iii. Mercy Health Springfield (Thrombectomy Capable)

END OF SECTION

4017 - Stroke Page **2** of 2

5000 Series

Pediatric Protocol



Pediatric Protocol

5001

Subject:

Apparent Life Threatening Event (ALTE)

Effective:

June 1, 2021

Last Modified:

Jan. 8, 2022

5001.1 General Guidelines

- a. An Apparent Life-Threatening Event involves any infant under 1 year of age that is witnessed with a frightening event by an observer and involves some combination of the following:
 - i. Apnea
 - ii. Choking or gagging
 - iii. Color change (cyanosis, pallor)
 - iv. Change in muscle tone (limpness, sometimes rigidity)
- b. Also referred to as a BRUE (Brief Resolved Unexplained Event)
- c. Children who experience an ALTE event often have a normal exam on assessment.
- d. A cause cannot be determined in 50% of ALTE cases.

5001.2 Important Information to Gather:

- a. Document the symptoms of the event given by the observer:
 - i. Was the child apneic, cyanotic or limp during event?
 - ii. Infant's color, respirations and muscle tone
 - iii. Was seizure-like activity noted?
 - iv. Was any resuscitation attempted or did event resolve spontaneously?
 - v. How long did the event last?
- b. Obtain past pertinent medical history:
 - i. Recent trauma, infection (e.g., fever, cough)
 - ii. History of gastroesophageal reflux (GERD)
 - iii. History of congenital heart disease
 - iv. History of seizures
 - v. Medication history
 - vi. Birth defects

5001.3 Clinical Management

- a. Support airway, breathing, circulation.
- b. Keep warm.
- c. Head-to-Toe exam for trauma, bruising, or skin lesions.
- d. Check anterior fontanel: is it bulging, flat or sunken?
- e. Pupillary exam.
- f. Respiratory exam for rate, pattern, work of breathing and lung sounds.
- g. Cardiovascular exam symmetry of brachial and femoral pulses.
- h. Neuro exam for level of consciousness.
- i. Observe for repetition of reported occurrences.
- j. The patient should be transported to the hospital for further assessment.

5001.4 Management and Transport of Febrile Pediatric Patients

a. Transport all infants less than 2 months of age with a history or reported temperature of greater than 38.0 C (100.4 F) or less than 35.6 C (96.0 F).



Pediatric Considerations

5002

Subject:

Newborn Care and Resuscitation

Effective: June 1, 2021

Last Modified:

Mar. 4, 2021

5002.1 General Guidelines

- a. Maintain airway. Place in the sniffing position (1" towel under shoulders).
- b. If drying and suctioning has not provided enough tactile stimulation, flick the infant's feet or rub the infant's back.
- c. Suction only infants in distress, until airway is clear of all secretions. Bulb suctioning is preferred.
- d. If meconium staining is present:
 - i. Newborn is vigorous, with strong respirations, good muscle tone, and heart rate greater than 100 BPM; monitor the patient and maintain a patent airway.
 - ii. Newborn is depressed, has poor respiratory effort, decreased muscle tone, or heart rate less than 100 BPM; clear the airway by suctioning before taking other resuscitative steps.
- e. Avoid direct application of cool oxygen to infant's facial area as may cause respiratory depression due to a strong mammalian dive reflex present immediately after birth.
- f. If stimulation does not improve the infant's breathing, then BVM assist may be necessary.

5002.2 Viable Fetus

- a. If the fetus is greater than 23 weeks gestation, follow normal resuscitative procedures.
- b. A fetus is viable if:
 - i. Eyelids not fused
 - ii. If measurable or known, must be greater 500 grams

5002.3 Clinical Management

		Assessment					
Pediatric CorNothing	nsiderations gadditional	 Signs & Symptoms Respiratory distress Central cyanosis Altered level of consciousness 	Diff	fferential Diagnosis Peripheral cyanosis (normal) Infection Maternal medication effect			
		Bradycardia	•	Hypothermia, hypoglycemia, hyp	oovolemia		
P P P Ventilat	Assess the airway and be Warm, dry and stimulate Position head lower that with BVM at 40-60/minurate is less than 60 bpm be Compress at 120/min. Compression to Ventilate	e h body. te to increase HR (if less than 100) or for apperent CPR.		stent central cyanosis.	EMR		
P Obtain	APGAR scores at 1, 5 and 1	0 minutes post-delivery.				EMT	
P Conside		over 5-10 minutes. IO or IM every 3 minutes until respirations i mI/kg if blood glucose less than 40.	mprove				AEMT
	rate remains less than 60 Epinephrine 1:10,000, 0	ppm after CPR:	5 minutes.				
	,	Consult					
 Contact 	MCP for instructions and	guidance when attempting to determine the	viability of a	a fetus.			
		Clinical Pearls					
		e on all neonatal resuscitations. n infants only if the suction pressure does n	ot exceed 10	00 mmHg or 136 cmH ₂ O.			



Pediatric Considerations

5003

Subject:

Pediatric Assessment Triangle

Effective: June 1, 2021

Last Modified:

Dec. 8, 2020

5003.1 General Guidelines

- a. The Pediatric Assessment Triangle establishes a level of severity, assists in determining urgency for life support measures, and identifies key physiological problems using observational & listening skills.
- b. This assessment tool can be utilized by providers of all certification levels.

5003.2 Appearance

- a. Appearance reflects adequacy of: oxygenation ventilation, brain perfusion, CNS function.
 - i. The mnemonic used for pediatric assessment of appearance is: TICLS.
 - 1. Tone- Moves spontaneously, sits or stands (age appropriate)
 - 2. Interaction- Alert, interacts with environment
 - 3. Consolability- Stops crying with comfort measures (holding, warmth, distraction)
 - 4. Look/gaze Makes eye contact with clinician, tracks objects
 - 5. **S**peech/cry Uses age appropriate speech or crying


5003.3 Work of Breathing

- a. WOB is a more accurate indicator of oxygenation and ventilation than respiratory rate or breath sounds.
- b. Assess for effort in breathing, accessory muscle use, and depth of breathing.
- c. Capillary refill is an accurate predictor of pediatric oxygenation.
- d. Under work of breathing, the patient should fall into one of four categories:
 - i. Normal Breathing
 - ii. Respiratory difficulty
 - iii. Respiratory failure
 - iv. Respiratory arrest

5003.4 Circulation

- a. Circulation reflects adequacy of cardiac output and perfusion of vital organs (core perfusion).
- b. Cyanosis reflects decreased oxygen levels in arterial blood, vasoconstriction and respiratory failure.
- c. Mottling of the skin indicates hypoxemia, vasoconstriction and respiratory failure.

5003.5 The Pediatric Assessment Triangle





5004

Safe Harbor

Effective: June 1, 2021

Last Modified:

Dec. 8, 2020

5004.1 General Guidelines

- a. Safe Harbor is for the voluntary separation of newborn infant.
- b. It is designed to allow desperate parents to separate from their babies to hospitals, EMS, or law enforcement agencies, confidentially.

5004.2 Clinical Management

- a. Stipulations of separation:
 - i. Infant can be no older than be 30 days old.
 - ii. Infant can have no signs of abuse or neglect
- b. History which should be obtained:
 - i. Date and time of birth
 - ii. Any pertinent family medical history
 - iii. Information regarding prenatal care
 - iv. Information concerning the birth.
- c. Information should be obtained in a manner, which will not lead to the revealing of the identity of the parents.
- d. Information collected should be based on patient (infant) care needs and assure confidentiality.
- e. Transport the infant to the hospital.

END OF SECTION

5004 – Safe Harbor Page 1 of 1



6000 Series

Special Operations Protocol



Hazardous Material Protocol

6001

Subject:

General Management for Haz Mat

June 1, 2021

Last Modified:

Dec. 8, 2020

6001.1 General Guidelines

a. This section will provide the responders with direction toward the management and mitigation of Hazardous Material events.

Effective:

b. The initial goal of any hazardous materials release is to isolate and identify.

6001.2 Initial Actions

- a. Personnel safety:
 - i. Consider potential for secondary devices
 - ii. Don appropriate PPE
 - iii. Stage personnel & equipment
- b. Call for additional resources. (Haz Mat Teams, Decon crews, Law Enforcement, etc.)
- c. Field decontamination:
 - i. Remove all contaminated clothing
 - ii. Thoroughly wash the patient with {Dawn} dishwashing detergents
 - iii. Pay special attention to skin folds and other areas where simple irrigation may not remove it
 - iv. If a patient has been contaminated with any fuel, irrigate well
- d. Contact Medical Control and the hospital immediately to allow time for their set-up of decontamination equipment.
 - i. Provide the following information:
 - 1. Estimated number of confirmed or potential adult and pediatric patients
 - 2. Signs and symptoms exhibited by the patients
 - 3. Name and identification information of the contaminant if known, or as much information as possible
 - 4. Form of the contaminant (liquid, gas, etc.) if known
 - 5. Routes of exposure of the patients (percutaneous, inhalation, ingestion, etc.) if known
 - 6. Additional anticipated decontamination needs if necessary.
 - ii. Obtain permission from hospital upon arrival before entering with a potentially contaminated patient or crew.
- e. In the event of an MCI involving cyanide or nerve agents, request an "Antidote free" order, allowing you to treat all of the patients on the scene with the appropriate antidote, rather than calling for patient orders individually.
- f. Do **not** transport a patient until gross decontamination is completed.
- g. Decontaminate EMS vehicles prior to leaving hospital.



6002

Subject: Antidote Resources

Effective: June 1, 2021

Last Modified:

Mar. 15, 2023

6002.1 Antidote Options

a. {EMS Departments are authorized to stockpile **Atropine**, **2-PAM**, auto-injectors, and antidote delivery supplies at their own expense}

b. Dayton MMRS Caches

- i. Dayton MMRS stores additional supplies of cyanide antidotes in each county in Ohio Homeland Security Region 3.
- ii. To obtain Dayton MMRS antidotes: call 937-333-USAR (8727).
- iii. The closest department with an antidote cache will respond as a mutual aid request.

c. CHEMPACK Resources:

- i. Store of antidotes to treat about 500 victims of a nerve agent or organophosphate incident
- ii. EMS CHEMPACK contents:
 - 1. Atropine—blocks effects of excess acetylcholine
 - a. **0.5 mg AtroPen** auto-injectors (for patients less than 20 kgs)
 - b. **1.0 mg AtroPen** auto-injectors (for patients 20-40 kgs)
 - c. Multi-dose vials
 - 2. Pralidoxime Chloride (2-PAM)—reduces levels of acetylcholine
 - a. 600 mg auto-injectors
 - b. Multi-dose vials
 - 3. **Diazepam (Valium)**—treats seizures.
 - a. Convulsive Antidote, Nerve Agent (CANA) (10mg Diazepam auto-injector)
 - 4. Both EMS and Hospital CHEMPACKs contain the same three drugs.

iii. Hospital CHEMPACK contents

- 1. More multi-dose vials for more precise dosing of children and long-term patients.
- 2. Hospitals have the option to keep the materials for use at their hospital.
- 3. If a hospital opens its CHEMPACK, it must notify OSP Central Dispatch.

iv. CHEMPACK Limitations

- 1. Only useful against nerve agents or organophosphate
- 2. Only to be utilized when other resources are inadequate for number of victims.
- 3. CHEMPACKs opened contrary to guidelines will not be replaced by CDC

6002 – Antidote Resources Page 1 of 2

6002

Subject: Antidote Resources

Effective: June 1, 2021

Last Modified:

Mar. 15, 2023

v. CHEMPACK procurement:

- 1. ♦ Obtain MCP approval
- 2. ♦ Contact OSP Central Dispatch 866-599-LERP (5377) and request a CHEMPACK
- 3. You must indicate that the scenario meets both of the following criteria:
 - The agent has been identified, or patients are exhibiting signs and symptoms of organophosphate/nerve agent exposure.
 - b. The need for antidotes is greater than the available resources.
- 4. OSP Central Dispatch will:

AND

- a. Notify closest CHEMPACK hospital
- b. Dispatch Troopers to deliver the CHEMPACK to the MCI's staging area.
- c. Troopers will expect EMS to sign a form indicating receipt.

6002 – Antidote Resources Page 2 of 2

6003

Subject:

Hazardous Drug Exposure

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

6003.1 Identification or Recognition of a Hazardous Drug Situation

- a. Hazardous drug situations include:
 - i. Patients who have just had IV chemotherapy at the clinic or hospital
 - 1. Body fluids could have traces of hazardous drugs for up to 48 hours.
 - ii. Patients taking oral chemotherapy drugs.
 - iii. Patients who have continuous IV chemotherapy at home.
- b. Potential routes of exposure include:
 - i. Absorption through skin or mucous membranes
 - ii. Accidental injection by needle stick or contaminated sharps
 - iii. Inhalation of drug aerosols, dust, or droplets
 - iv. Ingestion through contaminated food, tobacco products, beverage, etc.
- c. Don PPE listed below whenever there is a risk of hazardous drug being released into the environment.
 - i. When handling leakage from tubing, syringe, and connection sites.
 - ii. When disposing of hazardous drugs or items contaminated by hazardous drugs.
 - iii. When handling the body fluids of a patient who received hazardous drugs in the past 48 hours.
 - iv. When cleaning hazardous drug spills

6003.2 Guidelines for Personal Protective Equipment:

- a. Gloves: two sets of nitrile gloves are recommended. Change gloves every 30 minutes.
- b. Disposable, non-permeable gowns
- c. NIOSH-approved respirator masks
- d. Eye and face protection: wear a face shield whenever there is a possibility of splashing.

6003.3 Procedures:

- a. Wipe up liquids with an absorbent pad or spill-control pillow.
- b. If necessary, consult with the appropriate Haz-Mat team.
- c. Dispose hazardous drugs or contaminated materials per MSDS or Haz Mat Team direction.
- d. Report and document spills as required.
- e. <u>For accidental skin exposure</u>: Remove contaminated garments, place in leak-proof plastic bag, and immediately wash contaminated skin with soap and water. Rinse thoroughly.
- f. <u>For accidental eye exposure</u>: immediately flush eye with saline solution or water for at least 30 minutes or until patient transport is completed.

6003.4 Identification or Clarification

- a. For more information about a hazardous drug or handling procedures, contact:
 - i. The homecare agency that is supplying the infusion.
 - ii. The physician who ordered the infusion.
 - iii. A hospital pharmacy, if necessary (there should be a label on the IV bag with the drug's name, concentration, and dosage.



6004

Subject:

Hydrofluoric Acid Exposure

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

6004.1 Clinical Management

Signs & Symptoms Berathing difficulty Abdominal pain Chest pain Burns (with blisters) Stridor (if inhaled) Treatment Algorithm Ensure the safety of all responders. Begin decontamination and irrigate the chemical burn with water as quickly as possible. Flush affected eyes and skin with copious amounts of water or IV Fluids for a minimum of 30 minutes. Continue flush until patient transport is completed. If ingested, do not induce vomiting, Dilute with water or milk. Monitor for cardiac arrest. (Perform a 12-lead EKG and transmit it to the hospital) Intubate if apneic. Consider 1014 Pain Management Protocol When feasible, use (Magnesium Sulfate solution (Epsom salt)) as an additional irrigating solution for affected skin. Magnesium Sulfate is not for eyes or mucous membranes. Getting water on the burn is more urgent than the use of Epsom salt. Do not delay irrigation or decontamination. If available, use (Epsom salt solution) on the skin for at least 30 minutes. If ingested, in addition to water or milk, give (3-4 ounces of magnesium-containing antacid (i.e., Maalox or Mylanta)). Intubate if unconsclous or at first sign of pulmonary edema or respiratory distress. Perform a 12-lead EKG and monitor for prolonged CT interval. Apply (magnesium-containing antacid (Maalox or Mylanta)) topically to burned areas. Omit if topical agents have already been applied prior to arrival. If patient with HF exposure experiences tetany or cardiac arrest, administer Calcium Chloride 10% 1 g (10 ml), IV. Calcium Chloride 10% should be considered a first ind require a cardiac arrest associated with Hydrofluoric Acid. Only ABCs, definition, intubation and Epinephrine should precede its administration. If patient was exposed to high concentration HF (greater than 40%), discuss prophylactic Calcium Chloride 10% 400 mg (4 ml), slow IV with MCP. Consult The paramedic should contact MCP for administration of Calcium Chloride 10% Clinical Pearls		Assessmer		
Ensure the safety of all responders. Begin decontamination and irrigate the chemical burn with water as quickly as possible. Flush affected eyes and skin with copious amounts of water or IV Fluids for a minimum of 30 minutes. O Continue flush until patient transport is completed. If ingested, do not induce vomiting. Dilute with water or milk. Monitor for cardiac arrest. {Perform a 12-lead EKG and transmit it to the hospital} Intubate if apneic. Consider 1014 Pain Management Protocol When feasible, use {Magnesium Sulfate solution (Epsom salt)} as an additional irrigating solution for affected skin. O Magnesium Sulfate is not for eyes or mucous membranes. Getting water on the burn is more urgent than the use of Epsom salt. Do not delay irrigation or decontamination. If available, use {Epsom salt solution} on the skin for at least 30 minutes. If ingested, in addition to water or milk, give {3-4 ounces of magnesium-containing antacid (i.e., Maalox or Mylanta)}. Intubate if unconscious or at first sign of pulmonary edema or respiratory distress. Perform a 12-lead EKG and monitor for prolonged QT interval. Apply (magnesium-containing antacid (Maalox or Mylanta)) topically to burned areas. O Omit if topical agents have already been applied prior to arrival. If patient with HF exposure experiences tetany or cardiac arrest, administrat Calcium Chloride 10% 1 g (10 ml), IV. Calcium Chloride 10% should be considered a first line drug in cardiac arrest associated with Hydrofluoric Acid. Only ABCs, defibrillation, intubation and Epinephrine should precede its administration of Salcium Chloride 10% 400 mg (4 ml), slow IV with MCP. Consult The paramedic should contact MCP for administration of Calcium Chloride 10% Clinical Pearls	diatric Considerations None	 Breathing difficulty Abdominal pain Chest pain Burns (with blisters) 		
Ensure the safety of all responders. Begin decontamination and irrigate the chemical burn with water as quickly as possible. Flush affected eyes and skin with copious amounts of water or IV Fluids for a minimum of 30 minutes. O Continue flush until patient transport is completed. If ingested, do not induce vomiting. Dilute with water or milk. Monitor for cardiac arrest. {Perform a 12-lead EKG and transmit it to the hospital} Intubate if apneic. Consider 1014 Pain Management Protocol When feasible, use {Magnesium Sulfate solution (Epsom salt)} as an additional irrigating solution for affected skin. O Magnesium Sulfate is not for eyes or mucous membranes. Getting water on the burn is more urgent than the use of Epsom salt. Do not delay irrigation or decontamination. If available, use {Epsom salt solution} on the skin for at least 30 minutes. If ingested, in addition to water or milk, give {3-4 ounces of magnesium-containing antacid (i.e., Maalox or Mylanta)}. Intubate if unconscious or at first sign of pulmonary edema or respiratory distress. Perform a 12-lead EKG and monitor for prolonged QT interval. Apply (magnesium-containing antacid (Maalox or Mylanta)) topically to burned areas. O Omit if topical agents have already been applied prior to arrival. If patient with HF exposure experiences tetany or cardiac arrest, administrat Calcium Chloride 10% 1 g (10 ml), IV. Calcium Chloride 10% should be considered a first line drug in cardiac arrest associated with Hydrofluoric Acid. Only ABCs, defibrillation, intubation and Epinephrine should precede its administration of Salcium Chloride 10% 400 mg (4 ml), slow IV with MCP. Consult The paramedic should contact MCP for administration of Calcium Chloride 10% Clinical Pearls		Treatment Algo	orithm	
Intubate if apneic. Consider 1014 Pain Management Protocol When feasible, use {Magnesium Sulfate solution (Epsom salt)} as an additional irrigating solution for affected skin. Magnesium Sulfate is not for eyes or mucous membranes. Getting water on the burn is more urgent than the use of Epsom salt. Do not delay irrigation or decontamination. If available, use {Epsom salt solution} on the skin for at least 30 minutes. If ingested, in addition to water or milk, give {3-4 ounces of magnesium-containing antacid (i.e., Maalox or Mylanta)}. Intubate if unconscious or at first sign of pulmonary edema or respiratory distress. Perform a 12-lead EKG and monitor for prolonged QT interval. Apply {magnesium-containing antacid (Maalox or Mylanta)} topically to burned areas. Omit if topical agents have already been applied prior to arrival. If patient with HF exposure experiences tetany or cardiac arrest, administer Calcium Chloride 10% 1 g (10 ml), IV. Calcium Chloride 10% should be considered a first line drug in cardiac arrest associated with Hydrofluoric Acid. Only ABCs, defibrillation, intubation and Epinephrine should precede its administration. If patient was exposed to high concentration HF (greater than 40%), discuss prophylactic Calcium Chloride 10% 400 mg (4 ml), slow IV with MCP. Consult The paramedic should contact MCP for administration of Calcium Chloride 10% Clinical Pearls	Begin decontamination and irr Flush affected eyes and skin w Continue flush until If ingested, do not induce vom	igate the chemical burn with water as quickl ith copious amounts of water or IV Fluids for patient transport is completed.		
When feasible, use {Magnesium Sulfate solution (Epsom salt)} as an additional irrigating solution for affected skin. Magnesium Sulfate is not for eyes or mucous membranes. Getting water on the burn is more urgent than the use of Epsom salt. Do not delay irrigation or decontamination. If available, use {Epsom salt solution} on the skin for at least 30 minutes. If ingested, in addition to water or milk, give (3-4 ounces of magnesium-containing antacid (i.e., Maalox or Mylanta)}. Intubate if unconscious or at first sign of pulmonary edema or respiratory distress. Perform a 12-lead EKG and monitor for prolonged QT interval. Apply {magnesium-containing antacid (Maalox or Mylanta)} topically to burned areas. Omit if topical agents have already been applied prior to arrival. If patient with HF exposure experiences tetany or cardiac arrest, administer Calcium Chloride 10% 1 g (10 ml), IV. Calcium Chloride 10% should be considered a first line drug in cardiac arrest associated with Hydrofluoric Acid. Only ABCs, defibrillation, intubation and Epinephrine should precede its administration. If patient was exposed to high concentration HF (greater than 40%), discuss prophylactic Calcium Chloride 10% 400 mg (4 ml), slow IV with MCP. Consult The paramedic should contact MCP for administration of Calcium Chloride 10% Clinical Pearls	{Perform a 12-lead EKG and tra	ansmit it to the hospital}		EMT
 Magnesium Sulfate is not for eyes or mucous membranes. Getting water on the burn is more urgent than the use of Epsom salt. Do not delay irrigation or decontamination. If available, use (Epsom salt solution) on the skin for at least 30 minutes. If ingested, in addition to water or milk, give {3-4 ounces of magnesium-containing antacid (i.e., Maalox or Mylanta)}. Intubate if unconscious or at first sign of pulmonary edema or respiratory distress. Perform a 12-lead EKG and monitor for prolonged QT interval. Apply {magnesium-containing antacid (Maalox or Mylanta)} topically to burned areas. Omit if topical agents have already been applied prior to arrival. If patient with HF exposure experiences tetany or cardiac arrest, administer Calcium Chloride 10% 1 g (10 ml), IV. Calcium Chloride 10% should be considered a first line drug in cardiac arrest associated with Hydrofluoric Acid. Only ABCs, defibrillation, intubation and Epinephrine should precede its administration. If patient was exposed to high concentration HF (greater than 40%), discuss prophylactic Calcium Chloride 10% 400 mg (4 ml), slow IV with MCP. Consult The paramedic should contact MCP for administration of Calcium Chloride 10% 	·	ent Protocol		
The paramedic should contact MCP for administration of Calcium Chloride 10% Clinical Pearls		s not for eyes or mucous membranes. burn is more urgent than the use of Epsome on or decontamination. burn salt solution} on the skin for at least 30 rear or milk, give {3-4 ounces of magnesium-corst sign of pulmonary edema or respiratory of the sign of th	salt. ninutes. ntaining antacid (i.e., Maalox or Mylanta)}. distress. arned areas. ter Calcium Chloride 10% 1 g (10 ml), IV. rdiac arrest associated with Hydrofluoric Acid. seede its administration.	
Clinical Pearls		Consult		
	The paramedic should contact	MCP for administration of Calcium Chloride	10%	
Death due to Hydrofluoric Acid has been reported from hurns involving loss than 2% hody surface area		Clinical Pea	rls	
	Doath due to Hydrofluoric Asia	has been reported from burns involving les	s than 2% hady surface area	



Subject:

Organophosphate or Nerve Agent Exposure

June 1, 2021

Last Modified:

Oct. 10, 2021

6005.1 **Clinical Management**

	Assessme	nt	
Pediatric Considerations None	Signs & Symptoms Salivation Lacrimation Urination Defecation Gastrointestinal Issues Emesis Miosis Muscle Twitching	 Differential Diagnosis None with a recent history of exposure to nerve agents 	
	Treatment Algo	orithm	
 → DouDotes of 	by DouDote every 5 minutes, as available until the lean be given to adult and pediatric over 40 kgs patie zepam Auto-injector (CANA).	ents.	
No additional orders at this level.			
 ◆ Treat seizures with Midazolam or Diazepam Auto-injector (CANA). G For patients greater than 69 y/o, reduce dosing for sedatives and analgesics to one half (½) of the adult doses ◆ Administer Atropine every 5 minutes (up to a total of three doses), as available until lungs are clear to auscultation. Atropine may be given IV, IM, IO or by AtroPen auto-injector for children, or by DuoDote. A Adults and children greater than 40 kgs, give DuoDote, or Atropine 2 mg, IV, IM. P ◆ Children 20 – 40 kg, give 1.0 mg Atropine, or the 1.0 mg Atropen auto-injector. P ◆ Children less than 20 kg, give 0.5 mg Atropine, or the 0.5 mg Atropen auto-injector. A Follow Atropine with 2-PAM (Pralidoxime) 600 mg IM. If DuoDote was used, no second auto-injector is needed. P Infants and young children should recieve Pralidoxime, 25-50 mg/kg IV or IM, if available. Treat seizures with Midazolam or Diazepam Auto-injector (CANA). 			
	Consult		
Contact MCP for admir	nistration of medications listed above. Clinical Pea	arls	
Treat any case of know Tahun Sarin Soman N		g., insecticides such as Parathion or Malathion); or nerve agent (e.g.,	

- Tabun, Sarin, Soman, VX) exposure.
- Mild to moderate cases should be treated with one or two doses of **Duodote**.
 - Severe cases will generally require repeating every 5 minutes up to 3 doses.
 - Organophosphate poisonings may require more Atropine (3 DuoDotes).
 - Atropine in these circumstances is not for bradycardia, which may or may not be present.
- Procedures for DuoDotes, pediatric AtroPens, and Diazepam auto-injectors are the same as administering an Epi-Pen.
- Primary endpoints for treatment are diminished airway secretions (lungs are clear to auscultation), hypoxia improves, airway resistance decreases, and dyspnea improves





6006

Subject: Other Hazardous Materials

June 1, 2021

Last Modified:

Mar. 15, 2023

6006.1 General Guidelines:

- a. These guidelines are for the management of specific materials.
- b. Unless otherwise noted, these orders apply to all certification levels.

6006.2 Specific Materials

a. Biological materials

 i. ◆ {For the possibility of a bioterrorist attack, agencies may store their own supply of Ciprofloxacin (Cipro) or Doxycycline.}

Effective:

ii. They can also provide prophylaxis against Anthrax, Cholera, and some protection against Plague.

b. Pepper Spray

i. **{Sudecon Wipes}** can assist in the decontamination of patients or public safety personnel who have been sprayed with Pepper Spray.

END OF SECTION

6006 – Other Hazardous Materials Page 1 of 1



7000 Series

Administrative



June 1, 2021

7001

Subject: Drug Bag Exchange Program:

General Operating Guidelines

Effective:

Last Modified:


Mar. 1, 2022

7001.1 Drug Bag Exchange Committee Make-up

- a. Co-Chairpersons:
 - i. One Hospital EMS coordinator
 - ii. One Hospital pharmacy representative from each participating county
- b. Members:
 - i. EMS Coordinator from each participating hospital
 - ii. Pharmacy representative from each participating hospital
 - iii. Any interested GMVEMSC (Greater Miami Valley EMS Council) member
- c. Meetings
 - i. Two scheduled meetings per year
 - ii. Unscheduled as needed to discuss problem areas

7001.2 General Operating Guidelines

- a. In order to participate in the GMVEMSC Drug Bag program, an agency must have the capability to communicate with Medical Control at participating hospitals.
- b. There are two types of drug bags: ALS/BLS and BLS (fanny pack style).
- c. All drug bags, both ALS/BLS and BLS, are the property of the GMVEMSC
- d. GMVEMSC drug bags are only for use by EMS providers located or stationed within GMVEMSC's region.
- e. Agencies may not use GMVEMSC drug bags for runs originating from stations outside of or responding to an address outside of GMVEMSC's region (except in case of mutual aid responses to those areas).
- f. Except in extreme circumstances, a GMVEMSC drug bag should not be used on multiple runs.
- g. There is an initiation fee for each new bag that EMS agencies add to the program.
- h. There is an annual maintenance fee for each ALS/BLS bag and BLS bag.
- i. For replacement of lost or stolen drug bags, see 7005 Lost or Stolen Drug Bag Policy.
- j. To maintain the integrity of the drug bag contents, pharmacy departments' seal each compartment of stocked drug bags with a blue plastic device. The seal should only be broken for administration of prehospital emergency medical treatment by approved EMS personnel. After prehospital emergency medical treatment use, the drug bag should be cleaned and re-sealed with the red plastic device contained inside each drug bag compartment.
- k. The following actions may be taken for any department found to be in non-compliance with the Drug Bag Exchange Program Operating Guideline regarding opening and resealing the drug bag:
 - i. Notification of the Fire Chief, EMS Administrator, or Private Ambulance Administrator.
 - ii. The governing agency, e.g., city council, trustees, EMFTS for private ambulance service, will be notified that action is being initiated for the Fire, EMS and Private ambulance service.
 - iii. Removal of all drug bags from all locations of said Fire, EMS and Private ambulance service.
 - iv. Written notification to the following that the said service is in violation of the operating policy of the Drug Bag Exchange Program:
 - 1. Medical Director
 - 2. Regional Physician Advisory Board
 - 3. Ohio State Pharmacy Board
 - 4. Ohio Division of EMS
 - 5. All hospitals participating in the drug bag exchange program



7001

Subject: Drug Bag Exchange Program:

General Operating Guidelines

June 1, 2021

Last Modified:

Mar 1, 2022

- I. GMVEMS Council maintains an information database for all EMS personnel authorized to participate in the Drug Bag Exchange Program.
- m. Rosters with certification expiration dates for EMS providers are available via an online database for review and updates.

Effective:

7001.3 Participation Requirements

- a. Active membership in the GMVEMS Council.
- b. Each agency in GMVEMSC must understand that Council typically communicates with departments and agencies via email, and that some of those messages concern changes to Standing Orders, pharmaceuticals in our Drug Bags, or other critical issues. Council maintains two lists of emails:
 - i. The GMVEMSC Listserve
 - ii. A distribution list of Agency Contacts
- c. As such, to participate in the Drug Bag Program, each agency must provide a minimum of one functioning email contact for each of those lists (may be the same person or different). Council desires to communicate as freely and effectively as possible, and agencies may provide as many as they like for each list, but must have at least one person who can reliably receive messages. Since in rare cases, these messages may be urgent, we encourage use of the "three-deep" rule: provide Council with three (or more) emails for each list.
- d. Additional Requirements For Drug Bag Program
 - i. The protocol testing compliance letter (7008) must be signed by the Chief within two weeks after completion of the CBT cycle, then faxed to Council.
 - ii. The copy of the license needs to go to Council by March 31 of each calendar year that the agencies' drug license is renewed. This is required, as the Pharmacy at each hospital needs the license on file in order to exchange drug bags with your department.
 - iii. Complete drug bag updates when scheduled. This is essential. The Pharmacy Board has made it very clear that updates must be completed on time.
 - iv. Signed agreement to abide by the GMVEMS Council Operating Guidelines for the Drug Bag Exchange Program (see 7007 Drug Bag Exchange Program Agency Agreement Letter)
- e. No department which participates in the Drug Bag Exchange Program shall possess a DEA License.
- f. Area hospital participation according to Council guidelines. (See 7006 Hospital Participation Policy).
- g. Document medical advisor approval for the use of the GMVEMS Council Operating Protocols with a signed, notarized letter, which is attached to the drug license renewal application form with a copy submitted to Council. Notarized letter is not required for renewal unless medications are added or there is a change in Medical Director from previous year.
- h. Agreement to complete the GMVEMSC annual skills and annual written test between 1 March and 31 May unless otherwise scheduled by Council (see Non-Compliance Procedures).
- i. Maintain all drugs at all times in a clean, temperature-controlled environment per Rule 4729-33-03 of the OH State Pharmacy Board Administrative Code.
- j. The rules can be seen at: https://codes.ohio.gov/ohio-administrative-code/rule-4729:3-3-03
- k. The ideal temperature span is 59-86 degrees Fahrenheit.
- I. In order to utilize an ALS/BLS or BLS drug bag in the pre-hospital emergency setting, the following equipment must be available, unless otherwise noted:



June 1, 2021

7001

Subject: Drug Bag Exchange Program:

General Operating Guidelines

Effective:

Last Modified:

Mar. 1, 2022

i. BLS Provider:

- 1. Oxygen
- 2. Pulse Oximetry
- 3. Extraglottic Airways
- 4. CPAP administration and management
- 5. Oral Glucose
- 6. Glucometry
- 7. Ice Packs
- 8. Suction (manual is acceptable)
- 9. AED (if approved by Medical Advisor)

ii. ALS Provider:

- Oxygen
- 2. EtCO₂ detection, monitoring and waveform for intubated patients
- 3. 12-Lead acquisition, transmission and interpretation
- 4. Mucosal Atomizer Device (MAD)
- 5. IO and device
- 6. BAAM
- 7. Digital intubation
- 8. IV pressure infuser
- 9. Suction (manual is acceptable)
- 10. Monitor or defibrillator or AED & intubation equipment
- m. Departments are required to have a tracking system that tracks all drug bag exchanges.

7001.4 General Non-Compliance Procedures

- a. Each agency and their Medical Director(s) will be notified if the annual written test and skills check-off has not been completed within the prescribed time period.
- b. The Ohio State Board of Pharmacy will be notified that a department or individual members of a department have not completed the annual written test and skills check-off within the prescribed time period.
- c. Hospital EMS coordinators and pharmacy departments will receive a list of departments or individuals within a department that are not in compliance with the operating guidelines.
- d. At the end of the testing season, if a department does not have 100% of their personnel completing both skill and written tests (or explanations for individuals not in compliance) noted in the Standing Orders database, then appropriate action, up to and including the removal of department from the Drug Bag program, may be taken by the chair of the drug bag committee.
- e. If copy of drug license(s) is not received by due date, GMVEMS Council will notify the agencies' medical director. GMVEMS Council reserves the right to initiate the non-compliance action process for any Fire/EMS/Private Ambulance service that does not provide documentation for drug license(s) renewal.

7001.5 Levels of Participation

- a. Paramedic Level
 - i. Each drug bag consists of a navy, standard issue drug bag.



7001

Subject: Drug Bag Exchange Program:

General Operating Guidelines

Effective:

June 1, 2021

Mar. 1, 2022

- ii. Each standard issue bag is labeled with a metal tag reflecting the assigned bag number.
- iii. A Paramedic can access any of the compartments within the bag to obtain medications.

b. AEMT Level

- i. A side compartment will be labeled "Intermediate"
- ii. The AEMT can access compartments to obtain medications per their protocol.
- iii. They cannot access the Center inside Compartment

c. EMT Level

- i. The RED BLS Pouch on an ALS/BLS bag will carry the following medications ONLY:
 - 1. Nitrostat
 - 2. Baby Aspirin
- ii. The BLS fanny-pack style bag will carry:
 - 1. Albuterol
 - 2. Atrovent
 - 3. Baby Aspirin
 - 4. Nitrostat
- iii. The EMT can only access following to treat their patient per protocol:
 - 1. The Airway Pouch
 - 2. The BLS Pouch
 - 3. The Naloxone Pouch



7002

Subject: Drug Bag Exchange Program:

Wasted Drug Procedure

Effective:

June 1, 2021

Dec. 8, 2022

7002.1 Guideline

a. Some hospitals also require the use of the GMVEMSC approved Controlled Drug Usage Form in addition to documentation on the run sheet.

- b. This GMVEMSC approved form must be filled out for any controlled drug use, even if there is no wastage.
- c. This information shall be on both the original EMS department form and the hospital copy for reference if needed.
- d. Every crew transporting a patient will provide a completed run sheet to the hospital within 3 hours.

7002.2 Procedure

- a. Fentanyl, Ketamine, Morphine, Versed and Valium are all controlled drugs.
 - i. If a controlled medication is only partially administered, the paramedic or AEMT must account for the all of the unused portion.
- b. To insure the medications are properly accounted for, all paramedics and AEMTs will document:
 - i. The drug name
 - ii. The amount used
 - iii. The amount wasted (if all the medication was administered, then list "none")
 - iv. The signature of a second witness if there is wastage.
 - 1. The second witness can be a member of the EMS crew.
 - 2. Many hospital employees are no longer permitted to witness or sign for drug wastage.



7003

Subject: Drug Bag Exchange Program:

g bag Exchange i rogiani.

Exchange Process

Effective: June 1, 2021

Last Modified:

Dec. 12, 2022

7003.1 Exchange Process Guidelines

- a. Each department is assigned to a "home" hospital.
- b. The assigned hospital is the central resource for initial fulfillment of medications for the drug bags and wholesale exchanges, replacement, or additions as required by revisions to the protocols.
- c. Drug bags can be exchanged at any participating hospital or within the same department.
- d. ALS/BLS bags may be exchanged one-for-one with another ALS/BLS bag.
- e. BLS bags may be exchanged one-for-one with another BLS bag.
- f. It is not permissible to exchange drug bags between two different Fire/EMS Agencies.
- g. The primary care provider is responsible for the inventory of the drug bag prior to sealing it.
- h. If two departments have accessed a drug bag, they should jointly seal the drug bag.
- i. Each hospital designates a specific location for the exchange of drug bags.
- j. EMS personnel are **required** to complete the Sign In and Out log when exchanging a drug bag.
- k. Each agency is responsible to track drug bag exchanges within their own organization (i.e. documentation, internal log, tracking software, etc.)
- I. Once sealed, any provider can exchange the drug bag.
- m. Unless the patient was removed to a non-participating drug bag exchange hospital or the patient was a non-removal, the drug bag must be exchanged at the time of patient delivery to the hospital.
- n. In the exceptions listed above, the drug bag will be exchanged at a participating hospital within 8 hours.
- o. Drug Bag Exchange after field termination will be at the facility from where the order was given, unless that hospital is not part of the Drug Bag Exchange Program.

7003.2 Drug Bag Blue Seals

- a. Blue seals:
 - i. Blue seals are used by the pharmacy that inventories and restocks the ALS/BLS drug bags.
 - ii. The blue seals will have a hospital sticker attached to the seal that identifies the hospital and pharmacist that inventoried the bag and the expiration date of the next drug to expire.
 - iii. The inner compartment of the ALS bag and Intermediate will be sealed with a blue seal and will have the expiration date noted.
 - iv. The blue seal will be looped through the proximal portion of the zipper tab (not the outermost portion of the zipper tab).
 - v. EMS should verify the blue seal is intact and has an expiration date before accepting the bag.
 - vi. When a provider opens a drug bag compartment, they should keep the blue seal in their possession until they have verified the contents are accounted for.
 - vii. Once they have verified the contents, they should place the blue seal in the compartment, unless there is a discrepancy and then seal the compartment with RED tag.
 - viii. EMS MUST PLACE THE BLUE SEAL IN THE COMPARTMENT!

b. Red Seals:

- i. Red seals identify ALS/BLS bags as being used.
- ii. EMS providers are required to inventory each opened pouch, discard any used sharps and clean any contaminants from bag used and then take red seal from the inside compartment (supplied by pharmacy when restocking the ALS/BLS bag) and seal the used compartment.
- iii. The red seal will be looped through the proximal portion of the zipper tab (not the outermost portion of the zipper tab).





7004

Subject: Drug Bag Exchange Program:

June 1, 2021

Last Modified:

Mar. 22, 2022

7004.1 **General Guidelines**

Drug Bag Discrepancies

EMS providers are required to inventory each opened pouch prior to applying the red seal.

Effective:

- b. All discrepancies (missing meds, expired meds, wrong med or dose, altered or tampered meds, drug bag number discrepancy, etc.) that are identified shall be reported to GMVEMSC using the Drug Bag Discrepancy Report (Addendum E).
- c. If at any time, an EMS provider encounters a discrepancy they will:
 - i. Notify their EMS Officer of the discrepancy.
 - ii. If the discrepancy was discovered after opening the bag, retain the blue seal and the hospital sticker that was attached to the drug bag in question.
 - iii. If the EMS provider is at the hospital, he/she will log the bag in using the normal procedure at that hospital while retaining the blue seal.
 - iv. He/she will advise the pharmacist or EMS Coordinator of the discrepancy and that they will be initiating the Discrepancy form as described below (pharmacist may request a copy of the Discrepancy form).
 - v. The EMS Officer may contact the EMS Coordinator if assistance is needed.

7004.2 **Discrepancies Involving Controlled Drugs or Potential Tampering:**

- a. When an issue arises concerning any of the following, a collaborative effort between the EMS organization or provider and the Hospital EMS Coordinator or Pharmacist shall be made in an attempt to resolve the issue:
 - i. A controlled drug (Fentanyl, Ketamine, Valium, Versed, or Morphine)
 - ii. A stolen, missing or lost bag
 - iii. Any medication that appears to have been altered or tampered with.
- b. If the issue cannot be resolved, the following steps shall be taken:
 - i. If the discrepancy was discovered by the EMS organization/provider, the person designated by the organization/provider shall comply with the requirements of OAC 4729-9-15 and GMVEMSC requirements as indicated below.
 - ii. If the discrepancy was discovered by the hospital, the person designated by the hospital shall comply with the requirements of OAC 4729-9-15 and GMVEMSC requirements as indicated below.
- c. Required reporting for unresolved issues involving Controlled Drug or potential/suspected tampering or lost or stolen drug bags pursuant to Federal and State Laws and GMVEMSC Protocol include:
 - i. If you have knowledge of or suspect a discrepancy is due to a theft, contact your State of Ohio Board of Pharmacy agent immediately. Advise them you want to report a theft or drug discrepancy. They will connect you with the appropriate person. (OAC 4729-9-15)
 - ii. Notify the Drug Bag Exchange Committee Chairs immediately.
 - iii. File a report with the appropriate law enforcement authorities (ORC 2921.22).
 - iv. Notify the Drug Enforcement Agency within 24 hours of discovery using DEA Form 106
 - v. DEA Form 106: https://www.deadiversion.usdoj.gov/webforms/app106Login.jsp.
 - vi. A 30-day extension may be requested in writing from the DEA. (CFR 1301.76(b)).
 - vii. Submit a completed GMVEMSC Drug Bag Discrepancy Report located at Addendum #E, with appropriate supporting documentation, to the GMVEMSC.



7004

Subject: Drug Bag Exchange Program:

Drug Bag Discrepancies

Effective:

Last Modified:

Mar. 22, 2022

- d. "Dangerous drug" means any of the following:
 - i. Any drug to which either of the following applies:
 - Under the "Federal Food, Drug, and Cosmetic Act," 52 Stat. 1040 (1938), 21 U.S.C.A. 301, as amended, the drug is required to bear a label containing the legend "Caution: Federal law prohibits dispensing without prescription" or "Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian" or any similar restrictive statement, or the drug may be dispensed only upon a prescription;

June 1, 2021

- 2. Under Chapter 3715 or 3719 of the Revised Code, the drug may be dispensed only upon a prescription.
- ii. Any drug that contains a schedule V controlled substance and that is exempt from Chapter 3719. of the Revised Code or to which that chapter does not apply;
- iii. Any drug intended for administration by injection into the human body other than through a natural orifice of the human body;
- iv. Any drug that is a biological product, as defined in section 3715.01 of the Revised Code.

7004.3 Discrepancies Not involving Controlled Drugs or Potential Tampering:

- a. Examples may include:
 - i. Non-controlled drugs that were not in the bag
 - ii. Wrong number of medications or doses
 - iii. Wrong drug concentration
 - iv. Expired medications found
 - v. No expiration date on tag
 - vi. Medications improperly labeled
 - vii. Empty vials or packages left in bag. DO NOT PUT ANY USED VIALS BACK IN DRUG BAG
 - viii. Unsealed medications
 - ix. Wrong medication administered
 - x. Unsealed pouch discovered
 - xi. Bag logged out with red seal (used bag)
- b. If discovered by EMS, the EMS Officer will initiate the Discrepancy form. They shall provide a copy of the form and the Blue Seal to the Hospital EMS Coordinator and shall fax a copy of the report to the GMVEMSC.
- c. If the Hospital discovers the discrepancy, the EMS Coordinator will initiate the Discrepancy Form and submit to GMVEMSC. If the EMS Coordinator is able to determine which EMS agency/hospital is responsible for the discrepancy, the agency or hospital will be notified and will receive a copy of the Discrepancy Form and the Blue Seal if applicable.

7004.4 Follow Up Procedures

- a. The GMVEMSC will:
 - i. Maintain a record of all discrepancies that occur.
 - ii. Follow up with the agencies involved as needed.
 - iii. Advise the Drug Bag Chairperson of any and all discrepancies and action taken.



7004

Subject: Drug Bag Exchange Program:

Drug Bag Discrepancies

Effective:

June 1, 2021

Last Modified:

Mar. 22, 2022

- b. The Drug Bag Committee Chairperson will:
 - i. Report at the bi-annual Drug Bag Committee meetings for discussion and resolutions to all discrepancies encountered.
 - ii. Assist the Council and or affected departments with any issues or questions that may result.





7005

Subject: Drug Bag Exchange Program:

Lost or Stolen Drug Bag Policy

Effective:

June 1, 2021

Last Modified:

Mar. 1, 2022

7005.1 Purpose

a. To provide a uniform mechanism for the investigation and reporting of lost or stolen drug bags.

7005.2 Notification

- a. Upon discovery of a missing GMVEMSC drug bag, agencies will notify or cause to be notified the GMVEMSC Drug Bag Committee Chair(s).
- b. A responsible party at the agency will initiate the Drug Bag Discrepancy Form and follow instructions for reporting lost or stolen drug bags. Completed paperwork and reports will be submitted to GMVEMSC.
- c. The agency representative or the GMVEMSC Drug Bag Committee Chair (s) will notify the State of Ohio Board of Pharmacy (SOBP) at 614-466-4143
 - i. The Drug Bag Chair(s) may elect to notify the SOBP for the agency or advise the agency to contact them individually.
 - ii. Either way contact with the SOBP must be coordinated and accomplished

7005.3 Investigation

- a. The EMS agency shall develop and implement an internal search mechanism for lost drug bags.
- b. The internal search mechanism should include:
 - i. Determine if drug bag was left at the scene.
 - ii. Determine if drug bag was not exchanged on last run.
 - iii. Determine if drug bag is in the wrong vehicle.
- c. The GMVEMSC will seek the assistance of the GMVEMSC Drug Bag Chair(s) to check with all hospitals to determine if the bag might be in inventory or be alerted if it shows up at one of the hospitals.
- d. The GMVEMSC will contact the hospital EMS Coordinator with whom the EMS Department is assigned to work out a drug bag replacement.
 - i. Drug bag replacement will only occur after all paperwork is submitted
 - ii. The GMVEMSC will assess a fee for replacement bag to be paid for by the receiving agency.





7006

Subject: Drug Bag Exchange Program:
Hospital Participation Policy

June 1, 2021

Last Modified:

Dec. 8, 2020

7006.1 Purpose

a. To assure uniformity of hospital pharmacy participation in the Drug Bag Exchange Program.

Effective:

7006.2 The Hospital Shall:

- a. Purchase (at cost), fill, and maintain a supply of drug bags sufficient to meeting the needs of an average day, plus a few extra to meet peak demands for drug bag replacement.
- b. Accept responsibility for filling new drug bags for departments or vehicles as assigned by GMVEMS Council, at hospital expense.
- c. Assign one licensed pharmacist and an EMS coordinator to attend and participate in the Standing Orders and Drug Bag Exchange Program Committees.
- d. Agree to pay annual dues and any fees assessed by GMVEMS Council that are approved by the Drug Bag Exchange Program Committee and the GMVEMS Council that pertain to the Drug Bag Exchange Program.

7006.3 The Greater Miami Valley EMS Council shall:

- a. Maintain a current State Drug Licenses for all participants in the Drug Bag Exchange Program.
- b. Furnish hospital pharmacy with a current listing of all departmental personnel authorized to access the GMVEMSC drug bags and copy of the protocol.
- c. Assign departments to hospitals in both a geographic and otherwise equitable fashion.





June 1, 2021

7007

Subject: Drug Bag Exchange Program:

New Agency Member Policy

Effective:

Last Modified:

Dec. 8, 2020

7007.1 Purpose

a. To establish the procedures required to provide new agency members with an ALS or BLS drug bag from the GMVESMC Drug Bag Exchange Program.

7007.2 Procedure:

- a. Those agencies who have applied for membership and require a GMVEMSC Drug Bag to license their units may request a GMVEMSC Drug Bag be available 24 hours prior to the Ohio Medical Transportation Board (OMTB) inspection date.
- b. In order to receive a drug bag, the EMS agency shall:
 - i. Have applied for a GMVEMSC membership.
 - 1. Have been given a provisional membership by the GMVEMSC Executive Committee if the inspection is before regularly scheduled Council meeting.
 - ii. Provide a copy of their State Pharmacy License.
 - iii. Check off all agency personnel on Standing Orders and data entered in the GMVEMSC data base.
 - iv. Have the Medical Director submit a notarized letter to the State Pharmacy Board with License application stating they approve their department to use the GMVEMSC protocols.
 - 1. Medical Directors have the right to limit their personnel from using certain medications or procedures within the scope of the GMVEMSC protocols.
 - 2. Medical Directors may elect to change or add medications or procedures to the protocol.
 - 3. The Medical Director must include those protocols in addendum to the GMVEMSC, be responsible for the training and documentation of training in of their protocol as well as purchasing and maintaining those drugs that are not included in the standard inventory of the GMVEMSC ALS or BLS drug bag.
- c. The agency has 72 hours to show proof of a temporary permit from the date of inspection to the GMVEMS Council office.
- d. If they cannot demonstrate an OMTB permit in that time the drug bag must be returned to either the hospital to which the agency is assigned or the hospital that provided the drug bag.

7007.3 Agreement Letter

- a. In order to participate in the GMVEMS Council Drug Bag Exchange program, the agency will provide the agreement letter that follows to the Greater Miami Valley EMS Council.
- b. A similar example of the agencies' choosing may also be used.



7007

Subject: Drug Bag Exchange Program:

New Agency Member Policy

Effective:

June 1, 2021

Last Modified:

Dec. 8, 2020

Greater Miami Valley EMS Council Drug Bag Exchange Program Agency Agreement Letter

Please type or print legibly
DEPARTMENT/SERVICE:
CONTACT PERSON:
TELEPHONE:
FAX:
This department/service agrees to abide by the GMVEMS Council Drug Bag Exchange Program and Standing Orders.
SIGNATURE:
Fire Chief, EMS Administrator, or Private Ambulance Administrator
DATE:
Detum to
Return to: GMVEMSC
124 E. Third St.
Dayton OH 45402

7008

Subject: Drug Bag Exchange Program: Protocol Testing Compliance Letter

Effective: June 1, 2021

Last Modified:

Dec. 8, 2020

Protocol Testing Compliance

l,	_ (Chief's Name Printed), do hereby certify that all
members of	(Agency/ Department Name)
have completed the (Year) GMVEMSC Protoco	ol Testing as of(Date
of Completion) with the exception of the following perso	nnel:
(List anyone who has not completed testing)	
Chief's Signature	_





7009

Subject: Drug Bag Exchange Program:
GMVEMSC Drug Bag Discrepancy Report

June 1, 2021

Last Modified:

Dec. 8, 2020

7009.1 General Guideline

- a. If at any time an EMS provider encounters a discrepancy in the GMVEMS Council Drug Bag they are using, they will notify their agencies' EMS Officer (or their supervisor if an EMS Officer does not exist).
- b. If the EMS provider is at a hospital that participates in the GMVEMS Council Drug Bag Exchange Program, they will log the bag in using the normal procedure at that hospital.


Effective:

- c. If the discrepancy was discovered after opening the bag, retain the blue seal and the hospital sticker that was attached to the drug bag in question. The tags (or photo copies of the tags) should be attached to the **GMVEMSC Drug Bag Discrepancy Report.**
- d. They will advise the pharmacist or EMS Coordinator of the discrepancy and that they will be initiating the **GMVEMSC Drug Bag Discrepancy Report** provided on the opposite page.
- e. Examples of the **GMVEMSC Drug Bag Discrepancy Report** should be available at all hospitals. They will often be found in the EMS rooms.
- f. The **GMVEMSC Drug Bag Discrepancy Report** will be completed in triplicate with a copy going to the GMVEMS Council, the receiving pharmacy and the EMS agency reporting.
- g. The pharmacist may request a copy of the GMVEMSC Drug Bag Discrepancy Report.

GMVEMSC Drug Bag Discrepancy Report

If at any time an EMS provider encounters a discrepancy they will notify their EMS Officer of the discrepancy. If the discrepancy was discovered after opening the bag, retain the blue seal and the hospital sticker that was attached to the drug bag in question. If the EMS provider is at the hospital, they will log the bag in using the normal procedure at that hospital. They will advise the pharmacist or EMS Coordinator of the discrepancy and that they will be initiating the Discrepancy form as described below (pharmacist may request a copy of the Discrepancy form).

Date of report:	Bag Number:	g Number: Date Discrepancy discovered:			
Discovered by:		Hospital/EMS Dept making discovery:			
Have blue Hospital seal? YES/NO If yes	- Attach seal to rep	oort			
Tracking:					
Date bag was logged out: from	om (hospital)	To (EMS agency)			
Date Bag turned in: to (hosp	oital)				
Description of the discrepancy: (Attach a	addendum if additio	onal space needed)			
Describe efforts to resolve the discrepar	ncy: (Attach addend	lum if additional space needed)			
Was the discrepancy satisfactorily resolv	ed?	If not, what steps are to be taken:			
Reporting requirements:					
Was a police report filed?					
Was a DEA report filed?					
Was the Stat Pharmacy Board notified?		By whom?			
Required documents submitted to GMV	EMSC By:	Date:			
For Drug Bag committee use:					
rong medication stocked		Bag logged out with red seal			
Expired medication found		Empty vials/packages found			
Wrong dose packaged		Open pouch found			
Missing medications		Unsealed bottles found			
Wrong number packaged					
No expiration date on tag		Wrong medication administered			
Atrovent/Albuterol not labeled					
Damaged medications	Other:				
Other:					



7010.1 OAC 4729-9-15

- (A) Each prescriber, terminal distributor of dangerous drugs, or wholesale distributor of dangerous drugs shall notify the following upon discovery of the theft or significant loss of any dangerous drug or controlled substance, including drugs in transit that were either shipped from or to the prescriber, terminal distributor of dangerous drugs, or wholesale distributor of dangerous drugs:
 - (1) The state board of pharmacy, by telephone immediately upon discovery of the theft or significant loss;
 - (2) If a controlled substance, the drug enforcement administration (DEA) pursuant to section 1301.76(b), Code of Federal Regulations;
 - (3) Law enforcement authorities pursuant to section 2921.22 of the Revised Code.
- (B) Controlled substance thefts must also be reported by using the Federal DEA Report form whether or not the controlled substances are subsequently recovered and/or the responsible parties are identified and action taken against them. A copy of the federal form regarding such theft or loss shall be filed with the State Board of Pharmacy within thirty days following the discovery of such theft or loss.
 - (1) An exemption may be obtained upon sufficient cause if the federal form cannot be filed within thirty days.
 - (2) A request for a waiver of the thirty-day limit must be requested in writing.
- (C) Each prescriber, terminal distributor of dangerous drugs, or wholesale distributor of dangerous drugs immediately upon discovery of any theft or loss of:
 - (1) Uncompleted prescription blank(s) used for writing a prescription, written prescription order(s) not yet dispensed, and original prescription order(s) that have been dispensed, shall notify the state board of pharmacy and law enforcement authorities.
 - (2) Official written order form(s) as defined in division (Q) of section 3719.01 of the Revised Code shall notify the state board of pharmacy and law enforcement authorities, and the drug enforcement administration (DEA) pursuant to section 1305.12(b), Code of Federal Regulations.



Subject: Ambulance Restocking Policy

Effective: June 1, 2021

Last Modified:

Administrative

Dec. 8, 2020

7011.1 History

- a. The member hospitals of Greater Dayton Hospital Association (GDAHA) have supported Emergency Medical Services agencies in the region for decades.
- b. In 1998, GDAHA received permission (Advisory Opinion No. 98.7) from the Department of Health & Human Services to continue to exchange drugs (GMVEMSC Drug Bag Exchange Program) and supplies with EMS agencies and avoid violating the anti-kickback (safe harbor) statute of the Social Security Act.
- c. The hospitals named in the advisory are in the eight (8) county West Central Region: Champaign, Clark, Darke, Greene, Miami, Montgomery, Preble and Shelby.
- d. In December 2001, the Centers for Medicare and Medicaid Services issued an Ambulance Final Rule on Ambulance Restocking Safe Harbor.
 - i. Elements of the Safe Harbor include:
 - 1. Billing and claim submission
 - 2. Documentation
 - 3. Not tied to referrals
 - 4. Compliance with other laws

7011.2 EMS Supply Exchange Program:

- a. EMS agencies and personnel should understand the benefits of the EMS Supply exchange program, as offered by GDAHA members participating in this program.
- b. Hospitals are not required to participate in this restocking program.
- c. EMS agencies and personnel must adhere to the agreement, particularly the areas highlighted below:
 - i. For all transports to member hospitals, the EMS agencies will provide the receiving hospital with copies of the written records describing each of the medical supplies and/or medications utilized by or for the patient during the transport. In most cases, this should be done immediately after patient transfer.
 - ii. Participating hospitals will restock EMS agency ambulances, at no charge to the EMS agency, with the medical supplies and/or medications which were **utilized by or for the patient during the transport to the receiving hospital.**
- d. Hospitals will not restock items used on patients delivered to another hospital.
 - i. Restocking an ambulance at a participating hospital for items used on a patient delivered to a hospital not participating in the agreement will jeopardize this program.
 - ii. It is the responsibility of the EMS agencies to restock items used on patients delivered to a hospital that is not a participant in the Agreement.
- e. Participating hospitals will restock drug bags.
- f. Hospitals will not provide medical supplies to a new ambulance, or an old ambulance being returned to service.
 - i. These ambulances must be stocked for the first time by the EMS agency.



7012

Subject:

Diversion of Emergency Patients

Effective: June 1, 2021

Last Modified:

Jan. 5, 2024

Greater Dayton Area Hospital Association, Greater Miami Valley Emergency Medical Services Council, and Greater Montgomery County Fire Chiefs' Association Policy Statement for Temporary Diversion of Emergency Patients

7012.1 EMS and Dispatch Procedures

- a. When situations exist that prevent the timely treatment of additional emergency cases or certain types of emergency patients, the designated hospital or satellite emergency department (ED) Official will report that they are on "Diversion of Emergency Patients," formerly referred to as rerouting.
- b. For patients impacted by the type of diversion specified, EMS should utilize hospitals in normal status. Transport to a hospital in diversion status may jeopardize patient care more than the delay in treatment caused by longer transport times except for patients that are in extreme life/limb threatening circumstances.
- c. When a patient and /or the patient's physician requests EMS to transport to a hospital which is on diversion, EMS have the responsibility to advise the patient and/or the physician that "due to diversion patient care may be jeopardized."

7012.2 Monitoring Emergency Department Status:

- a. Anyone with a Juvare EmResources account can set up preferences to receive an alert when the hospital status changes.
 - i. Dispatch centers should set up Juvare EMResources preferences to receive an alert when the hospital status changes.
 - ii. Dispatch centers are encouraged to continuously monitor Juvare EMResources.
 - iii. Dispatch centers must notify EMS of hospital status changes.

7012.3 Diversion Categories:

- a. Hospitals communicate the following status information via Juvare EMResources:
 - i. **CLOSED:**
 - The hospital or satellite ED has activated its disaster plan because of an internal emergency or other situation rendering the hospital or satellite ED unable to accept any emergency patient. EMS will not transport any patient to a CLOSED Facility

ii. DIVERSION OF CERTAIN TYPES OF PATIENTS:

- 1. Limited Divert/Operations:
 - **a.** Limited operations/ability to handle some types of traffic/special situation (examples include CT scanner downtime, no ICU beds available, specialty care limitations). Write the specific issue in the comment section.
- 2. Divert/At Capacity:
 - **a.** Facility is at capacity and/or on diversion; ED is paused to inbound EMS traffic and the facility is not in a designated load balancing plan.

7012

Subject:

Diversion of Emergency Patients

Effective: June 1, 2021

Last Modified:

Jan. 5, 2024

7012.4 Hospital and Satellite ED Procedures:

- a. The hospital or satellite ED will:
 - i. Update the Juvare EMResources page with ED status and activity between 6 and 9 am daily and anytime the status or activity changes.
 - Notify EMS Coordinators and appropriate dispatch centers. Hospitals and satellite EDs located in the southern Miami Valley region may also need to contact northern Cincinnati area hospitals or dispatch centers.
- b. Status Management Changes/Updates
 - i. It is the responsibility of the **diverting** hospital or satellite ED to review and update their diversion status **hourly**, making changes as needed.
 - ii. When the status changes, including return to normal operations, notify EMS Coordinators and appropriate dispatch centers and update Juvare EMResources using the same notification protocols used to initiate the diversion procedure.

7012.5 Participating Hospitals (Additional hospitals added upon approval)

Atrium Medical Center (Middletown)

1 Medical Center Dr, Middletown, OH 45005

Austin Boulevard Emergency Center

300 Austin West Blvd., Miamisburg, OH 45342

Dayton Children's Hospital

1 Children's Plaza, Dayton, OH 45404

Dayton Children's Hospital - South Campus

South Campus 3333 W. Tech Blvd, Miamisburg, OH 45342

Dayton-Springfield Emergency Center

1840 Springfield Road, Fairborn, OH 45324

Joint Township District Memorial Hospital

200 St. Clair Ave, St. Marys, OH 45885

Kettering Health Dayton

405 W Grand Ave, Dayton, OH 45405

Kettering Health Network Franklin Emergency Center

100 Kettering Way, Franklin, OH 45005

Kettering Health Greene Memorial

1141 N Monroe Dr, Xenia, OH 45385

Kettering Health Hamilton

630 Eaton Ave, Hamilton, OH 45013

Kettering Health Network Huber Emergency Center

8701 Troy Pike, Huber Heights, OH 45424

Kettering Health Main Campus

3535 Southern Blvd, Kettering, OH 45429

Kettering Health Miamisburg

4000 Miamisburg Centerville Rd, Miamisburg, OH 45342

Kettering Health Middletown Emergency Center

6147 W. State Route 122 Middletown, OH, 45005

Kettering Health Preble Emergency Center

450-B Washington-Jackson Rd, Eaton, OH 45320

Kettering Health Springfield

2300 N. Limestone St., Springfield OH 45503

Kettering Health Troy

600 W. Main St., Troy, OH 45373

Kettering Health Washington Township

1997 Miamisburg Centerville Rd, Dayton, OH 45459

Mercy Health – Springfield

100 Medical Center Drive, Springfield, OH 45504

Mercy Health Urbana Hospital

904 Scioto St, Urbana, OH 43078

Miami Valley Hospital

1 Wyoming St, Dayton, OH 45409

Miami Valley Hospital - Beavercreek Emergency Center

2400 Lakeview Dr., Beavercreek, OH 45431

7012

Subject:

Diversion of Emergency Patients

Effective: June 1, 2021

Last Modified:

Jan. 5, 2024

Miami Valley Hospital - Jamestown Emergency Center

4940 Cottonville Rd, Jamestown, OH 45335

Miami Valley Hospital North

9000 N Main St, Dayton, OH 45415

Miami Valley Hospital South

2400 Miami Valley Dr, Centerville, OH 45459

Soin Medical Center

3535 Pentagon Blvd, Beavercreek, OH 45431

Upper Valley Medical Center

3130 N Co Rd 25A, Troy, OH 45373

END OF SECTION

Dayton VA Medical Center

4100 West 3rd Street, Dayton, OH 45428

Wayne Healthcare

835 Sweitzer St, Greenville, OH 45331

Wilson Memorial Hospital

915 West Michigan Street, Sidney, OH 45365

WPAFB 88th Medical Center

4881 Sugar Maple Dr, Wright-Patterson AFB, OH 45433



7013

Subject: Hospital Capabilities Chart

June 1, 2021

Effective:

Last Modified:

Jan. 5, 2024

HOSPITAL	Trauma	Burn	Interventional	Stroke	Stroke	Stroke	L&D
HOSFITAL	Center	Center	Cardiac Cath	Telemedicine	Primary	Comprehensive	LQD
Atrium Medical Center (Middletown)	A 3		Cardiac	Υ	Υ		Υ
Austin Blvd. Emergency Center				Υ			
Bethesda Arrow Springs				Υ			
Bethesda Butler Hospital				Υ			
Christ Hospital Liberty				Υ			Υ
Dayton Children's Hospital	P 1	Υ					
Dayton Children's - South Campus							
Dayton-Springfield Emergency Center				Υ			
Joint Township District Memorial Hosp.				Υ			
Kettering Health Dayton	A 3		Cardiac	Y	Υ		
Kettering Health Franklin				Y			
Kettering Health Greene Memorial				Y			
Kettering Health Hamilton			Cardiac	Y	Υ		Υ
Kettering Health Huber				Y			
Kettering Health Main Campus	A 2		Cardiac	Y	Υ	Υ	Y
Kettering Health Miamisburg				Y	Υ		
Kettering Health Middletown				Υ			
Kettering Health Preble				Υ			
Kettering Health Springfield				Υ			
Kettering Health Troy				Υ			
Kettering Health Washington Twp.				Υ	Υ		Y
McCullough-Hyde Hospital				Υ			Υ
Mercy Health - Springfield			Cardiac	Υ	Υ		Y
Mercy Health - Urbana Hospital				Υ			
Miami Valley Hospital	A 1	Υ	Cardiac	Υ	Υ	Υ	Υ
Miami Valley – Beavercreek EC				Υ			
Miami Valley - Jamestown EC				Υ			
Miami Valley Hospital North				Υ			
Miami Valley Hospital South	A 3		Cardiac	Υ	Υ		
Reid Health	A 3		Cardiac	Υ	Υ		Υ
Soin Medical Center	A 3		Cardiac	Υ	Υ		Υ
Upper Valley Medical Center	A3		Cardiac	Υ	Υ		
Dayton VA Medical Center							
Wayne Health Care				Υ			Υ
West Chester Hospital	A 3		Cardiac	Υ	Υ		Υ
Wilson Memorial Hospital			Cardiac	Υ			Υ
WPAFB 88 th Medical Center							Y

Notes: Comprehensive stroke centers have the capability of endovascular intervention 24/7. Primary stroke centers have CT and tPA capabilities and focus on evaluating patients for intravenous tPA. Telemedicine with tPA ready offers immediate access to a Neurologist.





Subject: Hospital Contact Info

Hospital Contact Information

Effective: June 1, 2021

Last Modified:

Jan. 16, 2024

Hospitals in **bold type** ask to be called for every patient.

HOSPITAL	PHONE	FAX
Atrium Medical Center, Middletown	513-424-3924	513-420-5133
Austin Boulevard Emergency Center	937-865-9663	937-641-2608
Bethesda Arrow Springs	513-282-7222	513-867-2581
Bethesda Butler Hospital	513-893-8222	513-893-8321
Christ Hospital Liberty	513-648-7874	513-648-7962
Cincinnati Children's Stat Line	513-636-8008	513-636-4050
Dayton Children's Hospital	937-641-4444	937-641-5301
Dayton Children's Hospital South	937-641-5642	937-641-4880
Dayton-Springfield Emergency Center	937-523-8792	937-523-8788
Joint Township District Memorial Hospital	419-394-7333	419-394-1902
Kettering Health Dayton	937-723-3419	937-723-4609
Kettering Health Franklin Emergency Center	937-458-4728	937-458-4737
Kettering Health Greene Memorial	937-372-2297	937-352-3501
Kettering Health Hamilton	513-867-2144	513-867-2581
Kettering Health Huber	937-558-3301	937-558-3349
Kettering Health Main Campus	937-395-8080	937-395-8347
Kettering Health Miamisburg	937-384-8766	937-384-8729
Kettering Health Middletown	513-261-3415	513-261-3419
Kettering Health Preble	937-456-8328	937-456-8377
Kettering Health Springfield	937-504-8306	937-504-8309
Kettering Health Troy	937-980-7015	937-980-7019
Kettering Health Washington Township	937-435-1832	937-401-6447
Maternity	937-401-6850	937-401-6861
McCullough-Hyde Hospital	513-524-5353	513-523-0144
Mercy Health - Springfield	937-523-1902	937-523-1950
Mercy Health Urbana Hospital	937-484-6160	937-484-6183
Miami Valley Hospital	937-208-2440	937-641-2608
Maternity	937-208-2408	937-208-2651
Miami Valley – Beavercreek Emergency Center	937-429-0708	937-641-2608
Miami Valley – Jamestown Emergency Center	937-374-5274	937-641-2608
Miami Valley North Hospital	937-540-1067	937-641-2608
Miami Valley South Hospital	937-438-2662	937-641-2608
Maternity	937-438-5817	337 312 2333
Regional Hospital Notification System	937-333-8727	
Reid Memorial Hospital	765-983-3161	765-983-3038
Soin Medical Center	937-702-4525	937-702-4509
Upper Valley Medical Center	937-440-9444	937-440-4346
Dayton VA Medical Center	937-262-2172	937-267-5364
Wayne Health Care	937-547-5777	937-569-6087
West Chester Hospital	513-298-7777	513-298-8978
Maternity	513-298-7777	
-		
Wilson Memorial Hospital	937-498-5300	

Hospitals in **bold type** ask to be called for every patient.



7015

Subject: Infectious Disease Exposure

Reporting Policy June 1, 2021

Last Modified:

Jan. 31, 2021

7015.1 General Guideline

a. The purpose of this policy is to provide public safety personnel (including fire, EMS, and law enforcement) and hospitals with a set of standard guidelines and expectations for defining, responding to, and following up on an infection control exposure incident involving an emergency response provider.

Effective:

b. This guideline is a cooperative effort between the Greater Miami Valley EMS Council (GMVEMSC) and the Greater Dayton Area Hospital Association (GDAHA).

7015.2 Bloodborne Exposure

a. <u>Definition Of A Bloodborne Exposure</u>

- i. An exposure incident that may place a public safety worker at risk for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV) infections or other blood borne pathogens that includes:
 - 1. A percutaneous injury (e.g., a needle stick or cut), or
 - 2. Contact of mucous membrane or non-intact skin (e.g., exposed skin that is chapped, abraded, or afflicted with dermatitis) with blood, tissue, or other body fluids that are potentially infectious.
- ii. What is NOT an exposure?
 - 1. A percutaneous injury with a clean or sterile needle or instrument.
 - 2. Intact skin splashed with potentially infectious blood, body fluid, or tissue.

b. Post Exposure Procedure

- i. An exposed public safety worker should take the following immediate "first aid" action steps:
 - 1. Immediately irrigate the involved area.
 - 2. Flush eyes with copious amounts of IV fluids, if indicated.
 - 3. Wash skin vigorously with soap and water.
 - 4. If soap and water is not available, rinse area with another available solution such as IV fluids or a water-based liquid.
 - 5. Waterless hand cleaners are not recommended for post-exposure gross decontamination, but can be used when other options are not available.
- ii. The Employee shall report the exposure incident to the receiving hospital and to their immediate supervisor.
- iii. Exposed employees are required to register as a patient at the same hospital as the source.
- iv. Once at the receiving hospital, the exposed employee should locate and complete the "Request for Information by Emergency Care Workers (RIECW)" form (see Appendix A).
- v. When completed, the form should be submitted to the nurse handling the exposed employee's care in the Emergency Department (ED).
- vi. The EMS Coordinator for the receiving hospital can serve as a liaison between the organization and the hospital.
- vii. The department's infection control officer (ICO) or designated supervisor should, upon receiving notification that there has been an exposure incident, notify the receiving hospital's EMS Coordinator.



7015

Subject: Infectious Disease Exposure

Reporting Policy

Effective: June 1, 2021

Last Modified:

Jan. 31, 2021

- viii. For the purpose of this policy the "department's Infection Control Officer (ICO), designated supervisor, or designee" refers to the person responsible for reporting and coordinating an exposed employee's incident within that Public Safety entity.
- ix. Follow-up care/exam(s) will be provided to each employee involved when indicated. All follow-up care/exam(s) will be coordinated through your employer.

c. <u>Testing The Source Patient</u>

- i. A blood sample is required to determine whether a patient has HIV, HBV or HCV. Blood/Body Fluid (B/BF) testing of a source patient includes the following (MMWR, June 29, 2001):
 - 1. HIV antibody
 - 2. HBV surface antigen (HBsAg)
 - 3. HCV antibody
- ii. If the source patient is <u>transported</u> to a hospital:
 - 1. The ED obtains patient consent and the blood specimen for testing.
 - 2. In the event that the patient refuses to or cannot give consent (e.g., due to an altered level of conscious) a hospital's "infection control committee... or other body of a health care facility performing a similar function" has the authority to obtain the HIV screening when there has been a significant exposure (Ohio Revised Code §3701.242).
- iii. If the source patient refuses transport to a hospital:
 - 1. If the patient refuses to give consent for blood sampling and refuses transport, the public safety worker must follow up with their ICO or designee.
 - 2. At this point it is a legal matter to obtain the source patient's blood for testing (Ohio Revised Code §3701.247).
 - 3. Following a significant exposure in which the source patient refuses to provide a blood sample and refuses transport, the employee should seek immediate medical evaluation and counseling for their selves (MMWR, Sept. 30, 2013).
 - 4. In cases where the patient refuses transport, or in exposure incidents where the source patient is unknown, an exposed employee should follow the steps outlined in **7018.2e Patients Not Transported to a Hospital**.
 - 5. EDs or hospitals will not run source patient blood samples if the source patient is not a patient at their hospital.

d. Source Patient (Transported To Hospital) Results

- i. Hospital-run HIV test results should be available within an hour (may be longer for "stand alone" or smaller EDs); HBV and HCV results may not be available for several days.
- ii. The exposed employee is expected to remain a patient in the ED until they have received the results of the rapid HIV test and any additional counseling from the attending physician.
- iii. The employee is expected to communicate his/her follow-up needs to your department's ICO or designated supervisor.
- iv. Written notification of positive test results shall be provided directly to the affected employee by the hospitals designated infection control point of contact within three (3) days after oral notification (Ohio Revised Code §3701.248).



7015

Subject: Infectious Disease Exposure

Reporting Policy

Effective: June 1, 2021

Last Modified:

Jan. 31, 2021

- v. Confidentiality of the source patient and public safety worker information shall be maintained
- vi. Only information pertaining to source patient results will be released to the organization's ICO or designee and/or an employee who is still present in the ED as described above.
- vii. The department ICO or designee and the public safety worker shall not disclose any medical information publicly about the source patient.

e. Patients Not Transported To A Hospital By EMS

- i. Employees should notify their immediate supervisor, and their immediate supervisor should notify the organization's ICO or designee. Federal regulations dictate that, "following report of an exposure, the employer shall make immediately available to the exposed employee a confidential medical evaluation and follow-up" (OSHA 29 CFR, 1910.1030(f) (3)).
- ii. Exposed employee should be directed to any ED for treatment.
- iii. Employee shall locate, complete, and sign the Request for Information by Emergency Care Workers (RIECW) Form (Appendix A), which should be available, completed, and submitted to the nurse handling care in the ED.
- iv. If the public safety worker is aware that the patient went to an ED by other means, the employee's supervisor may call the ED charge nurse of the patient's destination and notify them of the exposure, with a request to obtain baseline testing of the source patient.
- v. The written Request for Notification of Test Results shall be faxed to the ED charge nurse as soon as possible by the employee or the department's ICO.

f. <u>Prophylaxis For Blood/Body Fluid Exposed Public Safety Worker</u>

- i. Post-exposure prophylaxis (PEP) treatment may be offered to the public safety worker by the ED or workplace health provider in accordance with current clinical guidelines and local PEP protocols. Additionally, the employee may wish to consult their personal physician.
 - 1. The decision to take PEP includes a risk-based assessment based on known or unknown source patient and type of exposure.
 - 2. Employees receiving PEP treatment should be followed up within 72 hours of starting treatment.
 - 3. The PEP treatment decision should consider laboratory results when available.

ii. HIV prophylaxis:

- 1. Decisions about chemoprophylaxis can be modified if additional information becomes available.
- 2. Public safety workers must register as ED patients to receive HIV prophylaxis from the hospital.
- 3. HIV PEP should be started as soon as possible.
- Consideration should be given by the ED for expert consultation and guidance on HIV PEP (e.g., infectious disease physician, MMWR, 2011) or the National Clinicians' Post Exposure Prophylaxis Hotline @ #888-448-4911).
- 5. Counseling should be made available through the agency's employee assistance program (EAP) or by contractual agreements.

7015

Subject: Infectious Disease Exposure

Reporting Policy

June 1, 2021

Last Modified:

Jan. 31, 2021

iii. Hepatitis Prophylaxis

1. Hepatitis Prophylaxis is dependent on the public safety worker's vaccine status.

Effective:

- 2. A small percentage of immunized individual's protection from the vaccine declines over time, which may require Hepatitis B Immunoglobulin (HBIG) and additional doses of the Hepatitis B vaccine to protect against both the current exposure and future exposures.
- 3. The results of the HBV Surface Antibody test will demonstrate the employee's immunity to HBV, but are not typically given in the ED as the results of the HBV Surface Antibody test are usually not available immediately.
- 4. Employees must follow up with his/her organization's workplace health provider for related prophylaxis as soon as possible.
- 5. There is no prophylaxis for HCV at this time. In cases of positive source HCV results, the employee should follow up with their workplace health provider for evaluation and care.

g. Public Safety Worker Baseline Testing

- i. Baseline testing of the exposed public safety worker is the employee's choice.
- ii. Agencies should maintain signed statements of employees who decline baseline testing/evaluation at the time of an exposure.
- iii. Baseline testing is the term given to the set of initial laboratory tests that should be drawn on an exposed employee.
- iv. This data may be used to compare future assessments in determining if an infectious disease was contracted.
- v. Baseline testing is not emergent; however, evaluation for PEP as discussed above should be considered urgent and care sought immediately.
- vi. In cases where PEP was determined not an appropriate emergency treatment, the public safety worker should seek follow up care as instructed.
- vii. This follow up should be by the organization's workplace health provider. This follow up should optimally occur the next day and no later than seven days post exposure (MMWR, 2001).
- viii. In cases where the source patient testing is negative but the public safety worker still wants further testing, the employee is encouraged to follow up with their private physician or your department's workplace health provider.
- ix. Public safety worker baseline testing includes at minimum:
 - 1. HIV antibody
 - 2. Hepatitis B surface antibody
 - 3. Hepatitis C virus antibody
- x. A positive Hepatitis and/or HIV test of the source patient should trigger viral load testing of the source patient.

7015.3 Respiratory Exposure

a. <u>Definition Of A Respiratory Exposure</u>

- i. Respiratory exposure is defined as contamination with an infectious agent through the respiratory tract.
- ii. This occurs via one of two routes (CDC, Rationale for Isolation Precautions in Hospitals, 1996):



7015

Subject: Infectious Disease Exposure

Reporting Policy

Effective: June 1, 2021

Last Modified:

Jan. 31, 2021

- iii. Via airborne infectious agents with small-particle residue [5 μ m or smaller] of evaporated droplets containing microorganisms that remain suspended in the air for long periods of time (example is tuberculosis, rubella, and varicella virus).
- iv. Via droplet infectious agents which are propelled a short distance (less than three feet) through the air by coughing or sneezing: these droplets are acted upon rapidly by gravity (examples are meningitis, pertussis and influenza).
- v. Respiratory exposures may not be immediately known by the public safety worker, especially if the patient is not overtly symptomatic.

b. Immediate actions of the airborne-exposed public safety worker

- i. Don PPE as soon as possible at the scene or during transport if the patient is known to have a respiratory infection or is coughing or spraying secretions.
- ii. If secretions are splashed or coughed into the eyes or other mucous membranes, flush with copious amounts of IV fluids as soon as possible.
- iii. The public safety worker who suspects or is notified of respiratory exposure:
 - 1. Notify the department ICO that an exposure occurred
 - 2. Notify the ED charge nurse of the exposure upon delivery of the patient
 - 3. Complete the *Request for Notification of Test*.
 - 4. In these cases being checked in as an ED patient may or may not be necessary.
- iv. Upon receipt of the source patient's diagnosis, follow-up care and prophylaxis may be necessary for those exposed.
 - 1. At this point exposed employees may have to return to the receiving hospital and be checked in as a patient to receive care.
 - 2. In other situations follow-up care and prophylaxis may come from your department's workplace health provider.

c. Prophylaxis For The Airborne-Exposed Public Safety Worker


 If an exposed employee needs prophylaxis, prophylaxis should be coordinated thru the receiving (or notifying) hospital or when immediately available at the department's workplace health provider's clinic.

d. Testing The Source Patient

i. Source testing for respiratory exposures is done by the hospital based on patient symptoms.

e. Source Patient Results

- i. The hospital ICO or designee will notify the department ICO or designee of the infectious agent as soon as possible after symptoms of clinical presentation, or within 48 hours of a positive infectious agent determination.
- ii. Your organization's ICO, possibly after consulting with your department physician, will assess the potential exposure of the employee based on the interaction history with the source patient and the agent involved.
- iii. Confidentiality of source patient and the employee's information shall be maintained.



7015

Subject: Infectious Disease Exposure

Reporting Policy

June 1, 2021

Last Modified:

Jan. 31, 2021

iv. Only information pertaining to source patient results will be released to the department's ICO.

7015.4 Blood or Body Fluid & Airborne Exposures By Coroner's Cases

a. Exposure during resuscitation

- i. In cases where there is a public safety worker exposure during resuscitation efforts, it is recommended that crews transport the patient to the hospital where source testing can be performed, rather than follow field termination procedures.
- ii. However, in some incidents, exposure of a public safety worker may occur from a deceased victim who must remain at a scene for a period of time pending a coroner's investigation.

b. <u>Immediate actions of the exposed provider:</u>

- i. Decontaminate self as described in previous sections.
- ii. Notify the department ICO or designee that the exposure occurred.
- iii. At the direction of the department ICO or designee, seek treatment at an ED or at your organization's workplace health provider.
- iv. Consider prophylaxis based on the index of suspicion.

c. Actions of the ICO or designee:

- i. The Coroner or Coroner's Investigator shall be notified as soon as possible by the department's ICO or designee that an exposure has occurred.
- ii. A *Request for Information by Emergency Care Workers* form (Appendix A) shall be forward to the Coroner's Office as soon as possible after notification.

d. Testing the source patient:

- i. The Coroner shall make every effort to test a source patient by the next business day of being notified of the exposure.
- ii. In some cases, the Coroner may elect to send a specimen to an outside lab for testing. The public safety worker shall not wait for testing results from the Coroner to seek medical evaluation.

e. Source patients test results:

- i. The Coroner or Deputy Coroner shall notify the department ICO or designee of source patient test results as soon as possible.
- ii. Oral notification of source HIV status (positive or negative) shall be provided to the department ICO or designee within two days of test results, and written notification of positive test results shall be provided within three days after oral notification (ORC §3701.248).

Administrative

June 1, 2021

Infectious Disease Exposure Subject:

Effective:

Last Modified:

Reporting Policy

Jan. 31, 2021

Appendix A

REQUEST NO.

10349

REQUEST FOR INFORMATION BY EMERGENCY CARE WORKERS

PLEASE PRINT - Use Blue or Black Ink - PRESS HARD

This form is for use by emergency care workers to request information on the presence of a contagious or infectious disease (if known) of a person, alive or dead, who has been treated, handled, or transported for medical care by an emergency

Before you can be provided with this information, you must believe that you have suffered significant exposure through contact with the person about whom you are requesting the information. A significant exposure means:

(1) A percutaneous (break in skin or needle stick) or mucous membrane exposure (eyes, nose, mouth) to the blood,

semen, vaginal secretions, or spinal, synovial (joint, bone, tendon), pleural (lung), peritoneal (abdomen), pericardial (heart), or amniotic fluid of another person; or

(2) Exposure to a contagious or infectious disease.
You may expect to receive a reply to this request within 2 days after contagious or infectious disease testing results are known. This may be longer than 2 days after you submit your request. A written notification will follow. Your supervisor will also

Deposit top (white) copy in designated area or with charge nurse. Submit yellow copy to your agency or employer. Retain pink

The requestor should follow his/her agency's or employer's exposure control plan for post-exposure follow up.

1. Your Name:		ř:
2. Your Home Address:		
City/State/Zip:		
3. Your telephone number: Home: _	Work:	Pager:
4. Have you completed more than to	wo (2) injections in Hepatitis B series. Yes	No
5. Employer or volunteer agency for	whom you were administering health care wh	nen exposure occurred:
Employer or Agency:	0 AASTEC MINOR (1997 - 1997) AND (1997 - 1997) AARD (1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 -	1 C C C C C C C C C C C C C C C C C C C
	-	
	a listed place of employment or volunteer age	
7. Regarding the exposure, what was		
Name of Source Patient:		
Date:		
Place:		
Manner of exposure: Dirty Needle Stick	DK	Chi- F
Splash - Eye, Nose, Mou	ith Unp	en Skin Exposure rotected Mouth to Mouth
The state of the s	e specific)	The second secon
Office. Describe the incident (B)	e specific)	
his is to attest that the above statemer	nts are true and correct to the best of my know	wledge and belief.
rour Signature:		Date:
rodr dignature.	ACKNOWLEDGEMENT	Date
Name of Health Care Facility/Coroner:		
Signature of Person Receiving Reques	st:	
	Time	
White: Hospital/Coroner	Yellow: Agency/Employer	Pink: Requestor's

Yellow: Agency/Employer

Pink: Requestor's Copy

Administrative

7015

Subject: Infectious Disease Exposure

Reporting Policy

Effective:

June 1, 2021

Last Modified:

Jan. 31, 2021

Appendix B

THIS IN LAW. Y RELEAS FOR TH	IEST NOINFORMATION HAS BEEN DISCLOSED TO YOU FROM CONFIDENTIAL RECORDS PROTECTED FROM DISCLOSURE BY STATE YOU SHALL MAKE NO FURTHER DISCLOSURE OF THIS INFORMATION WITHOUT THE SPECIFIC, WRITTEN, AND INFORME ASE OF THE INDIVIDUAL TO WHOM IT PERTAINS, OR AS OTHERWISE PERMITTED BY STATE LAW. A GENERAL AUTHORIZA				
KESUL	THE RELEASE OF MEDICAL OR OTHER INFORMATION IS NOT SUFFICIENT FOR THE PURPOSE OF THE RELEASE OF HIV TEST LTS OR DIAGNOSES, DISCLOSED ON THIS FORM.	TION			
1.	Date of oral report:Person giving report:	_			
	Report given to worker Supervisor Supervisor's name				
	Written report will be given to worker and supervisor within 3 working days following oral notification of final results.				
2.	Date of written report: Person sending report:				
	Report sent to worker Supervisor Supervisor's name	_			
3.	Your request for information has been received.				
	a The request has been rejected because:				
	Presence of a contagious or infections disease at this time is unknown due to:				
	b No tests were performed. c The source person in question has refused HIV testing.				
	d Source patient discharged home. e No blood available				
	f Source patient discharged to health care facility/coroner's office/funeral home.				
	Address of facility/coroner's office/funeral home (if known):				
	g. The following tests were performed on source patient with negative results:				
Commi	nents;				
1.	Written and oral report included:				
	□ Name of disease □ (Medical) precautions necessary to prevent transmission				
	☐ Signs & symptoms of disease ☐ Recommended prophylaxis (if any)				
	□ Date of Exposure □ Suggested treatment				
	☐ Incubation period of disease ☐ Appropriate Counseling				
	☐ Mode of transmission				
i.	Sources of materials provided regarding disease:				
i.	It is expected that the emergency care worker will consult a physician in cases of true disease exposure. It is understood by provider of report and recipients that decisions related to prophylaxis, treatment, and counseling will be at the discretion of that physician.				
	that physician.				
	THIS RESPONSE PROVIDES ALL INFORMATION AVAILABLE AS OF THE DATE OF THIS WRITTEN RESPONSE. ANY ADDITIONAL REQUEST WILL NEED TO BE SUBMITTED FOR ANY FUTURE INFORMATION REGARDING				
	THIS RESPONSE PROVIDES ALL INFORMATION AVAILABLE AS OF THE DATE OF THIS WRITTEN RESPONSE.				

Administrative

7015

Subject: Infectious Disease Exposure


Effective:

Last Modified:

Reporting Policy

June 1, 2021 Jan. 31, 2021

Exposure Incident Flowchart



END OF SECTION



8000 Series

EMS Drug Formulary



8001

Subject:

Adenosine (Adenocard)

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic		
Packaging	6 mg (1 in drug bag) and 12 mg (2 in drug bag) prefilled syringes				
Indications	Stable Paroxysmal Supraventricular Tachycardia (PSVT)				
Adult Dosing	 A 6 mg rapid IV as quickly as possible A If not successful, may repeat 12 mg rapid IV. A If not successful, may repeat 12 mg rapid IV. A All doses of Adenosine are followed by 20 ml bolus of IV fluid. A Go directly to 12 mg if patient with history of PSVT advises it takes 12 mg. May repeat once. 				
Pediatric Dosing	P If unsuccessful, 0.2	followed by 10 ml rapid saline flush. mg/kg rapid IV followed by 10 ml ra mg. May repeat x one.			
Therapeutic Action		conduction through the AV node winode to decrease chronotropic activi	ithout causing negative inotropic effects ity		
Contraindications	Second or third degHypersensitivity to A	ree AV block or sick sinus syndrome Adenosine			
Precautions And Side Effects	Ventricular ectopyNauseaMetallic taste.	f sinus bradycardia, sinus pause, or a	nsystole ma and in patients with bronchopulmonary		
Medical Control	Adult patient: NoPediatric Patient: N	lo			
Protocols	Cardiac Protocol 2011 – Tachycardia				
END OF SECTION					

8001 - Adenosine Page 1 of 1



8002

Subject: Albuterol (Proventil)

Effective: June 1, 2021

Last Modified:

Oct. 29, 2021

EMR	EMT	AEMT	Paramedic	
Packaging	• 2.5 mg in 3 ml plastic	c ampule (4 in drug bag)		
Indications	 For the EMT, AEMT and Paramedic: Exacerbation of Asthma, Emphysema, or COPD Bronchospasm in Asthma, COPD Allergic reaction with wheezing For the Paramedic only: Hyperkalemia in the presence of Crush Syndrome Trauma 			
Adult Dosing	A Combine IpratropiurA May repeat AlbuteroA Give all 4 doses for h	ized with O_2 at 8-10 LPM. m with first dose of Albuterol. ol up to 2 times for a total of 3 doses yperkalemia administer 10 mg nebulized		
Pediatric Dosing	P Combine IpratropiurP May repeat Albutero	ized with O ₂ at 8-10 LPM. m with first dose of Albuterol. ol up to 2 times for a total of 3 doses administer 10 mg nebulized		
Therapeutic Action	 Bronchodilator 			
Contraindications	Prior hypersensitiveCardiac dysrhythmias	reaction to Albuterol s associated with tachycardia.		
Precautions And Side Effects	 Side Effects Restlessness Apprehension Dizziness Palpitations Tachycardia Dysrhythmia 	on		
Medical Control	Pediatrics: For the El	T or Paramedic: No		
Protocols	 General Protocol 1008 – Advanced Airway Management Trauma Protocol 3007 – Crush Syndrome Trauma (Paramedic only) Medical Protocol 4002 – Allergic Reaction/Anaphylaxis Medical Protocol 4003 – Asthma/Emphysema/COPD 			
END OF SECTION				

8002 - Albuterol Page 1 of 1



8003

Subject:

Amiodarone (Cordarone)

Effective: June 1, 2021

Last Modified:

Jan. 6, 2021

EMR	EMT	AEMT	Paramedic	
Packaging	 150 mg in 3 ml vial, 50 mg/ml 3 vials in drug bag 			
Indications	 Ventricular Fibrillation or Pulseless Ventricular Tachycardia Stable Wide-Complex Tachycardia 			
	A 300 mg IV o		or IO) no sooner than 10 minutes after first	
Adult Dosing	A 150 mg in 29	50 ml NS, IV wide open over 10 min	nia and no anti-arrhythmic has been given: utes using 60 gtt/ml tubing & 18 g angiocath	
	Stable Wide-Complex A 150 mg in 29		utes using 60 gtt/ml tubing & 18 g angiocath	
Pediatric Dosing	 Ventricular Fibrillation or Pulseless Ventricular Tachycardia P 5 mg/kg IV or IO (max first dose 300 mg). P May repeat 5 mg/kg IV or IO no sooner than 10 minutes after first dose. Max repeat dose is 150 mg 			
	Not indicated for stal	ole wide complex tachycardia		
Therapeutic Action	Antidysrhythmic agent with multiple mechanisms of action			
Contraindications	 Pulmonary congestion Cardiogenic shock Hypotension (SBP less than 100) Sensitivity to Amiodarone 			
Precautions And Side Effects	 Continuous EKG monitoring is required. Side Effects Hypotension Headache Dizziness Bradycardia AV conduction abnormalities Flushed skin Abnormal salivation 			
Medical Control	Adult patient: No Pediatric Patient: No			
Protocols	 Cardiac Protocol 2005 – Cardiac Arrest: Ventricular Fib or Pulseless V-Tach Cardiac Protocol 2011 – Tachycardia 			
END OF SECTION				

8003 - Amiodarone Page 1 of 1



8004

Subject:

Aspirin (Abbreviated as ASA)

Effective:

June 1, 2021

Last Modified:

Jan. 6, 2022

EMR	EMT	AEMT	Paramedic	
Packaging	 81mg tablets in a blist 	ter pack (4 tablets total)		
Indications	Given as soon as possible to the patient with AMI.			
Adult Dosing	• 324 mg chewed (Four	r 81 mg tablets)		
Pediatric Dosing	 Not applicable to pedi 	liatric patients		
Therapeutic Action	 Anti-platelet 			
Contraindications	 Hypersensitivity to salicylates Active ulcer disease Bleeding disorders Third trimester pregnancy 			
Precautions And Side Effects	 Suspected cardiac che Patient must chew the Side Effects Stomach irrit Heartburn or Nausea or vo Allergic react 	tation r indigestion omiting	25 y/o	
Medical Control		MTs: Yes	t is 25 y/o or younger with AMI symptoms.	
Protocol		8 – Suspected Cardiac Chest Pain 1 – Obstetrical Emergencies		
END OF SECTION				

8004 - Aspirin Page 1 of 1



8005

Subject: Atropine

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic
Packaging	 1mg in 10 ml prefilled syringe; (3 In Haz Mat/WMD Security Bag: Duodote: 2 mg auto-in In WMD Drug Caches and Chemp 2 mg, 1mg and 0.5 mg Multidose vial 8 mg in 	jector <i>(along with 2-Pam 600 a</i> packs: AtroPen auto-injectors;	mg autoinjector)
Indications	Symptomatic bradycardiaOrganophosphate or Nerve Agen	t poisoning (regardless of card	diac rate)
Adult Dosing		_	e auto-injector. Paramedic only: 2 mg IV, IO or IM aar to auscultation.
Pediatric Dosing	P Maximum total dose 1 P Organophosphate or Nerve Gas p P For EMR, EMT, AEMT o P Less than 2 P 20 - 40 kgs P Greater th P Paramedic only: May	of 0.1 mg, max single dose 0.5 mg ooisoning:	njector or to-injector or IM
Therapeutic Action	Anticholinergic	,	
Contraindications	 None for severe organophosphat Tachycardia Hypersensitivity to atropine Obstructive disease of GI tract Obstructive neuropathy Unstable cardiovascular status in Narrow angle glaucoma Thyrotoxicosis 		cardial ischemia
Precautions And Side Effects	 EMR, EMT and AEMT can only accepationts Pupillary dilation rendering the positive side of the positive side o	upils nonreactive. Pupil respordia, palpitations a when pushed too slowly or well (dryness, photophobia, blurre	jector to Organophosphate or Nerve Agent onse may not be useful in monitoring CNS status. when used at doses less than 0.5 mg and vision, urinary retention, constipation)
Medical Control	 Adult patient: Bradycardia — No. Pediatric Patient: Bradycardia — 		
Protocol	 Cardiac Protocol 2010 – Bradycal Special Operations Protocol 6002 Special Operations Protocol 6005 	2 – Antidote Resources	e agent Exposure

END OF SECTION

8005 - Atropine Page 1 of 1



8006

Subject:

Calcium Chloride 10%

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic
Packaging	1 gram in 10 ml vial,	100 mg/ml (1 in drug bag)	
	Renal dialysis patien	t in cardiac arrest or with ♦ bradyca	rdia
	 Calcium Channel Blo 	cker OD	
	 + Hydrofluoric Acid 	exposure with tetany <u>or</u> cardiac arre	est.
Indications		-	eflexes, spasms of the hands and feet,
		laryngospasm.	
			high concentration (> 40%) Hydrofluoric Acid
		Syndrome presenting with abnorma	I ECG or hemodynamic instability
	A 1 gm (10 ml) IV for:	act in ranal dialysis nationts	
		est in renal dialysis patients Hannel Blocker OD	
Adult Dosing		oric Acid exposure with tetany or ca	rdiac arrect
Addit Dosing		high concentration Hydrofluoric Acid	
		ent with bradycardia: 1 gm (10 ml) IV	
	A ◆ Crush syndrome: 1		
	P 20 mg/kg IV (max do		
Dedictric Desires	Cardiac arre	est in renal dialysis patients	
Pediatric Dosing	• • Calcium (Channel Blocker OD	
	P ◆ Call in advance to	treat crush syndrome or hydrofluor	c acid exposures in pediatric patients
Therapeutic	 Antagonizes cardiac 	toxicity in hyperkalemia associated	with dialysis patients.
Action	 Reverses symptoms 	of Calcium Channel Blocker	
Contraindications	 None in the emerger 	ncy setting	
	Do not administer w	ith Sodium Bicarbonate because if n	nixed, a precipitate develops.
	 Flush tubing betwee 	n drugs.	
	Side Effects:	_	
	 Bradycardia 	(may cause asystole)	
Precautions And	 Hypotension 		
Side Effects	Metallic taste		
		necrosis and sloughing following IV	nfiltration
		e vasospasm in coronary and cerebra	
		n and bradycardia may occur with ra	
		and bradycardia may occur with ra	più auministration.
	 Adults: Cardiac Arres 	st No	
		s patient in bradycardia- Yes	
	· ·	nnel Blocker OD—Yes	
		Acid Exposure—Yes	
Medical Control	Crush syndro	•	
	 Pediatrics 		
	o Arrest—No		
	o Calcium Chai	nnel Blocker OD— Yes	
	•	Acid Exposure—Yes	
	 Crush syndro 		
		94 – Cardiac Arrest - Renal Failure/Di	<u>alysis</u>
	Cardiac Protocol 201	•	
Protocol		07 – Crush Syndrome Trauma	
		12 – Overdose or Poisoning	
	 Special Operations P 	rotocol 6004 – Hydrofluoric Acid Exp	<u>oosure</u>

END OF SECTION

8006 – Calcium Chloride 10% Page 1 of 1



8007

Subject: Calcium Gluconate

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT AEMT Paral	medic
Packaging	1 gram in 10 ml vial, 100 mg/ml. Only in the drug bag in the event of Calciun	n Chloride 10% shortage
	Renal dialysis patient in cardiac arrest or with ♦ bradycardia	
	Calcium Channel Blocker OD	
	 Hydrofluoric Acid exposure with tetany or cardiac arrest. 	
Indications	 Tetany may present as: overactive neurological reflexes, spasms of t 	he hands and feet
marcations	cramps, and laryngospasm.	ne nanas ana reet,
		(> 100/) Hydroflyaric Acid
	May be given prophylactically, after exposure to high concentration	
	 Adults with Crush Syndrome presenting with abnormal ECG or hemodynar 1 gm (10 ml) IV for: 	nic instability
	A 1 gm (10 ml) IV for: O Cardiac arrest in renal dialysis patients	
	o ♦ Calcium Channel Blocker OD	
Adult Dosing	 ♦ Hydrofluoric Acid exposure with tetany or cardiac arrest 	
Addit Dosing	A ◆ For prophylaxis in high concentration Hydrofluoric Acid exposure: 400 mg	(4 ml) IV
	A ◆ Renal dialysis patient with bradycardia: 1 gm (10 ml) IV	(,
	A ◆ Crush syndrome: 1 gm (10 ml) IV	
	P 20 mg/kg IV (max dose 500 mg) for:	
Dedicate Desire	Cardiac arrest in renal dialysis patients	
Pediatric Dosing		
	P • Call in advance to treat crush syndrome or hydrofluoric acid exposures in	pediatric patients
Therapeutic	Antagonizes cardiac toxicity in hyperkalemia associated with dialysis patient	S.
Action	Reverses symptoms of Calcium Channel Blocker	
Contraindications	None in the emergency setting	
	Do not administer with Sodium Bicarbonate because if mixed, a precipitate devel	elops.
	Flush tubing between drugs.	
	Side Effects:	
	 Bradycardia (may cause asystole) 	
Precautions And	Hypotension	
Side Effects	 Metallic taste 	
	 Severe local necrosis and sloughing following IV infiltration 	
	 May produce vasospasm in coronary and cerebral arteries 	
	 Hypertension and bradycardia may occur with rapid administration. 	
	Adults:	
	Cardiac Arrest—No	
	 Renal dialysis patient in bradycardia- Yes 	
	 Calcium Channel Blocker OD—Yes 	
	 Hydrofluoric Acid Exposure—Yes 	
Medical Control	 Crush syndrome—Yes 	
	Pediatrics	
	o Arrest—No	
	Calcium Channel Blocker OD—Yes	
	Hydrofluoric Acid Exposure—Yes Crush sundrama, Yes	
	Crush syndrome- Yes Cardias Protocol 2004 Cardiavascular Emergencies: Panal Failure / Dialysis	
	Cardiac Protocol 2004 – Cardiovascular Emergencies: Renal Failure/Dialysis Cardiac Protocol 2010 – Producardia	
Protocol	Cardiac Protocol 2010 – Bradycardia Trauma Protocol 2007 – Cruch Syndrama Trauma	
Protocol	Trauma Protocol 3007 – Crush Syndrome Trauma Modical Protocol 4013 – Overdose or Reiceping	
	Medical Protocol 4012 – Overdose or Poisoning Special Operations Protocol 6004 – Hydrofluoric Acid Exposure	
	Special Operations Protocol 6004 – Hydrofluoric Acid Exposure	

END OF SECTION

8007 – Calcium Gluconate Page 1 of 1



8008

Subject:

Ciprofloxacin (Cipro)

Effective:

June 1, 2021

Last Modified:

Feb. 20, 2024

EMR	EMT	AEMT	Paramedic
Packaging	 Tablets 		
Indications	 As prophylaxis agair 	nst Anthrax, Cholera or Plague	
Adult Dosing	A ◆ 500 mg tablet by	mouth, twice a day	
Pediatric Dosing	P ◆ Dosage will be sp	ecified at time of incident.	
Therapeutic Action	• Antibiotic		
Contraindications	Allergy to quinoloneTendon pain or inflaPediatricsPregnancy		
Precautions And Side Effects	 Side Effects Atrial flutter Hypotension Premature Ventr QT prolongation Torsade De Point Tendon pain/infl 	tes,	
Medical Control	Adult: YesPediatric: Yes		
Protocol	 Special Operations F 	Protocol 6006 – Other Hazardous Ma	aterials
END OF SECTION			

8008 - Ciprofloxacin Page 1 of 1



8009

Subject:

Dextrose 10% (D10)

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic	
Packaging	500 ml of D10W, cont1 bag of solution in dr			
Indications	 Diabetic with mental status changes Evidence of hypoglycemia in cardiac arrest Generalized hypothermia with or without arrest Altered level of consciousness of unknown cause Seizures with BGL of less than 60 mg/dl No blood sugar monitor is available or suspicion of hypoglycemia despite glucometer readings. 			
Adult Dosing	A 250 ml IV at wide opeA May repeat in 10 minuA Maximum dose is 500	utes if patient fails to respond or BO	GL remains less than 60 mg/dl.	
Pediatric Dosing	P Pediatric patients: P 5 ml/kg P Maximum dose is 250 ml P Newborn patients: P 2 ml/kg if BGL is less than 40 mg/dl			
Therapeutic Action	Principal form of carbohydrate utilized by the body			
Contraindications	Known or suspected C	CVA in the absence of hypoglycemia	1	
Precautions And Side Effects	Side Effects:WarmthPainHyperglycem	n medication infusion	e deficient patients	
Medical Control	Adults: NoPediatrics: No			
Protocol		8 – Diabetic Emergencies - Hypoglyc ons 5002 – Newborn Care and Resus		

8009 – Dextrose 10% Page **1** of **1**



8010

Subject:

Diazepam (Valium) (JITSO) & CANA Pen

Effective:

June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic	
Packaging	One vial preWMD Drug Cache & 0	ramedic only nl vial (5 mg/1ml) sent in the drug bag in the event of CHEMPACK resource for all certific Antidote, Nerve Agent (CANA) 10 o	cation levels	
Indications	 CANA Auto-injector f 	associated with stimulant overdos		
Adult Dosing		ng slow IV; may repeat dose once crack use: 5 mg slow IV, may repe for all certifications		
Pediatric Dosing	P 0.5 P Ma • CANA Auto-injector f	mg/kg slow IV over 2 min. (maxing or mg/kg rectally, (maximum dose by repeat 0.2 mg/kg slow IV over 2 for all certifications	10 mg rectally)	
Therapeutic Action	 P 10 mg IM by auto-injector Treats alcohol withdrawal and grand mal seizure activity Used to treat anxiety and stress. 			
Contraindications	None in the emergency setting			
Precautions And Side Effects	ConfusionNauseaMay cause le	cardia (rare) depression or impairment ocal venous irritation		
Medical Control	 Vial for AEMT and Paramedic only Adults: No Pediatrics: No CANA Auto-injector for all certifications Adults: Yes Pediatrics: Yes 			
Protocol	Medical Protocol 401Special Operations Protocol	18 – Cyanide Poisoning 12 – Overdose/Poisoning rotocol 6002 – Antidote Resource rotocol 6005 – Organophosphate	-	

END OF SECTION



8011

Subject:

Diphenhydramine (Benadryl)

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR		EMT	AEMT	Paramedic
Packaging	•	50 mg in 1ml vial		
Indications	 Allergic reaction or Anaphylaxis In anaphylaxis, for the patient who goes into cardiac arrest if not previously given Extrapyramidal reaction 			
Adult Dosing	A	50 mg IM or slow IV		
Pediatric Dosing	P	1 mg/kg (max dose 5	60 mg) IM or slow IV	
Therapeutic Action	•	Prevents the physiolo	ogic actions of histamine by bloc	cking histamine receptors
Contraindications	•	None in the emerger	ncy setting	
Precautions And Side Effects	•	Side Effects:	d drowsiness oordination n , tachycardia or bradycardia of bronchial secretions	wer respiratory diseases such as asthma.
Medical Control	•			en treating Extrapyramidal Reactions when treating Extrapyramidal Reactions
Protocol	 Medical Protocol 4002 – Allergic Reactions/Anaphylaxis Medical Protocol 4010 – Extrapyramidal (Dystonic) Reactions 			
END OF SECTION				

8011 - Diphenhydramine Page **1** of **1**



8012

Subject:

Dopamine (JITSO)

Effective:

June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic
Packaging	 Premixed 250 ml bag (400 mg/250 ml) Concentration: 1600 mcg/ml Only present in the drug bag in the event of Norepinephrine shortage 		
Indications	Shock with or without Pulmonary Edema		
Adult Dosing	A IV drip rate, 5 to 20 mcg/kg/min of 400 mg/250 ml; increase by increments of 5 mcg/kg/min.		
Pediatric Dosing	 P IV drip rate, 5 to 20 mcg/kg/min of 400 mg/250 ml; start at 5 mcg/kg/min. P Titrate to maintain adequate perfusion 		
Therapeutic Action	 Acts on alpha, beta and dopaminergic receptors in dose dependent fashion Increases cardiac output in higher doses 		
Contraindications	None in the emergency setting		
Precautions And Side Effects	 Correct hypovolemia prior to using Dopamine. Infuse through large stable vein to avoid possibility of extravasation injury. Side Effects: Dose related tachydysrhythmias Hypertension Increased myocardial oxygen demand (ischemia) 		
Medical Control	 Adults: No Pediatrics: No 		
Protocol	 As a replacement for Norepinephrine: Cardiac Protocol 2009 – Cardiac Alert Program Medical Protocol 4015 – Sepsis Medical Protocol 4016 – Shock 		
END OF SECTION	o <u>Medical Pro</u>	otocol 4016 – Shock	

8012 - Dopamine Page **1** of **1**



8013

Subject:

Doxycycline

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic
Packaging	Tablets		
Indications	 As prophylaxis again 	nst Anthrax, Cholera or Plague	
Adult Dosing	A ◆ 100 mg tablet by	mouth, twice a day	
Pediatric Dosing	P ◆ Dosage will be spe	ecified at time of incident.	
Therapeutic Action	 Antibiotic 		
Contraindications	PregnancyAllergies to Tetracyc	cline antibiotics	
Precautions And Side Effects	 Use with caution 	control pills less effective in patients with liver disease, kidney d iche, blurred vision and flu-like sympto	
Medical Control	Adult: YesPediatric: Yes		
Protocol	Special Operations P	Protocol 6006 – Other Hazardous Mate	<u>rials</u>
END OF SECTION			

8013 - Doxycycline Page 1 of 1



8014

Subject: Duodote

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic
Packaging	 Auto-injector Atropine 2 mg and Pralidoxime Chloride (2-Pam) 600 mg In WMD Drug Caches and CHEMPACKS 		
Indications	Organophosphate or Nerve Agent poisoning		
Adult Dosing	${f A}$ $lacktriangle$ Single auto-injector	containing Atropine 2 mg and 2-F	Pam 600 mg
Pediatric Dosing	P ◆ Single auto-injector	containing Atropine 2 mg and 2-F	Pam 600 mg
Therapeutic Action	Anticholinergic as a result of WMD MCI; also reactivates cholinesterase.		
Contraindications	None in the emergence	cy setting	
Precautions And Side Effects	 Use with caution in myasthenia gravis, renal impairment, pregnancy, lactation or children. Atropine causes pupillary dilation rendering the pupils nonreactive. Pupil response may not be useful in monitoring CNS status. Side Effects: Tachycardia Paradoxical bradycardia when pushed too slowly or when used at doses less than 0.5 mg Palpitations or dysrhythmias Headache Dizziness Anticholinergic effects (dry mouth, nose, skin, photophobia. blurred vision, urinary retention, constipation) Nausea & vomiting Flushed, hot, dry skin Allergic reactions 		
Medical Control	Adults: YesPediatrics: Yes		
Protocol	Special Operations Pro	otocol 6005 – Organophosphate or	r Nerve Agent Exposure
END OF SECTION			

8014 - Duodote Page 1 of 1



8015

Subject: Epinephrine

Effective: June 1, 2021

Last Modified:

Jan. 21, 2024

EMR	EMT	AEMT	Paramedic
Packaging	 EpiPen auto-injector: 0.3 mg (one in drug bag) EpiPen Jr. auto-injector: 0.15 mg (one in drug bag) 1:10,000 – 1 mg/10ml prefilled syringes (six in drug bag) 1:1,000 – 1mg/ml ampule (two in drug bag) 		
Indications	 For the EMR, EMT, AEMT and Paramedic: Anaphylaxis or allergic reaction For the AEMT and Paramedic: Asthma in severe distress The EMR and the EMT cannot treat Asthma with Epinephrine For the Paramedic Ventricular Fibrillation, Pulseless Ventricular Tachycardia, Asystole, and PEA 		
Adult Dosing	A Asthma (AEMT and Paramedic) or Anaphylaxis (EMR, EMT, AEMT and Paramedic) A If equal to or greater than 30 kg, give both Adult EpiPen 0.3 mg and EpiPen Jr 0.15 mg A May repeat after 10 minutes A Asthma (AEMT or Paramedic) or anaphylaxis ({EMT}, AEMT and Paramedic) A Epinephrine (1:1,000) 0.5 mg IM A May repeat in 10 minutes A Asthma or anaphylaxis (AEMT and Paramedic) A If hypotensive after fluid bolus: 0.1 mg, 1:10,000, slow IV, every 3 minutes, up to 0.5 mg. A Ventricular Fibrillation, Pulseless Ventricular Tachycardia, Asystole, and PEA (Paramedic) A 1 mg (1:10,000) IV, repeat every 3-5 minutes		
Pediatric Dosing	P Asthma (AEMT and Paramedic) or Anaphylaxis (EMR, EMT, AEMT and Paramedic) P If less than 15 kg, EpiPen Jr 0.15 mg P If equal to or greater than 15 kg and less than 30 kg, Adult EpiPen 0.3 mg P If greater than 30 kg, give both Adult EpiPen 0.3 mg and EpiPen Jr 0.15 mg P May repeat after 10 minutes P Asthma (AEMT and Paramedic) or Anaphylaxis ({EMT}, AEMT and Paramedic) P If less than 15 kg, Epi (1:1,000) 0.01 mg/kg IM (max 0.15 mg). P If 15 kg or greater and less than 30 kg, Epi (1:1,000) 0.01 mg/kg IM (max 0.3 mg) P May repeat Epi (1:1,000) 0.01 mg/kg IM (max dose should equal initial dose) after 10 min P Ventricular Fibrillation, Pulseless Ventricular Tachycardia, Asystole, and PEA (Paramedic) P 0.01 mg/kg (1:10,000) IV; repeat every 3-5 minutes (max single dose 1 mg)		
Therapeutic Action	 Directly stimulates alpha and beta adrenergic receptors in dose-related fashion Causes bronchodilation, vasoconstriction, and increased cardiac output. 		
Contraindications	None in the emergency setting		
Precautions And Side Effects	 Headache Nausea Restlessness Weakness Dysrhythmias, including ventricular tachycardia and ventricular fibrillation Hypertension Tachycardia May increase myocardial oxygen demand or precipitation of angina pectoris Syncope has occurred following epinephrine administration to asthmatic children. 		

8015 – Epinephrine Page **1** of **2**

8015

Subject: Epinephrine

Effective: June 1, 2021

Last Modified:

Jan. 21, 2024

Medical Control	 Adults: Initial dose administration at all levels and follow-up dosing for AEMT and Paramedics – No In allergies/anaphylaxis, repeat doses by EMR/EMTs - Yes Pediatrics: Initial dose administration at all levels and follow-up dosing for AEMT and Paramedics – No In allergies/anaphylaxis, repeat doses by EMR/EMTs - Yes
Protocol	 Cardiac Protocol 2003 – Cardiac Arrest: Asystole or PEA Cardiac Protocol 2005 – Cardiac Arrest: V-Fib or Pulseless V-Tach Cardiac Protocol 2010 – Bradycardia Medical Protocol 4002 – Allergic Reactions/Anaphylaxis Medical Protocol 4003 – Asthma/Emphysema/COPD Pediatric Considerations 5002 – Newborn Care and Resuscitation Special Operations Protocol 6004 – Hydrofluoric Acid Exposure
END OF SECTION	

8015 – Epinephrine Page 2 of 2

8016

Subject: Etomidate

Effective: June 1, 2021

Last Modified:

Dec. 13, 2022

EMR	EMT	AEMT	Paramedic
Packaging	• 40 mg in 20 ml vial (2 i	mg/ml)	
Indications	To provide sedation price of the sedati	rior to Sedate to Intubate procedure	e
Adult Dosing	A 0.3 mg/kg IV A May repeat within 2 minutes if patient resistant to intubation. A Average dose is 15 mg - 25 mg G For patients greater than 69 y/o, reduce dosing for sedatives and analgesics to one half (½) of the adult doses		
Pediatric Dosing	P Not applicable		
Therapeutic Action	Short-acting, potent seHypnotic	edative	
Contraindications	 Hypersensitivity Not to be administered to pediatric patients 		
Precautions And Side Effects	 Must be authorized for use by the agencies' Medical Director Side Effects: Bradycardia Respiratory depression or tachypnea Sinus tachycardia Hypotension Nausea and vomiting 		
Medical Control	Adults: NoPediatrics: Not applica	able	
Protocol	General Protocol 1010 – {Sedate to Intubate and Rapid Sequence Intubation}		
END OF SECTION			

8016 – Etomidate Page **1** of **1**



8017

Subject:

Fentanyl (Sublimaze)

Effective: June 1, 2021

Last Modified:

Dec. 23, 2023

EMR	EMT	AEMT	Paramedic	
Dealasina	• 100 mcg/2 mL (50 m	cg/ml) vial		
Packaging	 One in drug bag 			
	Suspected Cardiac Ch	nest Pain		
	 Pain associated with 	traumatic events		
	 Extremity Fractures 			
Indications	 Dislocations or Sprain 	ns		
	 Frostbite 			
	 Abdominal Pain 			
	 Hydrofluoric Acid (Hf 	exposure		
	A 50-100 mcg slow IV,	provided SBP is greater than 100.		
	A May repeat	50-100 mcg slow IV, after 5 minu	tes provided SBP greater than 100.	
Adult Dosing	A If no IV, Fentanyl 50-	100 mcg IN, SQ or IM		
		Fentanyl 50-100 mcg IN, SQ or IN		
	G Patient greater than 6	9 y/o, reduce dosing for sedatives a	and analgesics to one half (%) of the adult dose	
	P Fentanyl is <u>not</u> to be	administered to anyone less than	2 years of age.	
	· —	-	adequate perfusion prior to administration.	
		treatment of abdominal pain		
	P First choice treatmer	nt for pain:		
	P 1 mcg/kg IN	, max dose 100 mcg., provided ag	ge appropriate SBP or adequate perfusion	
	P Repeat 1 mg	g/kg IN after 10 minutes, if an ad	ditional drug bag is available.	
Pediatric Dosing	P Second choice treatm	nent for pain:		
	P 1 mcg/kg, sl	ow IV, max dose 100 mcg,		
	P Repeat 1 mcg/kg, slow IV after 5 minutes, max dose 100 mcg			
	P Maintain ag	e appropriate blood pressure		
	P If unable to obtain IV	/: IM for pediatric patients is a las	t resort	
		or IM, max dose 100 mcg		
	P Repeat 1 mo	cg/kg SQ or IM, max dose 100 mcg	g, no sooner than 10 minutes after first dose.	
Therapeutic	 Provides analgesia 	Provides analgesia		
Action	_	Reduces cardiac preload by increasing venous capacitance and decreasing afterload		
Contraindications	Hypersensitivity	, , ,	<u> </u>	
		wooden chest syndrome") may oc	cur:	
		equate chest wall excursion and v		
		curs with high doses (6-7 mcg/kg)		
		vith naloxone.		
	 Provide continuous c 	ardiac monitoring, EtCO2 and pul	se oximetry with sedated patients.	
Precautions And	 Geriatric & debilitate 	ed patients require lower doses &	are more prone to side effects.	
Side Effects	Apnea			
	 CNS depression 			
	 Bradycardia which m 	-		
		 Ensure adequate ventilation and oxygenation first. 		
	Atropine only if bradycardia is symptomatic and hemodynamically significant.			
		medic, follow bradycardia protoc	COI.	
Medical Control	Adults: No Dedictrice: Vee for all	halaminal nain		
	Pediatrics: Yes, for all Carrel Protected 101	•		
	· · · · · · · · · · · · · · · · · · ·	L4 – Pain Management		
Protocol	Cardiac Protocol 200 Cardiac Protocol 200			
	<u>'</u>	8 – Suspected Cardiac Chest Pain 9 – Cardiac Alert Program		
	 Cardiac Protocol 200 	5 - Carulac Alert Program		

8017 - Fentanyl



8018

Subject:

Hydroxocobalamin (Cyanokit)

Effective: June 1, 2021

Last Modified:

July 23, 2023

EMR	EMT	AEMT	Paramedic
Packaging	 After reconstitution 	ng 5 g lyophilized Hydroxocobalamin dar ution with 200 ml fluid, the vial contains thes located in each county in Homeland	Hydroxocobalamin for injection, 25 mg/mL.
Indications	 Known or strongly suspected cyanide intoxication Smoke inhalation with suspected cyanide component. Victim exposed to fire or smoke who presents with altered mental status, seizures, shock, or difficulty breathing. 		
	A ◆ May repeat 5 response		n be given IO as a last resort) minutes to 2 hours depending on clinical
Adult Dosing	A Add 20 A Mix: Ti infusio	stitute: Place the vial in an upright posit 00 mL of NS or LR to the vial using the tr he vial should be repeatedly inverted or	ransfer spike. Fill to the line. rocked, not shaken, for at least 1 min. before
Pediatric Dosing	 P → 70 mg/kg slow IV over 15 minutes; max dose of 5 grams (Can be given IO as a last resort) P → May repeat a dose of 35 mg/kg IV; max dose 2.5 g, depending on severity of poisoning and clinical response. 		
Therapeutic Action	Binds to cyanide molecules and is eliminated as waste		
Contraindications	None in the emergency setting		
Precautions And Side Effects	 Must not be used in conjunction with other Cyanide antidotes May cause hypertension 		
Medical Control	 Adults: In cardiac arrest—No In patients not in arrest—Yes Pediatrics: In cardiac arrest—No In patients not in arrest—Yes 		
Protocol	Trauma Protocol 3008 – Cyanide Poisoning & Antidotes		
END OF SECTION			

8018 - Hydroxocobalamin Page 1 of 1



8019

Subject:

Ipratropium (Atrovent)

Effective: June 1, 2021

Last Modified:

July 23, 2023

Packaging	0.5 mg in 2.5 ml plastic1 in drug bag	ampule	
Indications	 Bronchospasm in Asthma, COPD, Emphysema Allergic reaction/Anaphylaxis with wheezing 		
Adult Dosing	A 0.5 mg (2.5 ml), nebulizeA Combined with first dos		
Pediatric Dosing	P 0.5 mg (2.5 ml), nebuliz P Combined with first dos	zed with O ₂ at 8-10 LPM se of Albuterol	
Therapeutic Action	Causes bronchodilation	n by anticholinergic effect	
Contraindications	 None in the emergency 	r setting	
Precautions And Side Effects		ent should be removed by EMS. cients with narrow-angle glaucoma and l	lactating mothers.
Medical Control	• Pediatrics: For the EMT	or Paramedic: No	
Protocols	 Medical Protocol 1008 – Advanced Airway Management Medical Protocol 4003 – Asthma/Emphysema/COPD Medical Protocol 4002 – Allergic Reactions/Anaphylaxis 		

8019 - Ipratropium Page 1 of 1



8020

Subject: Votamin

Ketamine (Ketalar)

Effective: June 1, 2021

Last Modified:

Feb. 11, 2024

EMR	EMT AEMT Paramedic	
Packaging	500 mg/10 mL vial (50 mg/ml)One in drug bag	
Indications	 For the AEMT and Paramedic Chemical restraint for combative patient, including excited delirium Pain control (should be considered a second line medication for the management of pai For the Paramedic {Sedate-to-Intubate} or {RSI} Conscious adult patient requiring pacing or cardioversion (preferred method) 	in)
Adult Dosing	A 25 mg IV, may repeat 25 mg IV after 5 minutes. A If unable to obtain IV: A 25 mg IN or 50 mg IM, may repeat 25 mg IN or 50 mg IM after 10 minutes. A For combative patients: A 250 mg IM anterolateral thigh. or A 100 mg slow IV A If no change in 10 minutes for IM or 5 minutes for IV, repeat: A 250 mg IM anterolateral thigh or A 100 mg slow IV A For the Paramedic performing {Sedate to Intubate} or {Rapid Sequence Intubation}: A 100 mg slow IV, may repeat 100 mg IV after 5 minutes o Do not reduce geriatric dosing to half dose when attempting to achieve complete sedat For the Paramedic preparing the conscious adult patient for pacing or cardioversion o 25 mg IV o Do not reduce geriatric dosing to half dose when sedating for pacing and cardioversion G For patients greater than 69 y/o, reduce dosing for sedatives and analgesics to one half (½) of the	
Pediatric Dosing	adult doses (Exceptions: {RSI or sedate-to-intubate}, pacing or cardioversion) P Not to be administered for pain to any patient less than 16 y/o P Emergency sedation for combative patient, including excited delirium: P Limited to use in patients age 8 or greater. P 1 mg/kg slow IV (max dose 100 mg). or P 5 mg/kg IM (maximum dose is two doses of no more than 250 mg or 500 mg total) P ◆ Call MCP for repeat doses	
Therapeutic Action	 Ketamine is a Schedule III Phencyclidine (PCP) derivative that is rapid acting and produces a "dissociative" anesthesia in which the patient's consciousness is detached from their nervous syste Due to its "dissociative" properties, Ketamine is a potent analgesic. May be given as an adjunct to narcotic pain medication, particularly in patients at risk for hypotens or respiratory depression. 	
Contraindications	 Suspected cardiac chest pain Hypertensive crisis When significant elevations in BP might prove harmful: Acute Myocardial Infarction Angina Pectoris Aortic dissection 	

8020 - Ketamine Page 1 of 2

8020

Subject: Ketamine (Ketalar)

Effective: June 1, 2021

Last Modified:

Feb. 11, 2024

Precautions And Side Effects	 Emergence reaction may occur, when patient is awakening (hallucinations, delirium, confusion, etc.) Provide continuous cardiac monitoring, EtCO₂ and pulse oximetry with sedated patients. Management should include use of a nasopharyngeal airway, proper positioning and persistent suctioning to maintain a clear airway. Geriatric & debilitated patients require lower doses & are more prone to side effects. Catecholamine release (hypertension, tachycardia) Hypersalivation (the ketamine drool) Nausea, vomiting, particularly prevalent in pediatrics. Minimal cardiac depression occasionally reported with high doses administered rapidly IV. May transiently increase heart rate and blood pressure by central sympathetic stimulation. May require administration of midazolam prior to wearing off.
Medical Control	 Adults: No Pediatrics: No For repeat sedation doses - yes
Protocol	 General Protocol 1008 – Advanced Airway Management General Protocol 1010 – {Sedate to Intubate and Rapid Sequence Intubation} General Protocol 1014 – Pain Management Cardiac Protocol 2010 – Bradycardia Cardiac Protocol 2011 – Tachycardia Trauma Protocol 3007 – Crush Syndrome Trauma Medical Protocol 4007 – Combative Patients/Emergency Sedation
TAID OF CECTION	

END OF SECTION

8020 - Ketamine Page 2 of 2

8021

Subject:

Lactated Ringers

Effective: June 1, 2021

Last Modified:

Jan. 29, 2024

EMR	EMT	AEMT	Paramedic		
	 Usually a 1000 ml flexible, 	non-latex plastic bag			
Packaging	 Generally with a pH of 6.5. 				
	 Not in drug bags or caches 	Not in drug bags or caches			
	 Solution for fluid and elect 	rolyte replenishment			
	 Hypovolemia 				
	 Hyperglycemia 				
Indications	 Flushing of wounds 				
	Shock				
	 Pulmonary edema with sys 	tolic BP over 100 mmHg			
	 Sepsis 	• Sepsis			
	A Non traumatic shock without the contract of the contract	ut pulmonary edema:			
	A 500 ml IV				
	A May repeat 500 r	nl IV up to two times if needed			
	A Non traumatic shock with i	oulmonary edema: 250 ml IV			
	A Sepsis:	•			
	A 1LIV				
	A ◆ Additional IV flu	uid if indicated			
Adult Davins			abbain a vadial vulca		
Adult Dosing	-	st or abdomen: enough fluid to	•		
	A If BGL reads over 400 mg/dL or "High" on glucometer, administer 500 ml fluid IV – wide open.				
	A Crush syndrome:				
	A Initial treatment:	1 L IV then 500 ml/hour IV			
	A If hypotensive and	the patient has been trapped	more than 1 hour, then additional 1 L IV		
	A Heat exposure:				
	A 500 ml IV , may re	peat one time			
	A ◆ Additional IV flu				
	P 20 ml/kg IV bolus	ina, ii iiiaicatea			
Pediatric Dosing		o administer additional fluid			
Therapeutic					
Action	 Used for hydration and ma 	nagement of hypotension			
Contraindications	None in the emergency set	ting			
Precautions And					
Side Effects	• None				
Madical Cantual	 Adults: Yes, for additional 	fluid administrations in some c	ircumstances		
Medical Control	Pediatrics: Yes, for addition	nal fluid administrations in som	ne circumstances		
	• General Protocol 1005 – Go	eneral Patient Management			
	 <u>Cardiac Protocol 2005 – Ca</u> 	rdiac Arrest; V-Fib or Pulseless	<u>V-Tach</u>		
	 Cardiac Protocol 2008 – Su 	spected Cardiac Chest Pain			
	Cardiac Protocol 2009 – Cardiac Alert Program				
	Trauma Protocol 3001 – General Trauma Management				
Protocol	Trauma Protocol 3004 – Trauma Arrest				
	Trauma Protocol 3007 – Cr				
	Trauma Protocol 3014 – He	<u> </u>			
	Medical Protocol 4002 – Allergic Reaction/Anaphylaxis Madical Protocol 4002 – Dichetic Francescopic de la consideration				
	Medical Protocol 4008 – Diabetic Emergencies – Hypoglycemia/Hyperglycemia Medical Protocol 4015 – Sonsis				
	Medical Protocol 4015 - Se				
	 Medical Protocol 4016 – Sh 	<u>IUCK</u>			



8022

Subject: Lidocaine 2%

Effective: June 1, 2021

Last Modified:

July 23, 2023

EMR	EMT	AEMT	Paramedic
Packaging	100 mg in 5 ml syringTwo in drug bag	ge (20 mg/ml)	
Indications	For Paramedic:O Intubation of	used by pressure of intraosseous fluid on conscious patient	d administration d Tachycardia, in the absence of Amiodarone
Adult Dosing	A 1.5 mg/kg IO A Intubation on conscion A 100 mg (5 more) A 100 mg (5 more) A JITSO for Cardiac Arm A 150 mg (7.5	e of 75 mg (3.75 ml) IV or IO a (Paramedic)	
Pediatric Dosing	P 0.5 mg/kg IO P Intubation on conscion P 1.5 mg/kg m P JITSO for Cardiac Arm P 1 mg/kg IV	IO infusion (AEMT, Paramedic): (O (maximum dose 100 mg) ious patient (Paramedic): nebulized with 8-10 LPM O ₂ or IN (marest: V-Fib or Pulseless V-Tach (Paramor IO (maximum dose 100 mg) e of 1 mg/kg IV or IO (maximum dose	redic):
Therapeutic Action	Decreases automatic	city	
Contraindications	Hypercancitivity		an artificial pacemaker
Precautions And Side Effects	respiratory depression Side Effects: Altered level Cardiovascu Bradycardia Blurred vision irritability	el of consciousness, confusion or light ular collapse and/or hypotension a	e heart block or bradycardia and atrial fib.
Medical Control	Adults: No Pediatrics: No		
Protocol	 General Protocol 101 Cardiac Protocol 200 Cardiac Protocol 200 Cardiac Protocol 201 Medical Protocol 400 	08 – Advanced Airway Management 12 – Intraosseous Infusion 03 – Cardiac Arrest: Asystole or PEA 05 – Cardiac Arrest: V-Fib or Pulseless 11 – Tachycardia 02 – Allergic Reactions/Anaphylaxis 03 – Asthma/Emphysema/COPD	V-Tach



8023

Subject:

Lidocaine 2% Gel

Effective:

June 1, 2021

Last Modified:

July 23, 2023

EMR	EMT	AEMT	Paramedic
Packaging	 2% gel in a tube Not carried in drug bag 	g	
Indications	 Lubrication of airway a 	adjunct on conscious patient	
Adult Dosing	${f A}$ Apply to airway adjunc	ct.	
Pediatric Dosing	P Apply to airway adjund	ct.	
Therapeutic Action		n of the upper airway activity such	n as, swallowing, gagging or coughing that can ranial pressure
Contraindications	• None		
Precautions And Side Effects	• None		
Medical Control	Adults: NoPediatrics: No		
Guidelines	General Protocol 1008	3 – Advanced Airway Management	<u>t</u>
END OF SECTION			

8023 – Lidocaine 2% Gel

Page 1 of 1



8024

Subject:

Magnesium-Containing Antacid

Effective:

June 1, 2021 Las

Last Modified:

July 23, 2023

EMR	EMT	AEMT	Paramedic
Packaging	 Varies by manufacturer or vendor Not carried in drug bag Examples include Maalox and Mylanta 		
Indications	 Ingestion of Hydrofluoric Acid Hydrofluoric Acid on skin 		
Adult Dosing	 A For Ingestion: A Following dilution with water or milk, have patient drink 3-4 oz. Maalox or Mylanta. A For exposure: A Following irrigation, apply topically to burned area unless industry has already applied topical agents. 		
Pediatric Dosing	P Apply to airway a	djunct.	
Therapeutic Action	Neutralize acid and increases the pH		
Contraindications	None in the emergency setting.		
Precautions And Side Effects	 Use with caution in: Neonates Geriatric patients Patients with renal impairment Side Effects: Hypercalcemia Hypermagnesemia Hypotension Nausea & vomiting 		
Medical Control	 Adults: No Pediatrics: No 		
Protocol	Special Operations Protocol 6004 – Hydrofluoric Acid Exposure		
END OF SECTION			



8025

Subject:

Methylprednisolone (Solu-medrol)

Effective: June 1, 2021

Last Modified:

July 23, 2023

EMR	EMT	AEMT	Paramedic
Packaging	125 mg in 2 mlOne in drug bag		
Indications	 Severe allergic reactions Anaphylaxis Asthma COPD Emphysema Intended to augment standard therapy for anaphylaxis, allergic reaction, and to address airway edema and inflammation in asthma. 		
Adult Dosing	 A Solu-Medrol 125 mg IV A Given to patients in the line medications have 	e Allergic reaction or Anaphylaxis p	protocol only after all other applicable first-
Pediatric Dosing	 P Solu-Medrol 2 mg/kg IV, max dose 125 mg P Given to patients in the Allergic reaction or Anaphylaxis protocol only after all other applicable first-line medications have been delivered. 		
Therapeutic Action	Potent anti-inflammatAccelerates detoxificat		
Contraindications	None in emergency setting		
Precautions And Side Effects	 Intended for cases that are of a more urgent nature. No significant change in patient condition in the field should be expected after administration. Do not to initiate an IV only to administer this medication. Side Effects: Cardiac arrhythmias Syncope 		
Medical Control	 Adults: No Pediatrics: No 		
Guidelines	 Medical Protocol 4002 – Allergic Reactions/Anaphylaxis Medical Protocol 4003 – Asthma/Emphysema/COPD 		
END OF SECTION			

8025 - Methylprednisolone Page 1 of 1



8026

Subject: Midazolam (Versed)

Effective: June 1, 2021

Last Modified:

Dec. 23, 2023

EMR	EMT AEMT Paramedic
Packaging	• 10 mg in 2 ml vial, (5 mg/ml)
rackagilig	Two in drug bag
	For the AEMT and Paramedic
	 Seizures
	 As chemical restraint for combative patient
	 Chest pain associated with stimulant overdose (adults only)
Indications	Paramedic
	 Conscious patient requiring cardioversion
	Conscious patient requiring pacing
	 {Sedate-to-Intubate} or {RSI} in normotensive patients
	After intubation, if patient is resisting and SBP is normal for age. A life converse or chamical restraint for compatitive nation to a chast pain in stimulant every less (ASMT).
	A If seizures, or chemical restraint for combative patients, or chest pain in stimulant overdose (AEMT, Paramedic):
	${f A}$ 10 mg IN (5 mg in each nostril) or 2.5 mg slow IV or 5 mg IM
	A Repeat 5 mg IN (after 10 min.) or 2.5 mg slow IV (after 5 min.) or 5 mg IM (after 10 min.)
	A If conscious patients requiring cardioversion/pacing or patient resisting ETT (Paramedic)
Adult Dosing	A 2.5 mg slow IV
	A In {Sedate-to-intubate} or {RSI}, 5 mg slow IV (in patients who are normotensive), may repeat up to 5
	mg IV (Paramedic)
	G For patients greater than 69 y/o, reduce dosing for sedatives and analgesics to one half (½) of the
	adult doses {Except in the case of sedation for RSI or sedate-to-intubate}
	P If seizures, or chemical restraint for combative patients (AEMT, Paramedic):
	P 0.2 mg/kg IN (maximum dose 10 mg) or
	P 0.1 mg/kg slow IV (maximum dose 2.5 mg) or
Pediatric Dosing	P 0.2 mg/kg IM (maximum dose 5 mg)
rediatric Dosing	P In seizures, repeat same doses (maximum IN 5mg, maximum IV 2.5 mg, maximum IM 5 mg)
	P ◆ In chemical restraint, call MCP for repeat doses
	P If conscious patients requiring cardioversion/pacing or patient resisting ETT (Paramedic)
	P 0.1 mg/kg slow IV (maximum dose 2.5 mg)
Therapeutic Action	Provides sedation
Contraindications	Respiratory distress
	 Use with caution with lactating mothers.
	 Geriatric & debilitated patients require lower doses & are more prone to side effects.
Precautions And	Can cause respiratory depression
Side Effects	 Monitor respirations and ventilate if necessary.
	 The Paramedic should intubate as indicated, the AEMT should intubate if apneic.
	 Provide continuous cardiac monitoring, EtCO₂ and pulse oximetry with sedated patients.
	Adults: No
Medical Control	Pediatrics:
	o No
	 Yes, for repeat doses in Combative Patient/Emergency Sedation Protocol
	General Protocol 1008 – Advanced Airway Management
	General Protocol 1010 – {Sedate to Intubate and Rapid Sequence Intubation}
	Cardiac Protocol 2006 – AICD Activations
	Cardiac Protocol 2010 – Bradycardia
Protocol	Cardiac Protocol 2011 – Tachycardia
	Medical Protocol 4007 – Combative Patients/Emergency Sedation
	Medical Protocol 4012 – Overdose/Poisoning
	Medical Protocol 4014 – Seizures
	Special Operations Protocol 6005 – Organophosphate or Nerve Agent Exposure
END OF SECTION	
EIAD OL SECTION	



8027

Subject:

Morphine (JITSO)

Effective: June 1, 2021

Last Modified:

July 23, 2023

EMR	EMT	AEMT	Paramedic
Packaging	 5 mg in 1ml vial Two in drug bag in the absence of fentanyl 		
Indications	 Pain relief in suspected cardiac chest pain, trauma emergencies, extremity fractures, dislocations, sprains, frostbite, abdominal pain, Hydrofluoric Acid (HF) exposure 		
Adult Dosing	A Up to 5 mg slow IV based on patient's weight, provided SBP greater than 100. A May repeat up to 5 mg slow IV A If unable to establish IV, Morphine 5 mg IM G For patients greater than 69 y/o, reduce dosing for sedatives and analgesics to one half (½) of the adult doses		
Pediatric Dosing	P Pain relief in pediatric patients greater 2 years old P 0.1 mg/kg slow IV (maximum dose 5 mg) provided appropriate SBP. P → May repeat 0.1 mg/kg, (maximum dose 5 mg) P If unable to establish IV, 0.1 mg/kg IM (maximum dose 5 mg)		
Therapeutic Action	 Provides analgesia, reduces cardiac preload by increasing venous capacitance and decreasing afterload 		
Contraindications	 Hypersensitivity to narcotics Hypotension Head injury, increased intracranial pressure Severe respiratory depression Patients who have taken MAO inhibitors within 14 days 		
Precautions And Side Effects	 Use with caution in the elderly, those with asthma, and in those susceptible to CNS depression. Provide continuous cardiac monitoring, EtCO₂ and pulse oximetry with sedated patients. Geriatric & debilitated patients require lower doses & are more prone to side effects. Hypotension Tachycardia, or bradycardia May worsen bradycardia or heart block in inferior MI (vagotonic effect) Palpitations Syncope Euphoria Facial flushing Respiratory depression Bronchospasm Dry mouth Allergic reaction 		
Medical Control	Adults: No Pediatrics:		
Guidelines	 General Protocol 1014 – Pain Management Cardiac Protocol 2006 – AICD Activations Cardiac Protocol 2008 – Suspected Cardiac Chest Pain Cardiac Protocol 2009 – Cardiac Alert Program 		



8028

Subject: Naloxone (Narcan)

June 1, 2021

Effective:

Last Modified:

July 23, 2023

EMR	EMT	AEMT	Paramedic
Packaging	 2 mg in 2 ml vial (1 mg/ml) Six in drug bag 		
Indications	 High index of suspicion of narcotic overdose Respiratory depression Suspicion of drug abuse in cardiac arrest A (EMR or EMT) Up to 4 mg IN (half dose per nostril) 		
Adult Dosing	A (AEMT or Paramedic) A Up to 4 mg IN (half dose per nostril) or 2 mg IV A If no IV, up to 4 mg IM A Titrate dosing to adequate respirations, repeat as needed		
Pediatric Dosing	P (EMR or EMT) P If 20 kg or less, then 0.1 mg/kg IN (maximum dose 2 mg) (half dose per nostril) P If greater than 20 kg, then 2 mg IN, may repeat as needed P (AEMT or Paramedic) P For neonates, consider 0.1 mg/kg IV, every 3 minutes until respirations improve) P If 20 kg or less, then 0.1 mg/kg IN (half dose per nostril), IV or IM (maximum dose 2 mg) P If greater than 20 kg, then 2 mg IN (half dose per nostril) P If using IN route and respirations don't improve after 2 mins., establish and administer via IV P Titrate dosing to adequate respirations, repeat as needed.		
Therapeutic Action	A competitive narcotic antagonist		
Precautions And Side Effects	 Hypersensitivity Any intranasal administration should be given at a half dose in each nostril Onset of action is two minutes, if no response two minutes after dosing, then give additional doses For the Paramedic: if the patient has a pulse, Naloxone should be given before intubation. After administration, patient transport by EMS is encouraged, even if patient becomes responsive. Use with caution in narcotic-dependent patients who may experience withdrawal syndrome (including neonates of narcotic-dependent mothers). Caution should be exercised when administering to narcotic addicts (may precipitate withdrawal symptoms) Side Effects: Tachycardia Hypertension Dysrhythmias Diaphoresis Blurred vision Nausea and vomiting May not reverse hypotension 		
Medical Control	Adult: No Pediatric: No		
Guidelines	General Protocol 1012 –Medical Protocol 4012 –		<u>scitation</u>
END OF SECTION			

8028 - Naloxone Page 1 of 1



8029

Subject:

Nitroglycerin (Nitrostat)

Effective:

June 1, 2021

Last Modified:

July 23, 2023

EMR	EMT	AEMT	Paramedic
Packaging	 Dark brown glass bottle, 0.4 mg SL tablets One bottle in drug bag 		
Indications	 For the EMT, AEMT and Paramedic: Cardiac related chest pain For the AEMT and Paramedic: Pulmonary edema with systolic BP over 100 mmHg Stimulant overdose with chest pain 		
Adult Dosing	A 0.4 mg SL every 5 min	for continued chest pain up to a	a total of 3 tablets
Pediatric Dosing	P Not applicable		
Therapeutic Action	Vasodilator which decreased preload and to a lesser extent, afterload		
Contraindications	 Hypersensitivity Hypotension Use of sexual enhancement drugs (Viagra, Cialis, Levitra) in last 24 hours Taking Revatio (a pulmonary hypertension medication) Head injury 		
Precautions And Side Effects	 Use only on patients who are greater than 25 years old or have been prescribed Nitroglycerin Side Effects: Transient headache Reflex tachycardia Hypotension Diaphoresis Postural syncope Nausea & vomiting 		
Medical Control	 Adult: For the EMT: For the AEMT Pediatric: Not applicable 	Γ and Paramedic: No	
Protocol	 <u>Cardiac Protocol 2008 – Suspected Cardiac Chest Pain</u> <u>Medical Protocol 4012 – Overdose/Poisoning</u> <u>Medical Protocol 4013 – Respiratory Distress/Pulmonary Edema</u> 		



8030

Subject:

Norepinephrine (Levophed)

Effective: June 1, 2021

Last Modified:

Feb. 20, 2024

EMR	EMT	AEMT	Paramedic
Packaging	4 mg in 4ml (1mg/mOne in drug bag	l) vial for dilution in 250 ml of IV fluid	ls
Indications	 For blood pressure of 	control in acute hypotensive states in	the non-trauma patient.
Adult Dosing	A Add 4 mg to 250 ml A Infuse starting at 30 A Increase by 5 drops	drops per minute (max 45 drops) with	th 60 drop tubing and titrate to effect. gtts/min
Pediatric Dosing	P → Contact MCP for d	osing and administration guidance.	
Therapeutic Action	Peripheral vasoconsPositive inotrope (in	trictor. creases cardiac contractility) and chro	onotrope (increases heart rate).
Contraindications	 Should not be given to patients who are hypotensive from acute hemorrhage. Do not use the solution if its color is pinkish or darker than slightly yellow or if it contains particles. 		
Precautions And Side Effects	Administer in free-flAvoid hypertension.If extravasation occu	iluted before administration. owing IV and watch for infiltration. urs, stop the infusion immediately as	necrosis may occur. e given through the infiltrated catheter.
Medical Control	Adult: NoPediatric: Yes		
Protocol	 Cardiac Protocol 200 Medical Protocol 40 Medical Protocol 40 		
END OF SECTION	_		

8030 - Norepinephrine Page 1 of 1



8031

Subject:

Normal Saline (Sodium Chloride Solution)

Effective:

June 1, 2021

Last Modified:

Jan. 24, 2024

EMR	EMT AEMT Paramedic		
LIVIIV	Usually a 1000 ml flexible, non-latex plastic bag		
Packaging	Generally with a pH of 6.5.		
rackaging	Not in drug bags or caches		
	Solution for fluid and electrolyte replenishment		
	Hypovolemia		
	Hyperglycemia		
Indications	Flushing of wounds		
indications	Shock		
	Pulmonary edema with systolic BP over 100 mmHg		
	Sepsis		
	A Non traumatic shock without pulmonary edema:		
	A 500 ml IV		
	A May repeat 500 ml IV up to two times if needed		
	A Non traumatic shock with pulmonary edema: 250 ml IV		
	A Sepsis:		
Adult Dosing	A 1LIV		
	A ◆ Additional IV fluid if indicated		
	A Penetrating trauma to chest or abdomen: enough fluid to obtain a radial pulse		
	A If BGL reads over 400 mg/dL or "High" on glucometer, administer 500 ml fluid IV – wide open.		
	·		
	A Initial treatment: 1 L IV then 500 ml/hour IV		
	A If hypotensive and the patient has been trapped more than 1 hour, then additional 1 L IV		
	A Heat exposure:		
	A 500 ml IV, may repeat one time		
	A ◆ Additional IV fluid, if indicated		
Dedictric Desires	P 20 ml/kg IV bolus		
Pediatric Dosing	P ◆ In shock, call for orders to administer additional fluid		
Therapeutic	Head for budgeting and generalized for the standing		
Action	Used for hydration and management of hypotension		
Contraindications	None in the emergency setting		
Precautions And			
Side Effects	• None		
	Adults: Yes, for additional fluid administrations in some circumstances		
Medical Control	Pediatrics: Yes, for additional fluid administrations in some circumstances		
	General Protocol 1005 – General Patient Management		
	Cardiac Protocol 2005 – Cardiac Arrest; V-Fib or Pulseless V-Tach		
	Cardiac Protocol 2008 – Suspected Cardiac Chest Pain		
	Cardiac Protocol 2009 – Cardiac Alert Program		
	Trauma Protocol 3001 – General Trauma Management		
	Trauma Protocol 3004 – Trauma Arrest		
Protocol	Trauma Protocol 3007 – Crush Syndrome Trauma		
	Trauma Protocol 3014 – Heat Exposure		
	Medical Protocol 4002 – Allergic Reaction/Anaphylaxis		
	Medical Protocol 4008 – Diabetic Emergencies – Hypoglycemia/Hyperglycemia		
	Medical Protocol 4015 - Sepsis		
	Medical Protocol 4016 – Shock		

END OF SECTION

8031 – Normal Saline Page 1 of 1



8032

Subject: Normosol-R

Effective: June 1, 2021

Last Modified:

Jan. 29, 2024

EMR	EMT	AEMT	Paramedic	
	Usually a 1000 ml flexi	Usually a 1000 ml flexible, non-latex plastic bag		
Packaging	 Generally with a pH of 	6.5.		
	 Not in drug bags or car 	ches		
	 Solution for fluid and e 	electrolyte replenishment		
	 Hypovolemia 			
	Hyperglycemia			
Indications	 Flushing of wounds 			
	• Shock			
	 Pulmonary edema witl 	h systolic BP over 100 mmHg		
	Sepsis	,		
	-	vithout pulmonary edema:		
	A 500 ml IV			
	A May repeat 5	500 ml IV up to two times if neede	Ч	
		vith pulmonary edema: 250 ml IV	-	
		vitii puilionary edema. 230 mi 10		
	A Sepsis:			
Adult Dosing	A 1LIV			
	A ◆ Additional	IV fluid if indicated		
	A Penetrating trauma to chest or abdomen: enough fluid to obtain a radial pulse			
	A If BGL reads over 400 mg/dL or "High" on glucometer, administer 500 ml fluid IV – wide open.			
	A Crush syndrome:			
	•	ent: 1 L IV then 500 ml/hour IV		
			d more than 1 hour, then additional 1 L IV	
	A Heat exposure:	and the patient has been trapped	a more than I hour, then additional I I II	
	·	u rongat and time		
		ry repeat one time		
		IV fluid, if indicated		
Pediatric Dosing	P 20 ml/kg IV bolus			
	P ◆ In shock, call for ord	lers to administer additional fluid		
Therapeutic	 Used for hydration and 	d management of hypotension		
Action				
Contraindications Precautions And	None in the emergence	y setting		
Side Effects	 None 			
	Adults: Yes, for additional controls	onal fluid administrations in some	circumstances	
Medical Control	Pediatrics: Yes, for add	ditional fluid administrations in sor	me circumstances	
	,	– General Patient Management		
Protocol		- Cardiac Arrest; V-Fib or Pulseles	s V-Tach	
	· · · · · · · · · · · · · · · · · · ·	– Suspected Cardiac Chest Pain		
	Cardiac Protocol 2009	– Cardiac Alert Program		
	Trauma Protocol 3001	– General Trauma Management		
	 Trauma Protocol 3004 	— Trauma Arrest		
	 Trauma Protocol 3007 	 Crush Syndrome Trauma 		
	 Trauma Protocol 3014 	– Heat Exposure		
	· · · · · · · · · · · · · · · · · · ·	- Allergic Reaction/Anaphylaxis		
	 Medical Protocol 4008 	— Diabetic Emergencies — Hypogly	vcemia/Hyperglycemia	
	 Medical Protocol 4015 	<u> </u>		
	 Medical Protocol 4016 	- Shock		

END OF SECTION

8032 – Normasol-R Page 1 of 1



8033

Subject:

Ondansetron (Zofran)

Effective:

June 1, 2021

Last Modified:

July 23, 2023

EMR	EMT	AEMT	Paramedic	
Packaging	 4 mg in 2 ml vial, (2 mg/ml) 1 vial in drug bag 4 mg tablet 1 tablet in drug bag 			
Indications	For nausea or active vomiting			
Adult Dosing	A For the AEMT and Paramedic: A 4 mg tablet PO A For the Paramedic: A 4 mg slow IV, preferred route for active vomiting as patient may need hydration. A If no IV, may use 4 mg tablet PO A Consider administering 4 mg (2 ml) of the IV form by spraying it into the patient's mouth.			
Pediatric Dosing	P For the AEMT and the Paramedic: P 4 mg tablet PO if patient is 12 y/o or older and weight is 40 kg or more. P Transport time should be considered prior to administration. P For the Paramedic P 0.1 mg/kg IV (max 4 mg) if the patient is 12 y/o or older and the weight is 40 kg or more			
Therapeutic Action	 Stimulation of 5-HT 3 receptors causes transmission of sensory signals to the vomiting center via vaga afferent fibers to induce vomiting. By binding to 5-HT 3 receptors, Ondansetron blocks vomiting mediated by serotonin release. 			
Contraindications	• Known hyper	rsensitivity to Ondansetron		
Precautions And Side Effects	 During pregnancy it should only be used where clearly needed. Side effects: Constipation or diarrhea Fever Headache. Sudden blindness of 2-3 minutes duration. (the speed of delivery may contribute to the blindness) 			
Medical Control	Adults: NoPediatrics: No			
Protocol	Medical Protocol 4001 – Abdominal Pain			

8033 - Ondansetron Page 1 of 1



8034

Subject: Oral Glucose

Effective: June 1, 2021

Last Modified:

July 23, 2023

EMR	EMT	AEMT	Paramedic
Packaging	Tube; concentration variesNot carried in drug bag	s, check label	
Indications	 Hypoglycemia Generalized hypothermia Altered level of consciousr Seizures with BGL of less t reading For the AEMT and Parame 	ness of unknown cause :han 60 mg/dl, no BGL monitor;	or suspicion of hypoglycemia despite BGL
Adult Dosing	A 1 tube A May be repeated in 10 mi	nutes if BGL remains less than (60 mg/dl
Pediatric Dosing	P 1 tube P May be repeated in 10 min	nutes if BGL remains less than 6	60 mg/dl
Therapeutic Action	Raise blood glucose conce	entration	
Contraindications	 Inability to control the air 	way	
Precautions And Side Effects	Use caution when giving toHyperglycemia	o unresponsive patients.	
Medical Control	Adults: NoPediatrics: No		
Protocol	• Medical Protocol 4008 – D	Diabetic Emergencies - Hypoglyo	<u>cemia</u>
END OF SECTION			

8034 – Oral Glucose Page 1 of 1



8035

Subject: Plasmalyte-A

Effective: June 1, 2021

Last Modified:

Jan. 29, 2024

EMR	EMT	AEMT	Paramedic	
	Usually a 1000 ml flexible	, non-latex plastic bag	·	
Packaging	 Generally with a pH of 6. 	5.		
	Not in drug bags or caches			
	Solution for fluid and electrical	trolyte replenishment		
	 Hypovolemia 			
	Hyperglycemia			
Indications	 Flushing of wounds 			
	• Shock			
	 Pulmonary edema with s 	ystolic BP over 100 mmHg		
	• Sepsis			
	A Non traumatic shock with	nout pulmonary edema:		
	A 500 ml IV			
	A May repeat 500	ml IV up to two times if needed	1	
		n pulmonary edema: 250 ml IV	•	
		i pullionary edema. 230 mi iv		
	A Sepsis:			
	A 1LIV			
	A ◆ Additional IV	luid if indicated		
Adult Dosing	A Penetrating trauma to ch	est or abdomen: enough fluid to	o obtain a radial pulse	
	${f A}$ If BGL reads over 400 mg	/dL or "High" on glucometer, ad	minister 500 ml fluid IV – wide open.	
	A Crush syndrome:			
	A Initial treatment	: 1 L IV then 500 ml/hour IV		
		•	more than 1 hour, then additional 1 L IV	
	A Heat exposure:			
	A 500 ml IV, may r	anast ana tima		
	•			
	A ♦ Additional IV t	Tuid, if indicated		
Pediatric Dosing	P 20 ml/kg IV bolus	and a description of a distance of floated		
The successive	P ◆ In shock, call for orders	s to administer additional fluid		
Therapeutic	 Used for hydration and m 	nanagement of hypotension		
Action	· · · · · · · · · · · · · · · · · · ·			
Contraindications	None in the emergency s	etting		
Precautions And Side Effects	• None			
Side Lifects	Adults: Yes, for additional	I fluid administrations in some c	ircumstances	
Medical Control	·	onal fluid administrations in son		
	•	General Patient Management	Te circumstances	
		Cardiac Arrest; V-Fib or Pulseless	: V-Tach	
		suspected Cardiac Chest Pain	TV Tach	
	Cardiac Protocol 2009 – C			
		General Trauma Management		
.	Trauma Protocol 3004 – 1			
Protocol	Trauma Protocol 3007 – 0			
Protocol				
FIOLOCOI	 Trauma Protocol 3014 – I 	icat Exposure		
Fiotocoi	The state of the s	Allergic Reaction/Anaphylaxis		
FIOLOCOI	 Medical Protocol 4002 – A 		cemia/Hyperglycemia	
FIOLOCOI	 Medical Protocol 4002 – A 	Allergic Reaction/Anaphylaxis Diabetic Emergencies – Hypogly	cemia/Hyperglycemia	

END OF SECTION

8035 – Plasmalyte-A Page 1 of 1



8036

Subject: Pralidoxime (2-PAM)

Effective: June 1, 2021

Last Modified:

July 23, 2023

EMR	EMT	AEMT	Paramedic
Packaging	• 600 mg auto-injector		
Indications	 Both for treatment of civ 	opine in organophosphate, or n vilian patients at the scene, as w vecome unexpectedly contamina	vell as for protection of public safety personnel
Adult Dosing	A ◆ 600 mg IM auto-injec	tor	
Pediatric Dosing	P ◆ Patients greater than	20 kg: 600 mg IM auto-injector	
Therapeutic Action	Nerve Gas)	se after poisoning with antichol is after organophosphate poisor	inesterase agents, (Organophosphate or ning
Contraindications	 Hypersensitivity 		
Precautions And Side Effects	Use with caution in myaCan spread to child thro	sthenia gravis, renal impairment ugh breast feeding	t, pregnancy, children.
Medical Control	Adults: YesPediatrics: Yes		
Protocol		ocol 6002 – Antidote Resources ocol 6005 – Organophosphate o	r Nerve Agent Exposure
END OF SECTION			

8036 - Pralidoxime Page **1** of **1**



8037

Subject: Sodium Bicarbonate

Effective: June 1, 2021

Last Modified:

July 23, 2023

EMR	EMT	AEMT	Paramedic
Dealacina	50 mEq in 50 ml syri	nge (1 mEq/ml)	
Packaging	 Two in drug bag 		
	 Not for routine arres 	sts. Studies indicate no proven effica	acy.
	 Renal dialysis patien 	t in asystole or PEA cardiac arrest	
Indications	 Excited delirium pat 	ients that go into cardiac arrest	
	 Known tricyclic over 	dose	
	 Crush Syndrome 		
	A Cardiac Arrest:		
		lysis patient: 100 mEq IV	
	A ◆ Consider	for the excited delirium patient who	o goes into arrest: 100 mEq IV
Adult Dosing	A Tricyclic antidepress	ant OD:	
Addit Dosilig	A ♦ 100 mEq	IV	
	A ◆ May repe	eat dose of 50 mEq IV for persistent	or prolonged QRS
	A Crush syndrome:		
	A 100 mEq IV	,	
	P Cardiac Arrest:		
	P In renal dia	lysis patient: 1 mEq/kg IV	
	P Tricyclic antidepress	ant OD:	
Pediatric Dosing	P ◆ 1 mEq/k	g IV	
	P ◆ May repe	eat dose of 0.5 mEq/kg IV for persist	tent or prolonged QRS
	P Crush syndrome:		
	P 1 mEq/kg I	V	
Therapeutic Action	Buffers metabolic ac	cidosis	
Contraindications	None in the emerge	ncy setting	
		·	
	Metabolic alkalosis		
Precautions And	Hypoxia Rise in intracellular I	OCO, and increased tissue acidesis	
Side Effects	Rise in intracellular IElectrolyte imbalance	PCO ₂ and increased tissue acidosis	
Side Lifects	Seizures	e (Hypernatienna)	
	 Tissue sloughing at i 	niection site	
	Adults:	injection site	
		sis Arrest – No	
	 Tricyclic OE 		
	=	lirium Arrest - Yes	
Medical Control	Pediatrics:		
	o Arrest – No)	
	 Tricyclic OE 		
	o Crush Synd		
		04 – Cardiac Arrest - Renal Failure/Di	<u>ialysis</u>
	 Cardiac Protocol 202 		
Protocol	· · · · · · · · · · · · · · · · · · ·	07 – Crush Syndrome Trauma	
	· · · · · · · · · · · · · · · · · · ·	07 – Combative Patients/Emergency	<u> Sedation</u>
	 Medical Protocol 40 	12 – Overdose/Poisoning	

END OF SECTION

8037 – Sodium Bicarbonate Page 1 of 1



8038

Subject: Sodium Nitrite (JITSO)

Effective: June 1, 2021

Last Modified:

July 23, 2023

EMR	EMT	AEMT	Paramedic
Packaging	 300 mg in 10 ml vial (30 Available in caches locat 	mg/ml) red in each county in Homeland Security	y Region 3.
Indications	Patients with known or s	suspected cyanide poisoning	
Adult Dosing	A ◆ 300 mg (10 ml) 3% sol	lution slow IV	
Pediatric Dosing	P Not applicable		
Therapeutic Action	Oxidizes hemoglobin wh	iich then combines with cyanide to forn	n an inactive compound
Contraindications	Nitrite/nitrate allergy		
Precautions And Side Effects	Methemoglobinemia if g	given in excessive amounts	
Medical Control	Adults: YesPediatrics: Not applicable	le	
Guidelines	Trauma Protocol 3008	3 – Cyanide Poisoning & Antidotes	
END OF SECTION			

8038 – Sodium Nitrite Page 1 of 1



8039

Subject:

Sodium Thiosulfate

Effective: June 1, 2021

Last Modified:

July 23, 2023

EMR	EMT AEMT	Paramedic
Packaging	 12.5 gm in 50 ml vial (250 mg/ml) Available in caches located in each county in F 	Homeland Security Region 3.
Indications	 Conscious patient with known or suspected cy Smoke inhalation with suspected cyanide com Cardiac arrest from known or suspected cyani 	mponent
Adult Dosing	A ◆ 12.5 gm (50 ml) 25% solution slow IV	
Pediatric Dosing	P ◆ Greater than 25 kg: 12.5 gm (50 ml) 25% so P ◆ Less than 25 kg: 412.5 mg/kg (1.65 ml/kg) of	
Therapeutic Action	Accelerates detoxification of cyanide	
Contraindications	• None	
Precautions And Side Effects	Possible hypotension	
Medical Control	 Adults: In cardiac arrest—No In patients not in arrest—Yes Pediatrics: In cardiac arrest—No In patients not in arrest—Yes 	
Protocol	Trauma Protocol 3008 – Cyanide Poisoning &	. Antidotes
END OF SECTION		

8039 – Sodium Thiosulfate Page **1** of **1**



8040

Subject: Tetracaine

Effective: June 1, 2021

Last Modified:

July 23, 2023

EMR	EMT	AEMT	Paramedic
Packaging	0.5%/ml eye drop bottOne in drug bag	le (10 ml)	
Indications		n cases of chemical injury to the y of penetrating trauma to eye.	eye and in other situations with significant eye
Adult Dosing	A 2 drops in each affecte	ed eye	
Pediatric Dosing	P 2 drops in each affecte	ed eye	
Therapeutic Action	 Provides rapid, brief, so nerves 	uperficial anesthesia by inhibitinį	g conduction of nerve impulses from sensory
Contraindications	Hypersensitivity to TetOpen injury to eye	racaine	
Precautions And Side Effects	 Can cause epithelial da 	stinging sensation or irritation amage and systemic toxicity cury or silver salts often found ir	n ophthalmic products
Medical Control	Adults: NoPediatrics: No		
Protocol	Trauma Protocol 3011	– Eye Injuries	
END OF SECTION			

8040 - Tetracaine Page 1 of 1



8041

Subject: Vasopressin (JITSO)

Effective: June 1, 2021

Last Modified:

July 23, 2023

EMR	EMT	AEMT	Paramedic
Packaging	 20 units in 1 ml vial, 20 Usually 2 vials (20 ml) Not routinely present i 	present	
Indications	Adult patients in cardia	ac arrest	
Adult Dosing	A 40 units IV A Once IV is established,	Vasopressin is permitted after ei	ther first or second dose of Epinephrine.
Pediatric Dosing	P Not applicable		
Therapeutic Action	 Potent peripheral vaso May be used as an alterand PEA 		the treatment of adult shock-refractory VF
Contraindications	 None in the adult card 	iac arrest	
Precautions And Side Effects	May produce cardiac is	schemia and angina	
Medical Control	Adults: NoPediatrics: Not applica	able	
Protocol	Cardiac Protocol 2005	– Cardiac Arrest: V-Fib or Pulseles	ss V-Tach
END OF SECTION			

8041 – Vasopressin Page 1 of 1



Appendix A

2024 Protocol Changes



Appendices

Δ

Subject:

2024 Protocol Changes

Effective: Jan. 21, 2024

Last Modified:

Feb. 18, 2024

Appendix A.1 General Guidelines

- a. All the important changes made to the 2024 GMVEMSC protocol are identified in this section.
- b. Any changes made since the Aug. 21, 2023 release are included.
- c. Grammatical changes, formatting or clerical corrections are not mentioned.
- d. The different tabs are:
 - i. <u>General Protocol Changes</u> includes any changes that effect the protocol as a whole or all of the different disciplines
 - ii. EMR changes affecting the patient care from an EMR
 - iii. EMT changes affecting the patient care from an EMT, including from EMR tabs
 - iv. AEMT changes affecting the patient care from an EMT, including from EMR & EMT tabs
 - v. Paramedic changes affecting the patient care from a Paramedic, including from all other tabs
 - vi. <u>Drug Formulary</u> changes made to the 8000 series drug listings, affecting all levels
- e. It is recommended that each discipline review the changes to all the other levels as well as their own as some changes could affect their practice.

Appendix A.2 2024 GMVEMSC Protocol Changes

General	General Protocol Changes			
Tab	Section	Change/Edit/Addition		
TOC	Trauma	Re-ordered Spinal Motion Restriction from Tab 3018 to Tab 3017		
TOC	Trauma	Re-ordered Trauma Triage Guidelines from Tab 3019 to Tab 3018		
TOC	Trauma	Re-ordered SALT Triage Systems from Tab 3017 to 3019		
1001	1001.1	Minor adjustments to introductory statements		
1003	1003.3.a.ii	Defined cardiac arrest as traumatic cardiac arrest		
1005	1005.4 Pearls	Recommended patients discharged in the last 24 hours return to same facility or network		
1005	1005.4 Pearls	Recommended post-op patients with surgical complications return to facility or network that did the procedure		
1008	1008.1 Pearls	Removed references to specific airway devices, leaving it to Medical Directors to approve agency devices		
1009	1009.2 Pearls	Removed redundant statement about continuous capnography already mentioned in 1009.3.b		
2002	2002.2 Pearls	Moved "Hydrogen Ion" in the Hs & Ts from the AEMT level to the Paramedic level		
4008	Whole Tab	Changed Tab title to "Diabetic Emergencies Hypoglycemia/Hyperglycemia"		
4008	4008.1.b	Added, Hyperglycemia is defined as a blood glucose level at or above 250 mg/dL."		
4015	4015.2 Pearls	Added consideration to call ahead with potentially septic patients to give the ED a "heads up"		
4017	Whole Tab	Re-worked the entire Stroke Tab General Guidelines		
4017	4017.1	Added language referencing alternative stroke screening scales		
4017	4017.3	Removed references to "tPa" as some facilities are using different thrombolytics		
4017	4017.3	Added Mercy Health – Springfield as a Thrombectomy Capable Center		
7012	7012.5	Removed Kettering Health Piqua from the list of participating hospitals		
7013	List	Removed trauma designation from Kettering Health Hamilton		
7013	List	Removed Kettering Health Piqua from the list		
7013	List	Removed Labor & Delivery from Upper Valley Medical Center capabilities		
7014	List	Removed Kettering Health Piqua from the list		
Various	Various	Changed/standardized intervals for most IV medications to every 5 minutes (exceptions where noted)		
Various	Various	Changed/standardized intervals for most IM, SQ and IN medications to every 10 min. (exceptions where noted)		

Emerge	Emergency Medical Responder		
Tab	Section	Change/Edit/Addition	
3002	3002.1 EMR	Added "Oxygenate the patient with 100% O ₂	
4002	4002.2 EMR	Changed interval for repeat Epinephrine from 5 minutes to 10 minutes	

Appendices

Subject:

2024 Protocol Changes

Effective:

Jan. 21, 2024

Last Modified:

Feb. 18, 2024

Emerge	Emergency Medical Technician			
Tab	Section	Change/Edit/Addition		
1008	1008.1 EMT	Moved recommendation to secure advanced airway after confirmation from AEMT to EMT sections		
3002	3002.1 EMR	Added "Oxygenate the patient with 100% O ₂		
4002	4002.2 EMR	Changed interval for repeat Epinephrine (Epi-pen or {IM}) from 5 minutes to 10 minutes		
4002	4002.2 EMT	Added an option for EMTs to use a syringe to draw and administer IM Epinephrine, with Med. Director approval		
4005	4005.2 Pearls	Added statement to encourage transport to the closest L&D facility when dealing with complicated deliveries		
4015	4015.2 EMT	Added recommendation to do a blood glucose screening		
4017	4017.2 EMT	Added Large Vessel Occlusion Screening		

Advance	Advanced Emergency Medical Technician			
Tab	Section	Change/Edit/Addition		
1004	1004.4.e	Added disclaimer that no cardiac monitor is required when administering pain medications in a DNR patient		
1008	1008.1 EMT	Moved recommendation to secure advanced airway after confirmation from AEMT to EMT sections		
1014	Pedi Consideration	Added bullet point to identify adequate perfusion in patients where a blood pressure is unobtainable		
1014	1014.2 AEMT	Changed repeat IV Fentanyl interval from 15 minutes to 5 minutes for adult and pediatric patients		
1014	1014.2 AEMT	Changed repeat IN, SQ, or IM Fentanyl interval from 15 minute to 10 minutes for adult and pediatric patients		
1014	1014.2 AEMT	Added "evidence of adequate perfusion" in indications for pediatric fentanyl administration		
1014	1014.2 AEMT	Moved pediatric BP/perfusion qualifier to first IN administration, added emphasis that IV dose is second choice		
1014	1014.2 AEMT	Changed repeat IV Ketamine interval from 15 minutes to 5 minutes for adult patients		
1014	1014.2 AEMT	Changed repeat IN/IM Ketamine interval from 15 minutes to 10 minutes for adult patients		
2005	2005.2	Added section addressing and explaining {Vector Change Defibrillation}		
2005	2005.3 AEMT	Added {Vector Change Defibrillation} in refractory V-Fib/PVT		
3002	3002.1 EMR	Added "Oxygenate the patient with 100% O ₂		
3007	3007.1 AEMT	Changed repeat IM Ketamine interval from 2 minutes to 10 minutes for adult patients		
4002	4002.2 AEMT	Changed repeat IM Epinephrine interval from 5 minutes to 10 minutes		
4003	4003.2 AEMT	Changed interval for repeat Epinephrine (Epi-pen or {IM}) from 5 minutes to 10 minutes		
4005	4005.2 Pearls	Added statement to encourage transport to the closest L&D facility when dealing with complicated deliveries		
4007	4007.3 AEMT	Changed intervals for repeat meds to 10 min. for IM and IN administrations and 5 min. for IV administration		
4008	4008.2 AEMT	Added, "If BGL reads over 400 mg/dL or "High" on glucometer, administer 500 ml fluid IV – wide open."		
4008	4008.2 AEMT	Added, "Do not administer fluid to a hyperglycemic pediatric patient, unless otherwise indicated. "		
4014	4014.1 AEMT	Changed IN Midazolam interval from 5 minutes to 10 minutes for adult and pediatric patients		
4015	4015.2 EMT	Added recommendation to do a blood glucose screening		

Paramedic				
Tab	Section	Change/Edit/Addition		
1004	1004.4.e	Added disclaimer that no cardiac monitor is required when administering pain medications in a DNR patient		
1008	1008.1 EMT	Moved recommendation to secure advanced airway after confirmation from AEMT to EMT sections		
1008	1008.1 Paramedic	Edit nasal intubation to identify the skill as an alternative to oral procedures		
1010	1010.2 Paramedic	Added a reminder that half dosing Ketamine or Midazolam for patients over 69 y/o does not apply in RSI/STI		
1014	Pedi Consideration	Added bullet point to identify adequate perfusion in patients where a blood pressure is unobtainable		
1014	1014.2 AEMT	Changed repeat IV Fentanyl interval from 15 minutes to 5 minutes for adult and pediatric patients		
1014	1014.2 AEMT	Changed repeat IN, SQ, or IM Fentanyl interval from 15 minute to 10 minutes for adult and pediatric patients		
1014	1014.2 AEMT	Added "evidence of adequate perfusion" in indications for pediatric fentanyl administration		
1014	1014.2 AEMT	Moved pediatric BP/perfusion qualifier to first IN administration, added emphasis that IV dose is second choice		
1014	1014.2 AEMT	Changed repeat IV Ketamine interval from 15 minutes to 5 minutes for adult patients		
1014	1014.2 AEMT	Changed repeat IN/IM Ketamine interval from 15 minutes to 10 minutes for adult patients		
2005	2005.2	Added section addressing and explaining Vector Change and Double Sequential Defibrillation		
2005	2005.3 AEMT	Added {Vector Change Defibrillation} in refractory V-Fib/PVT		
2005	2005.3 Paramedic	Added {Double Sequential Defibrillation} in refractory V-Fib/PVT after one round of antiarrhythmics		
2010	2010.2 Paramedic	Added Ketamine 25 mg IV as the preferred method for sedation/analgesia prior to pacing		
2010	2010.2 Paramedic	Added a reminder that the half dosing for patients greater than 69 y/o doesn't apply for sedation		

Appendices

Δ

Subject:

2024 Protocol Changes

Effective: Jan. 21, 2024

Last Modified:

Feb. 18, 2024

2011	2011.2 Paramedic	Added Ketamine 25 mg IV as the preferred method for sedation/analgesia prior to cardioversion
2011	2011.2 Paramedic	Added a reminder that the half dosing for patients greater than 69 y/o doesn't apply for sedation
3002	3002.1 EMR	Added "Oxygenate the patient with 100% O ₂
3008	3008.4 & 3008.5	Removed small chart from pediatric section and added a new, revised pediatric dosing chart in 3008.5
4002	4002.2 EMR, AEMT	Changed interval for repeat Epinephrine (Epi-pen or {IM}) from 5 minutes to 10 minutes
4003	4003.2 AEMT	Changed interval for repeat Epinephrine (Epi-pen or {IM}) from 5 minutes to 10 minutes
4005	4005.2 Pearls	Added statement to encourage transport to the closest L&D facility when dealing with complicated deliveries
4007	4007.3 AEMT	Changed intervals for repeat meds to 10 min. for IM and IN administrations and 5 min. for IV administration
4008	4008.2 AEMT	Added, "If BGL reads over 400 mg/dL or "High" on glucometer, administer 500 ml fluid IV – wide open."
4008	4008.2 AEMT	Added, "Do not administer fluid to a hyperglycemic pediatric patient, unless otherwise indicated. "
4014	4014.1 AEMT	Changed interval for IN Midazolam from 5 minutes to 10 minutes for adult and pediatric patients
4015	4015.2 EMT	Added recommendation to do a blood glucose screening
4015	4015.2	Removed call for order from administering Norepinephrine to hypotensive patients

Drug Fo	Drug Formulary				
Tab	Section	Change/Edit/Addition			
8015	Adult Dosing	Clarified that only AEMT and Paramedic may treat Asthma with Epinephrine			
8015	Adult Dosing	Added option for EMT to administer IM Epinephrine with approval from their Medical Director			
8015	Adult Dosing	Changed interval for repeat Epinephrine (Epi-pen or {IM}) from 5 minutes to 10 minutes			
8015	Pediatric Dosing	Clarified that only AEMT and Paramedic may treat Asthma with Epinephrine			
8015	Pediatric Dosing	Added option for EMT to administer IM Epinephrine with approval from their Medical Director			
8015	Pediatric Dosing	Changed interval for repeat Epinephrine (Epi-pen or {IM}) from 5 minutes to 10 minutes			
8017	Adult/Pedi Dosing	Changed repeat IV Fentanyl interval from 15 minutes to 5 minutes for adult and pediatric patients			
8017	Adult/Pedi Dosing	Changed repeat IN, SQ, or IM Fentanyl interval from 15 minute to 10 minutes for adult and pediatric patients			
8017	Pediatric Dosing	Moved pediatric BP/perfusion qualifier to first IN administration			
8017	Pediatric Dosing	Added the bullet that if a pediatric B/P is not possible, then look for signs of adequate perfusion prior to dosing			
8020	Indications	Added sedation prior to pacing or cardioversion in adults (preferred method)			
8020	Adult Dosing	Changed repeat IV Ketamine interval from 15 minutes to 5 minutes for adult patients			
8020	Adult Dosing	For Paramedics, added adult dosing of 25 mg IV for sedation prior to pacing and cardioversion			
8020	Adult Dosing	Changed repeat IN/IM Ketamine interval from 15 minutes to 10 minutes for adult patients			
8020	Adult Dosing	Added reminders of exceptions where the paramedic should administer a full dose to geriatric patients			
8021	Adult Dosing	Added dosing for administering fluid to hypoglycemic patients			
8021	Protocol	Added links to more tabs that recommend IV fluid administration			
8026	Adult/Pedi Dosing	For seizures, changed IN Midazolam interval from 5 minutes to 10 minutes for adult and pediatric patients			
8026	Adult Dosing	Added reminder that in STI/RSI scenarios, the paramedic should administer a full dose to geriatric patients			
8030	Medical Control	Removed call for order in septic patients			
8031	Adult Dosing	Added dosing for administering fluid to hypoglycemic patients			
8031	Protocol	Added links to more tabs that recommend IV fluid administration			
8032	Adult Dosing	Added dosing for administering fluid to hypoglycemic patients			
8032	Protocol	Added links to more tabs that recommend IV fluid administration			
8035	Adult Dosing	Added dosing for administering fluid to hypoglycemic patients			
8035	Protocol	Added links to more tabs that recommend IV fluid administration			

END OF SECTION

